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ABSTRACT 
Introduction: Pregnancy is associated with physiological and immunological changes that 
leave women vulnerable to influenza infection and associated complications. This 
evolutionary adaptation is not fully understood, but evidence indicates a shift from 
cell-mediated immunity toward humoral immunity, which places pregnant women at a 
heightened risk to severe influenza illness, exacerbated further by co-infection with HIV. 
Tuberculosis (TB) is a major health issue resulting in ill-health among millions of people 
every year, with approximately one third of the population having latent TB. The 
considerable gains achieved in reducing the incidence of TB have reversed in recent years 
due to the emergence of HIV. Currently little data exist on the effectiveness of influenza 
vaccination in individuals co-infected with HIV and TB. We evaluate and compare the 
cellular and humoral immune responses to the trivalent inactivated influenza vaccine in 
these high-risk groups.  
Methods: In 2013 we conducted (1) a double-blind randomised controlled trial, involving 
HIV-infected pregnant women, (2) two prospective, open labelled trials involving 
HIV-infected non-pregnant women, and HIV-uninfected pregnant and non-pregnant 
women, respectively, as well as in 2014 (3) a prospective, open labelled four arm trial 
involving HIV/TB co-infected, HIV-infected TB-uninfected, HIV-uninfected TB-infected 
and HIV-uninfected TB-uninfected adults. Cell-mediated, as measured by 
interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay, and humoral, as 
measured by hemagglutination inhibition (HAI) assay, immune responses to the seasonal 
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trivalent inactivated influenza vaccine were evaluated and compared between respective 
study groups at baseline and approximately 1 month post-vaccination.  
Results: in this study we report no significant differences in cell-mediated immune (CMI) 
responses among HIV-infected pregnant and non-pregnant women at both pre-vaccination 
and post-vaccination. Vaccination improved CMI responses to all three influenza strains, 
with the only significant increases observed for A/H1N1 in HIV-infected pregnant and 
non-pregnant women and B/Yamagata in HIV-infected non-pregnant women.  
Following stratification of women into low- (LB) and high-baseline (HB) responses we 
found significantly improved cellular immune responses to the influenza viruses in the LB 
groups for both HIV-infected and HIV-uninfected pregnant and non-pregnant women, 
whereas HB women tended to exhibit a declined immune response.  
We show significantly enhanced humoral immune responses to the influenza vaccination in 
TB-infected and TB-uninfected adults living with HIV post-vaccination, with little 
significant differences between the two groups. We found a similar trend in HIV-uninfected 
adults infected with and without TB; however HIV-uninfected adults achieved higher 
geometric mean titers than adults living with HIV.  
Conclusion: among the HIV-infected pregnant and non-pregnant women, it appears 
pregnancy did not play as significant a role in attenuating CMI responses to vaccination as 
HIV infection. However, a significantly higher percentage of HIV-infected pregnant 
women were on antiretroviral therapy (ART) at the time of enrolment which may have 
influenced the role of CD4+ T-cell count on CMI responses and could possibly explain the 
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similar responses observed in these two study groups. Cellular immune responses to 
vaccination were significantly greater in HIV-uninfected non-pregnant women compared to 
HIV-uninfected pregnant women, adding further evidence to the detrimental impact 
pregnancy has on CMI responses.  
Pre-existing immunity to influenza vaccination plays a major role on CMI responses 
following vaccination. Women with high-baseline responses tended to display decreased 
responses whereas women with low-baseline responses showed significantly improved 
responses. We propose that a potential threshold may exist where the quantity of memory 
T-cells reaches maximal levels in the blood system.  
We also show that vaccination with trivalent inactivated influenza vaccine (IIV3) was 
relatively immunogenic in HIV-infected TB-infected/uninfected adults, albeit not the 
magnitude observed in healthy populations. However, in adults living without 
HIV-infection, we showed that influenza vaccination was significantly immunogenic in 
both adults infected with TB and those without. Additionally, we show that infection with 
TB does not appear to affect humoral immune responses, even in the HIV-infected 
population.  
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1.0 Introduction 
1.1 Influenza Epidemiology 
Respiratory diseases are a major cause of global morbidity and mortality to which influenza 
virus infections make significant contributions (1). In the United States of America (USA) 
an estimated 225 000 hospitalisations and 36 000 deaths per year as a result of seasonal 
influenza (2,3). In the younger age groups considerable loss of life was associated with the 
‘moderate’ 2009 influenza A/H1N1 pandemic (4). There are roughly 1.1 billion people live 
in sub-Saharan Africa, an area with high population growth rates, low life expectancy, and 
many of the world’s poorest countries (5). Despite the copious amount of information from 
numerous areas of the world, there is very little known about influenza epidemiology in 
sub-Saharan Africa (6). 
Influenza viruses have been circulating in the human population for centuries, and is an 
highly contagious airborne disease normally manifesting as acute febrile respiratory illness 
with considerable medical and socioeconomic burden that have pandemic potential. The 
World Health Organisation (WHO) estimates that during annual seasonal epidemics, which 
occur in the winter months in temperate climates (7), 5% – 15% of the world population is 
typically infected by influenza virus, with 3 – 5 million cases of severe illness and up to 
500 000 influenza-associated deaths per year (8). Influenza-associated morbidity and 
mortality is highest in the elderly (>65 years of age) with an approximate annual rate of 
17 deaths per 100 000, accounting for 88% of the overall estimated annual 
influenza-associated deaths in the USA (9). In children, annual attack rates can exceed 40% 
in pre-school and 30% in school-age children (10). Further, the rate of influenza-associated 
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hospitalisations is high in young children and pregnant women (11,12). Considering work 
absenteeism as well as direct medical costs, the economic impact of influenza virus 
infection in the USA has been estimated to approximately US $12 – 14 billion per year 
(13). Influenza therefore continues to have a drastic worldwide impact, resulting in 
significant human suffering and economic burden (14). 
The incubation period for influenza A and B viruses is generally 1 – 3 days and 1 – 4 days, 
respectively. The majority of influenza virus infections are self-limited, with the common 
symptoms being headache, coughing, fever, throat pain and a general discomfort (15). In 
high-risk groups, particularly those with certain pre-existing medical conditions, influenza 
infection can have life-threatening complications, including secondary bacterial pneumonia 
(16-18).  
For the past 60 odd years the primary strategy to prevent and control seasonal and 
pandemic influenza virus is vaccination (19), with the first population-scale use of an 
inactivated influenza vaccine was in the USA military personnel in 1945 (20). During the 
early 1960s, the US Surgeon General recommended annual influenza vaccination for 
individuals with chronic debilitating diseases, people aged 65 years or older and pregnant 
women (21). This recommendation was made without data of vaccine efficacy or 
effectiveness in these high-risk groups, but rather based on studies showing efficacy in 
young, healthy military personnel (22). In 1964, the Advisory Committee on Immunisation 
Practices (ACIP) reaffirmed this recommendation but noted the absence of efficacy data 
among high-risk groups (23). Due to longstanding public health recommendation of annual 
vaccination in high-risk populations, over the last 50 years such patients have generally 
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been excluded from influenza vaccine clinical trials. The ACIP does support the inclusion 
of individuals at high-risk of influenza virus infection in placebo-controlled trials as 
unethical (24). 
In 2010, the ACIP recommended seasonal trivalent inactivated influenza vaccine (IIV3) for 
all individuals ≥6 months, or the live attenuated influenza vaccine (LAIV) for healthy, 
non-pregnant people between the ages of 2 and 49 years (24). This global influenza 
vaccination recommendation was a result of a decade of cumulative changes during which 
the ACIP expanded recommendations to include an increasing proportion of the USA 
population. 
Influenza epidemics and pandemics are a consequence of high genetic variability in the 
viruses hemagglutinin (HA) and neuraminidase (NA) antigens (25). Hemagglutinin is the 
major antigen for neutralising antibodies and is involved in the binding of virus particles to 
host cell receptors; NA is responsible for removal of the cell surface sialic acid receptor and 
critical for virus release (26). Because influenza A and B viruses are the cause for the 
majority of seasonal epidemics, current vaccines are generally designed to target these 
viruses. In contrast, influenza C is less common and mainly causing mild disease in 
children (27).  
Influenza virus A and B differ in the range of animal hosts that they can infect. Influenza B 
is confined to humans only, whereas influenza A can be found in a much broader range of 
species. The ancestral host of influenza A is wild aquatic birds and sporadically viruses are 
transmitted from this host to domestic poultry and mammals, including humans (25). 
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Currently, H1 and H3 subtypes of influenza A are endemic in humans (28). Given the 
multiple subtypes, higher mutation rates and diverse host range, influenza A poses the 
greatest pandemic threat. In contrast, influenza B viruses typically cause a milder form of 
disease, have a lower mutation rate and have less antigenic diversity (29), thereby posing 
no pandemic threat (25).  
 
1.2 Family Orthomyxoviridae 
The family orthomyxoviridae has a segmented, negative-sense, single-stranded genome 
with helical symmetry and different size ribonucleoproteins, 50 – 150 nm in length. There 
are six different genera in the family: the influenza viruses A, B, and C, Thogoto virus, Isa 
virus and Quaranfil virus (30). The virions are spherical or pleomorphic and approximately 
80 – 120 nm in diameter. The virion envelope is derived from the cell membrane, 
incorporating virus glycoproteins and non-glycosylated proteins. Virion surface 
glycoprotein projections are 10 – 14 nm in length and 4 – 6 nm in diameter (31). The name 
Orthomyxoviridae is derived from Greek – orthos, meaning correct or right and myxa, 
meaning mucus.  
 
1.2.1 Influenza Virus Classification 
The influenza virus genus comprise of three types: A, B and C, defined by the antigenicity 
of the nucleoproteins (NP) and matrix proteins (M1 and M2) in the viral core (32). 
Influenza A viruses are further divided into subtypes according to the antigenic properties 
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of the external glycoproteins (HA and NA). Eighteen antigenically different HAs (H1–18) 
and eleven different NAs (N1–11) have been identified and their combination designates 
the virus subtype (33). Influenza B viruses are classified as either Yamagata-like or 
Victoria-like (34). Viruses belonging to any of the three types of influenza are capable of 
genetic reassortment, and as a result, readily exchange genetic information. However, 
reassortment between members of different genera has not been reported. The lack of 
genetic exchange between viruses of different genera is one indication of speciation as a 
result of evolutionary divergence (14). The systematic naming of the different influenza 
virus strains involve their type, the species from which the virus was isolated (omitted if 
human), the location of the isolate as well as the number of the isolate, the year the virus 
was isolated, and, in the case of the influenza A viruses, the HA and NA subtypes (35).  
 
1.2.2 Genome Structure 
All influenza virus type A and B possess eight viral RNA (vRNA) segments, whereas 
influenza C has only seven vRNAs. The segmented genome (Figure 1.1) encodes 
11 proteins: nine structural and two non-structural proteins (31,36). Virus particles are 
encapsulated by a lipid envelope derived from the host cellular membrane during the viral 
budding process, with four viral proteins (HA, NA, M1 and M2) embedded within the lipid 
bilayer (37). The genetic material consists of single, negative-stranded RNA segments that 
are complexed with NP and minor amounts of nuclear export protein (NEP, also referred to 
as non-structural protein, NS2) and three polymerase proteins (basic polymerase 1 (PB1) 
and 2 (PB2) and acidic polymerase (PA)) (38). Replication and transcription of vRNA 
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occur within the nucleus of the infected cell, whereas assembly and budding occur on the 
plasma membrane (26). The 8 gene segments of the influenza virus genome have various 
functions in the life cycle (Table 1.1).  
The HA protein is a homotrimeric type I membrane glycoprotein and plays an important 
role in the influenza virus life cycle by mediating receptor binding and membrane fusion 
(39). Cleavage of the HA protein by the host cell proteases determines the pathogenicity of 
the influenza virus (40,41). The type II transmembrane protein, NA is a homotetramer and 
plays a role in the release of virions by destroying host cell surface receptors necessary for 
progeny release (33). The structural protein, M1, functions as a nuclear exporter of vRNA 
and viral budding, whereas M2 functions as an ion channel for the acidification of the viral 
core during the uncoating of the virus in endosomes (42). As mentioned, the viral 
ribonucleoproteins (vRNP) complex is comprised of the vRNA segments, PB1, PB2, PA, 
NEP and NP (43). PB1 and PB2 are necessary for cap binding and endonuclease activity 
(44), PA functions as an RNA polymerase subunit (45) and NP is the structural component 
of the RNP complex. The NEP functions as a nuclear export protein for vRNA in infected 
cells (46,47). The NS1 and NEP proteins are the only non-structural proteins (48), where 
NS1 is considered a non-essential virulence factor with multiple accessory functions, such 
as the inhibition of host immune responses (49).  
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Table: 1.1: Viral proteins and their functions 
Protein Function 
HA (hemagglutinin) Viral entry into target cell 
NA (neuraminidase) Release of viral particles from target cells; help in dissemination of 
virion particles throughout respiratory tract  PA (acidic polymerase protein) Endonuclease activity and help in cap binding mechanism 
PB1 (basic polymerase protein 1) Viral mRNA transcription by 5' cap binding mechanism 
PB2 (basic polymerase protein 2) Unprimes replication of viral mRNA 
PB1-F2 Apoptosis of host cell 
M1 (matrix protein) Attachment of vRNP to cell membrane and provide stability 
M2 (ion-channel protein) Release of vRNP from endosome to cytoplasm 
NP (nucleoprotein particle) Nuclear import and export of vRNP and viral replication 
NS1 (non-structural protein 1) Suppress IFN-β and host protein production 
NEP/NS2 (nuclear export protein) Nuclear import of vRNP 
 
 
Figure 1.1: The structure of the influenza virus. Eight segments of single-stranded, negative 
sense RNA molecules are enclosed within the viral envelope. Image from (33).  
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1.3 Influenza Virus Life Cycle 
1.3.1 Attachment 
Initially the influenza virus HA attaches to the surface glycoproteins containing sialic acid 
residue on the host respiratory epithelium cells. The specificity of the sialic acid 
(α2,3-linked or α2,6-linked sialic acid) and the preferred binding of a particular strain of 
influenza virus to a specific sialic acid receptor are important determinants for 
species-specific restrictions of influenza viruses (50). Avian and equine influenza viruses 
recognise mainly α2,3-linked sialic acid receptors in these species (51,52) and while 
humans have both types of receptors, human influenza viruses mainly recognise the 
α2,6-linked sialic acid receptors (53). Pigs also have both types of receptors, which may 
explain why they are susceptible to viruses from both human and avian origins (54).  
 
1.3.2 Membrane Fusion and Uncoating 
Following cell attachment, the influenza virus is internalised into endosomes by means of 
endocytosis, mediated by host epsin-1, a cargo-specific adaptor for virus entry through the 
clathrin dependent pathways (55,56). The HA precursor polypeptide (HA0) must first be 
activated by proteolytic cleavage into HA1 (globular domain) and HA2 (transmembrane 
domain) by trypsin or a trypsin-like endogenous host protease before it is able to undergo 
an acid pH-triggered conformational change into a fusogenic form (40). Next, the viral and 
endosomal membranes fuse, while the ion channel M2 in the viral membrane is activated 
by endosomal acid pH. This results in an influx of protons into the virion and the 
dismantling of M1 from the vRNP core (57).The vRNP is released into the cytoplasm of 
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the host cell as a result of dismantling. The precise timing and location of uncoating 
(maturity of the endosome) is dependent on the pH-mediated transition of specific HA 
molecules involved (58). Uptake of vRNP molecules through nuclear pores is an active 
process, involving the nucleocytoplasmic trafficking machinery of the host cell, where 
transcription and replication of the viral genome occur (59).  
 
1.3.3 Transcription and Replication 
After uncoating, the vRNP are transported into the nucleus and become the template for the 
transcription of messenger RNA (mRNA) and replicated via complementary RNA (cRNA) 
(36). The viral polymerase subunits (PB1, PB2, and PA) and NP catalyse both genome 
replication and transcription. The mRNA products are incomplete copies of the vRNA 
templates and are capped and polyadenylated, unlike vRNA. The replication process occurs 
in two steps: firstly, a full length, positive-sense copy of the vRNA is made, known as the 
cRNA and secondly, this cRNA in turn is used as a template to produce additional vRNA 
(43).  
 
1.3.4 Assembly and Release 
Once replication occurs, the newly formed RNP complexes are assembled in the nucleus 
and exported into the cytoplasm. Both the M1 and the NEP are involved in assisting the 
export of RNPs to the cytoplasm. Once in the cytoplasm, the vRNAs are translated into 
viral proteins (HA, M2 and NA) which are processed in the endoplasmic reticulum (ER), 
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glycosylated in the Golgi apparatus, and transported to the cell membrane (33). With the 
help of M1, the production of viral particles begins. Budding initiates and the progeny virus 
is released from the cell membrane by NA activity which destroys host and viral membrane 
receptors. This process is essential for progeny release (26).  
 
1.4 Antigenic Variation 
The spread of human influenza viruses, and its success, is a direct result of constant 
antigenic variation to escape host immune responses. In contrast to most other respiratory 
viruses, influenza viruses possess two different mechanisms of antigenic variation: 
antigenic drift and antigenic shift (60). Due to the relatively low fidelity of the 
RNA-dependent RNA polymerase of the influenza virus and the lack of a proof reading 
mechanism, a rapid rate of mutation occurs in its genome. These mutations result in 
antigenic variation primarily in the HA and NA proteins (14,61). 
 
1.4.1 Antigenic Drift 
Antigenic drift is defined as the gradual evolution of viral strains, due to frequent mutations 
(62) and generally occurs every 2 – 8 years in response to selection pressure by host 
immunity (63). Antigenic drift is a result of point mutations in influenza A and B viruses; 
more specifically, from positive selection of spontaneous mutants by neutralising 
antibodies where the rate of mutation being about one nucleotide change every copied 
genome (64). This translates to minor, gradual, antigenic alterations in the HA and NA 
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proteins. Eventually, these proteins on the virus particle become significantly different to a 
point where host antibodies are unable to neutralise the virus, resulting in a variant capable 
of causing illness (25). Antigenic drift is often associated with seasonal epidemics 
(Figure 1.2), where new strains have amino acid changes in the HA and NA protein coding 
genes.  
 
1.4.2 Antigenic Shift 
The second, far less frequent, yet more profound, type of antigenic variation is known as 
antigenic shift and occurs only in influenza A viruses. It is defined as the appearance in the 
human population of a new influenza virus containing a novel HA or NA. This occurs when 
two different influenza viruses (potentially from different host species) co-infect a single 
host. Genome segment reassortment results in a new virus that contains elements from both 
original viruses (Figure 1.2) (61). These newly introduced proteins are immunologically 
distinct from the proteins expressed by previously circulating strains and these may result 
in high infection rates of the novel virus in the immunologically naïve population, leading 
to potential pandemics. Since the beginning of the last century, five antigenic shifts have 
occurred: in 1918 the appearance of A/H1N1 viruses caused the Spanish Flu pandemic; in 
1957, when the A/H1N1 subtype was replaced by A/H2N2 causing the Asian influenza 
pandemic; in 1968, when A/H3N2 viruses replaced the A/H2N2 leading to the Hong Kong 
influenza; in 1977, when the A/H1N1 subtype reappeared (Russian influenza); and in 2009, 
when a novel, antigenically distinct A/H1N1 virus caused a pandemic. This strain has now 
largely replaced the previous A/H1N1 (14).  
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Figure 1.2: Evading immunity by antigenic drift and shift. Antigenic drift: the gradual 
accumulation of mutations. Antigenic shift: novel subtypes are introduced into the human 
population and may cause pandemics. Image from (65).  
 
1.5 Influenza Virus Vaccines 
Vaccination is the most effective public health intervention against influenza (66). Current 
influenza vaccines require annual updating and the rate of protection conferred by 
vaccination at population level varies from season to season being mostly dependent on 
how good the match is between the circulating viral strains and the strains in the vaccine 
(67). The WHO, in its position paper on “Vaccines against influenza” in 2012, 
recommended that annual vaccination should be prioritised for pregnant women at any 
stage of pregnancy, children aged between 6 months to 5 years, elderly individuals (aged 
more than 65 years), individuals with chronic medical conditions and health-care workers 
(69).  
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Influenza virus strains included in the seasonal vaccine are selected based on the antigenic 
profile of circulating strains in both hemispheres’ winter periods. The chosen strains then 
normally undergo co-infection of chicken eggs with viruses that are well adapted for 
growth in this media. Although in recent years there has been a shift away from influenza 
vaccine propagation in chicken eggs, this technique continues to provide the bulk of 
vaccine viruses produced today (70). The vaccine viruses are selected are those that retain 
the required antigenic properties, yet show enhanced yield in chicken eggs. Once 
propagated, the viruses are purified by means of density gradients or by chromatography, 
followed by chemical inactivation with formalin or β-propriolactone, and, in most cases, 
disrupted by lysis of the viral envelope with detergent (7,71). Currently seasonal influenza 
vaccines are available as inactivated influenza vaccines formulations (IIV) with three-
components (trivalent, IIV3) and four-component (quadrivalent, IIV4); live-attenuated 
influenza vaccines (LIAV); and trivalent recombinant influenza vaccines (RIV3) (68,72).  
Due to the constant changing in antigenicity of the two viral proteins in influenza A viruses, 
HA and NA, influenza vaccines are updated on an annual basis. When the vaccines contain 
antigens that are well matched to the circulating viral strains, the vaccines are highly 
efficacious, however if the antigens are not well matched protection is reduced (73). Even 
in years when one or more of the vaccine strains are the same as the preceding season, 
vaccination is recommended due to the decline in antibody levels (74). Because influenza 
vaccines generally take months to manufacture and distribute, vaccine strains need to be 
selected several months prior to the influenza season in order to provide sufficient time to 
prepare and distribute the vaccines (75). 
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The immunogenicity of influenza vaccines can be measured by the level of antibodies 
against the two major viral surface glycoproteins, HA and NA, in the blood or in nasal 
secretions. The gold standard for measuring protection against influenza is the 
hemagglutination inhibition (HAI) antibody assay in serum or plasma (19). The HAI assay 
measures the ability of antibodies to inhibit binding of the HA protein to sialic-acid on red 
blood cells present in sera. An HAI titer of ≥1:40 is regarded as a relative measure of 
sero-protection, with this threshold being predictive of 50% efficacy against influenza 
illness in healthy adults (76). In vaccine studies individuals displaying post-vaccination 
HAI titers of ≥1:40 and ≥4-fold increase over baseline HAI titers are referred to as having 
sero-converted (77).  
 
1.6 Influenza Infection and Vaccination in South Africa 
In South Africa it is estimated that the mean annual number of seasonal 
influenza-associated all respiratory deaths is approximately 450 in children <5 years old 
and 9 000 among individuals ≥5 years old (78,79). Hospital surveillance in South Africa 
from 2009 to 2011 for patients with acute lower respiratory tract infection revealed that the 
influenza detection rate varied by age group, being, 11%, 12%, 9%, 9% and 12% among 
age groups <1 year, 1 – 4 years, 5 – 24 years, 25 – 44 years, 45 – 64 years, and the elderly, 
respectively (80). Influenza viral infections are also responsible for 43% – 67% of 
outpatient visits for influenza-like illness at the peak of the influenza season (81).  
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Individuals infected with human immunodeficiency virus (HIV) have been shown to be at 
greater risk for severe influenza illness (80). In South Africa, before widespread use of 
active antiretroviral therapy (ART) influenza-related excess mortality rate among young 
adults living with HIV/AIDS was estimated at 570 deaths per 100 000 for all-cause deaths 
(82). The high prevalence of underlying medical conditions, including HIV and 
tuberculosis (TB), is a likely contributor to higher influenza-associated mortality in South 
Africa (83,84). 
In South Africa, annual influenza vaccination is recommended as per WHO 
recommendations (28). There are limited number of free doses available in the public sector 
for high-risk groups, including the elderly, pregnant or postpartum (within 2 weeks of 
delivery) women, and persons with underlying medical conditions (such as lung disease 
and HIV infection). Uptake of influenza vaccine remains low in South Africa with less than 
1 million doses distributed in the public and private sectors annually between 2011 and 
2014, despite an estimated 20 million South Africans belonging to high-risk groups (85). 
The number of influenza vaccine doses imported into South Africa is based on the uptake 
of the vaccine during the previous year. Low uptake of vaccine was, however, not thought 
to be due to shortage of vaccine (86,87). Despite the relatively low coverage (3.5%) among 
patients attending general practitioners, vaccination with IIV3 has shown to be effective 
against influenza-associated respiratory illness, most notably in years when good vaccine 
strain match was reported (2010, 2011, 2013) (85). 
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1.7 Influenza Infection and Vaccination in Pregnant Women 
Pregnancy is associated with immunologic alterations and physiologic changes that affect 
the respiratory, cardiovascular, and other organ systems that place women at increased risk 
for infections and/or associated complications, including severe influenza illness. These 
physiological changes include increased heart rate, stroke volume, oxygen consumption, 
and decreased lung capacity (88,89) and possibly death due to influenza infection (90). 
The immune system adapts during pregnancy to tolerate a genetically foreign foetus. 
Although how this adaptation occurs is not fully understood, it includes dampening of 
cell-mediated immunity (CMI) responses while humoral immune responsiveness is 
sustained (91). This immunologic adaptation may contribute to the increased risk of 
complications that are associated with certain infections where CMI plays a critical role in 
viral clearance, including infection with influenza viruses (92). Heightened susceptibility to 
severe influenza illness during pregnancy is particularly evident during periods of influenza 
virus drift and pandemics (14,93,94), which was well documented during the 2009 
influenza A/H1N1 pandemic (95,96).  
A study from Canada reported that pregnant women in their first, second and third trimester 
have a 1.7 (95% confidence interval [CI]: 1.0 – 2.8), 2.1 (95% CI: 1.3 – 3.3), and 
5.1 (95% CI: 3.6 – 7.3) fold greater risk, respectively, of hospitalisation for 
influenza-related acute cardio-respiratory illness than non-pregnant women (97). 
Additionally, influenza illness during pregnancy may increase the risk of premature 
delivery, foetal distress and emergency caesarean sections (91). To prevent possible 
complications of influenza infection in pregnant women, the WHO recommends 
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immunisation with IIV3 at any time during pregnancy (98). Influenza vaccination during 
pregnancy is also beneficial for the young infants born to vaccinated mothers as they gain 
protection against influenza infection by transplacental acquisition of antibody from the 
mother (99). 
To date there have been several immunogenicity studies comparing the effect of influenza 
vaccine in pregnant and non-pregnant women, which have yielded similar sero-conversion 
rates, however with variations in geometric mean titers (GMT) (100-104). The first study 
by Bischoff et al. aimed at comparing humoral immune responses to MF59®-adjuvanted 
monovalent A/H1N1 vaccine in pregnant and non-pregnant women at baseline and three 
weeks post-vaccination. The sero-conversion rate between the two time-points was similar 
between non-pregnant and pregnant women (98% [95% CI: 91 – 100] vs. 95% 
[95% CI: 82 – 99], respectively) (100). Similarly, Christian et al. showed no significant 
difference in sero-conversion rates to seasonal IIV3 in pregnant versus non-pregnant 
women (A/H1N1: 70% [95% CI: 50 – 86] vs. 74% [95% CI: 54 – 89], A/H3N2: 
63% [95% CI: 42 – 81] vs. 59% [95% CI: 39 – 78], B/Yamagata: 63% [95% CI: 42 – 81] 
vs. 74% [95% CI: 54 – 89]), suggesting that pregnancy does not alter humoral responses to 
influenza vaccination (101). These observations are further supported by a study from 
Schlaudecker et al. where the authors reported that the percentage of women who 
sero-converted (and achieved sero-protective titers) one month post-IIV3 were similar 
among pregnant and non-pregnant women, however, the fold increase in HAI titers for 
A/H1N1 tended to be lower in pregnant women –albeit not significant (p=0.09). 
Additionally, HAI GMTs were similar in both groups of women prior to IIV3 
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immunisation, but were significantly reduced in pregnant women to two of the three strains 
included in the vaccine one month post-vaccination (102).  
A clinical randomised controlled trial in Bangladesh from 2004-2005 documented strong 
antibody responses in pregnant women following IIV3 vaccination, with efficient antibody 
transfer to their foetus, and similar percentages of mothers and infants at birth with 
sero-protective titers (104). A more recent randomised placebo-controlled trial in South 
Africa (103) added further support to the immunogenicity of the influenza vaccines in 
pregnant women. The authors reported high proportions of HIV-uninfected women 
post-IIV3 with sero-protective HAI titers (72.5% [95% CI: 64.4 – 79.7] for A/H1N1, 
64.8% [95% CI: 56.8 – 72.6] for A/H3N2 and 92.3% [95% CI: 86.6 – 96.1)] for 
B/Victoria) (103).  
The safety of influenza vaccination during pregnancy has been demonstrated, with no 
indication of adverse effects of influenza vaccines on pregnancy or birth outcomes 
(90,105,106). Several studies have also shown that maternal influenza vaccination is a 
cost-effective intervention in reducing the rates and severity of disease during both seasonal 
influenza epidemics and pandemics (107,108). Nevertheless, vaccine coverage remains low 
in pregnant women, especially in low-middle income countries (109).  
 
1.8 Influenza Infection and Vaccination in HIV-Infected Individuals 
Influenza infection in individuals with HIV is associated with prolonged duration as well as 
increased severity of illness compared to the general population (110-115) and annual 
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vaccination is recommended by many national immunisation guidelines. A temporal 
association between an increase in the number of deaths during the influenza seasons in 
USA cities with a high prevalence of HIV infection, coupled with reports of severe 
influenza-related cases in HIV-infected individuals was the impetus for recommending 
annual influenza vaccination for HIV-infected individuals by the ACIP in the USA (116). A 
subsequent study reported that influenza-attributable hospitalisation rates in HIV-infected 
adults were 48 (95% CI: 16 – 91) per 1 000 persons in 1995 and decreased to 
5 (95% CI: 0.5 – 11) per 1 000 persons per year during 1996 through 1999, after the 
introduction of highly active anti-retroviral treatment (HAART) (117). Although 
influenza-associated hospitalisations have declined in patients with HIV infection following 
the introduction of HAART, the rates remained comparable to rates in other high-risk 
groups for which annual influenza vaccination was recommended (117). A more recent 
study showed that in the USA, prior to the introduction of HAART, influenza related 
mortality rate in adults with acquired immune deficiency syndrome (AIDS) was 150 
(95% CI: 49 – 460) and 208 (95% CI: 74 – 583) times greater than those observed in the 
general population for all-cause deaths and pneumonia and influenza deaths, respectively. 
Although influenza-related mortality in adults with HIV/AIDS dropped 3 – 6-fold after the 
introduction of HAART, it remained higher than the general population (82). 
Although there are case reports of severe influenza illness in HIV-infected adults, in 
general the spectrum and severity of influenza-associated illness have been described to be 
similar between HIV-infected and HIV-uninfected adults (112,118,119). There is, however, 
a trend for HIV-infected adults being more likely to be hospitalised, evaluated in an 
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emergency room or have an illness of ≥14 days than HIV-uninfected adults (21% vs. 0%, 
p=0.06) (118). There also does not appear to be any evidence for clinical, immunological or 
virological progression of HIV during the course of an influenza season (120).  
In South Africa before the introduction of antiretroviral therapy, the incidence of severe 
pneumonia in which influenza virus was identified was 8-fold (95% CI: 5.1 – 12.8) greater 
in HIV-infected compared to HIV-uninfected children aged <2 years (121). Although the 
duration of hospitalisation for influenza-associated pneumonia was similar between 
HIV-infected and HIV-uninfected children (median 4 – 5 days), there was a statistically 
non-significant increased risk of mortality among HIV-infected children (8.0% vs. 
2.2%, p=0.20) (122). Furthermore, differences in the clinical spectrum of 
influenza-associated pneumonia included HIV-infected children remaining at risk of severe 
influenza pneumonia beyond early infancy, which is the major age-risk group in HIV-
uninfected children, as well as there being more severe chest radiographic changes in HIV-
infected children. The latter may be related to impairment of CMI, which is imperative for 
controlling influenza virus replication and is compromised in HIV-infected individuals 
(92,123). 
There is a paucity of data on the burden of influenza illness in HIV-exposed-uninfected 
infants, yet these infants are increasingly being recognised as having greater morbidity and 
mortality than infants born to HIV-uninfected women (124-128). The biological reason 
for this is not yet known, although aberrations of the immune system of 
HIV-exposed-uninfected children have been described (129-131). A possibility for the 
increased morbidity and mortality, primarily experienced during early infancy in 
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HIV-exposed-uninfected children, may relate to impaired transplacental antibody 
acquisition compared to new-borns of HIV-uninfected women. This may consequently 
affect any strategy targeting vaccination of pregnant women in relation to optimising 
protection against the targeted pathogen in the mother as well as their new-born (132).  
Trivalent inactivated influenza vaccines approved for use in immunocompromised patients 
have shown to be immunogenic in an HIV-infected population with normal 
CD4+ T-lymphocyte cell (T-cell) counts (133,134). However, immunogenicity is reduced 
in patients with CD4+ T-cell counts <100/µL (135,136) and as a result might be associated 
with reduced vaccine-induced protection (118). In a randomised, double-blind, 
placebo-controlled trial conducted in Johannesburg, South Africa, evaluating the 
immunogenicity of IIV3 in HIV-infected individuals with CD4+ T-cell counts >100/µL, 
participants had a moderate humoral responses to the three strains in the vaccine, which 
was lower than the normally observed in HIV-uninfected adults (137). Furthermore, the 
authors reported a 75% reduction in influenza-confirmed illness in IIV3-recipients, 
corroborating the 66% risk reduction estimated in a meta-analysis on IIV3 effectiveness in 
HIV-infected adults (138).  
 
1.9 HIV Infection in Human Population and in Pregnant Women 
Globally, there are approximately 35 million people infected with HIV, including 
2.5 million children mainly infected through mother-to-child transmission (139). The 
overwhelming majority of women living with HIV are in resource-poor countries, and most 
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of them are unaware of their status until they become pregnant (140). Infection with HIV is 
associated with a progressive depletion of CD4+ T-cell populations in close association 
with progressive impairment of cellular immunity and increased susceptibility to 
opportunistic infections. The progression of HIV disease in untreated humans can take 
several years and was originally hypothesized to be a consequence of slow, viral-mediated 
CD4+ T-cell destruction. However, massive CD4+ memory T-cell destruction is now 
known to occur in the early stages of infection. In most individuals, this initial destruction 
is countered by CD4+ memory T-cell regeneration that preserves CD4+ T-cell numbers and 
functions above the threshold associated with overt immunodeficiency. This regeneration, 
which occurs in the setting of chronic immune activation and immune dysregulation does 
not, however, restore all functionally important CD4+ T-cell populations and is not stable 
over the long term. Ultimately, CD4+ memory T-cell homeostasis fails and critical effector 
populations decline below the level necessary to prevent opportunistic infections. The onset 
of overt immune deficiency appears to be intimately linked with CD4+ memory T-cell 
dynamics and reflects the complex interplay of direct viral cytopathogenicity and the 
indirect effects of persistent immune activation on CD4+ memory T-cell proliferation, 
differentiation, and survival (377). 
Over the past decade, the number of HIV-infected pregnant and breastfeeding women 
receiving ART has increased dramatically. The expansion of access to and uptake of ART 
during pregnancy has greatly help drive significant global reductions in mother-to-child 
HIV transmission (374). The primary concern regarding HIV in pregnancy is the 
progression of maternal disease and mother-to-child transmission (141). In the absence of 
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antiretroviral treatment, 15 – 45% of HIV infected pregnant women will pass the infection 
to their infants. Five to ten percent of these infants would have been infected in utero, 10 – 
20% from exposure during the peripartum period and 5 – 20% through breastfeeding 
(142,143). However, robust evidence showed that effective ART use can nearly eliminate 
mother-to-child-transmission under ideal conditions with less than 2% transmission 
occurring in resource-limited settings and, since 1995, nearly 1.6 million new HIV 
infections among children have been prevented in South Africa due to the implementation 
of prevention of mother-to-child-transmission programmes (375,376).  
During pregnancy, immune functions are attenuated in both HIV-infected and -uninfected 
women (144,145). Pregnancy does not appear to negatively affect HIV progression or 
survival (146-149), yet dual infection with HIV and malaria has been associated with 
increased risk of maternal, perinatal and early infant deaths (150). Although HIV RNA 
levels seem to remain stable during pregnancy, some studies have shown increased viral 
load in the post-partum period (151). There are conflicting reports on whether maternal 
HIV-infection is associated with increased rates of adverse pregnancy outcomes such as 
preterm birth, growth restriction, pre-eclampsia and gestational diabetes (141,152-157).  
In developed countries, HIV is rarely associated with maternal mortality due to easy access 
to specialised health-care. In contrast HIV infection complications are important causes of 
maternal mortality in Africa (158). In African areas with high prevalence of HIV, the 
infection has become a major cause of maternal mortality (159,160). Numerous reports 
from Southern African countries have reported this trend which includes maternal mortality 
rates that are 5-fold higher in HIV infected women compared with uninfected women 
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(158). Around 24% of pregnancy-related deaths in sub-Saharan Africa may be attributable 
to HIV-infection – higher than any other direct obstetric cause (161).  
Quantifying the contribution of HIV to maternal mortality is challenging. Attributing the 
death of a pregnant or post-partum woman to HIV not only requires knowledge of the 
woman’s HIV status, but also decisions about whether it is indirectly attributable to the 
pregnancy, where the latter is not considered as maternal death. A recent systematic review 
suggested that HIV does not increase the risk of direct obstetric complications, except for 
puerperal sepsis (162). Empirical evidence supporting acceleration of HIV disease 
progression during pregnancy is inconclusive, with some studies on HIV-infected women 
showing that CD4+ T-cell counts decrease faster during pregnancy (163,164), while one 
study found that CD4+ T-cell counts rebound postpartum, matching those of non-pregnant 
women (163).  
Antiretroviral therapy (ART) has proven to be a life-saving intervention in HIV-infection. 
Immune restoration after ART dramatically reduces the incidence and severity of 
opportunistic infections and mortality. In certain settings, immune restoration may be 
erratic, leading to acute inflammatory responses shortly after ART initiation, or incomplete 
with residual inflammation despite chronic treatment, leading to non-infectious morbidity 
and mortality. ART may not always restore the perfect balance of innate and adaptive 
immunity in strategic milieus, predisposing HIV-infected persons to complications of acute 
or chronic inflammation. The best current strategy for fully successful immune restoration 
is early antiretroviral therapy, which can prevent acquired immunodeficiency syndrome 
(AIDS)-associated events, restrict cell subset imbalances and dysfunction, while preserving 
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structural integrity of lymphoid tissues (378). In a setting where ART is readily available, 
little evidence exists attributing pregnancy to the accelerated progression to HIV/AIDS-
defining illnesses, mortality and CD4+ T-cell depletion. In settings without ART 
availability, all the effect estimates were consistent with pregnancy increasing the risk of 
progression to HIV/AIDS-defining illnesses and HIV-related or all-cause mortality (165).  
The main argument supporting the adverse effect of pregnancy on HIV disease progression 
stems from the systemic suppression of CMI during pregnancy, which increases 
susceptibility of infections (92). Infectious diseases such as influenza (166), malaria (167), 
measles (168) and varicella (169) are more severe during pregnancy (170-172). 
 
1.10 Influenza Infection and Vaccination in HIV-Infected Pregnant Women 
To date there is a paucity of data on the immunogenicity of IIV3 in HIV-infected pregnant 
women. In 2011, HIV-infected and HIV-uninfected pregnant women were enrolled in two 
maternal influenza vaccination trials conducted in Soweto, South Africa (103). The safety, 
efficacy and immunogenicity of a single dose IIV3 (administered between 20 and 36 weeks 
gestation) was investigated. One month post-vaccination, a significantly greater number of 
HIV-infected women who received IIV3 achieved HAI titers ≥1:40 compared to the 
placebo group for all vaccine strains (A/H1N1: 42.9% vs. 5.5%, p<0.001, 
A/H3N2: 35.7% vs. 3.6%, p<0.001 and B/Victoria: 40.0% vs. 16.4%, p<0.005). Vaccine 
efficacy among the IIV3 recipients against confirmed influenza illness was 70.6%, similar 
to that reported in a trial of IIV3 in South African HIV-infected individuals conducted in 
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2008 (75.5%) (137). Although IIV3 was shown to be immunogenic in HIV-infected 
pregnant women, higher proportions of HIV-uninfected women achieved HAI titers ≥1:40 
after IIV3 vaccination for A/H1N1 (72.5%), A/H3N2 (64.8%) and B/Victoria (92.3%) with 
a corresponding vaccine efficacy against confirmed influenza infection of 54.4% (103).  
Another small prospective study evaluating the immunogenicity of influenza vaccination in 
pregnant women in the USA also found that HIV-infected compared to HIV-uninfected 
pregnant women had lower GMTs and a lower percentage had a 4-fold titer increase to 
A/H1N1 and A/H3N2 strains. Antibody responses to influenza B were equally low in both 
participant groups (173).  
Abzug et al. evaluating the safety and immunogenicity of a monovalent A/H1N1 vaccine 
containing 30 µg of HA in HIV-infected pregnant women observed no severe 
vaccine-related adverse events among the participants and at baseline 21% had HAI titers 
≥1:40. Sero-protection and sero-response, 21 days post-vaccination, occurred in 73% and 
66% of the women, respectively. Of the women lacking sero-protection at baseline, 66% 
attained sero-protection post-vaccination (174). These results compare favourably with 
another study by El Sahly et al. where a monovalent vaccine with higher dose of HA 
(30 µg) increased sero-protection, sero-response and GMTs in HIV-infected adults, but 
responses were still poorer than in the HIV-uninfected population (175).  
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1.11 Cell-Mediated Immune Responses to Influenza Vaccine 
Protection against influenza infection is mediated by both humoral (antibodies) as well as 
CMI responses (123,176,177). Neutralising antibodies are capable of preventing infection, 
whereas CMI is important in clearing infected cells (178,179). Influenza infection induces a 
cellular response that recruits virus-specific CD4+ and CD8+ T-cells (Figure 1.3). Current 
vaccine approaches mostly rely on the induction of antibodies to the viral surface proteins 
HA and NA that neutralise the virus and interfere with the release of newly replicated virus 
from the host cell (180,181). When the vaccine virus closely matches the infecting virus 
vaccines are effective; however, the virus frequently undergoes mutations and in so doing 
the vaccine becomes less effective. This is further exacerbated when a new subtype of 
influenza virus emerges and there are no cross-reactive antibody sites to HA between the 
vaccine and circulating influenza strains. The LAIV, which in some study was shown to 
confer higher protection against influenza illness in children compared with the IIV3, 
generates robust CMI, but lower humoral response than IIV3 (123), underscoring the 
importance of CMI in protection against influenza disease. Ideally, influenza vaccines 
should induce humoral as well as cellular immunity. Influenza virus-specific cytotoxic 
T-lymphocytes (CTL) have also been shown to limit influenza A virus replication and 
protect against lethal viral challenge (182).  
Activation of CD4+ T-cells occur after recognition of viral epitopes associated with class II 
major histocompatibility complex (MHC) molecules and interaction with co-stimulatory 
molecules on antigen presenting cells (APC) (183). Effective CD4+ T-cell activation is 
reliant on three distinct signals, namely antigen recognition by T-cell receptors, 
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co-stimulation of the CD28 found on the T-cell and APC-produced co-stimulatory 
cytokines. Combined, these signals drive the CD4+ T-cell activation, with the cytokine 
milieu playing a major contributing factor in determining the polarization into type 1 (Th1), 
type 2 (Th2), or type 17 (Th17) helper T-cells subsets (372). Naïve CD4+ T-cells recognise 
the virus and are activated in the draining mediastinal lymph nodes during the first few 
days of infection and differentiate into effectors that migrate to the lung. These naïve 
CD4+ T-cells differentiate Th1 or Th2 cells (184), where Th1 cells produce 
interferon-gamma (IFN-γ) and interleukin-2 (IL-2) and are predominantly involved in 
promoting CTL responses (185), and are essential for the induction of memory 
CD8+ T-cells (186). While classically the functions of CD4+ T-cells is to assist 
CD8+ T-cell effector generation, it was shown that such assistance is not essential for an 
effective primary immune response to influenza (373). Recent studies have however shown 
the importance of CD4+ T-cell during the priming of CD8+ T-cells in the formation of 
CD8+ resident memory T-cells in lung airways during influenza infection (372). The Th2 
cells produce IL-4, IL-5 and IL-13 and promote activation and differentiation of B cells, 
resulting in antibody production (187-189). Following induction by primary influenza 
infection, memory CD4+ T-cells contribute to faster control of subsequent influenza virus 
infections (190). In addition to helper function, CD4+ T-cells also display cytolytic activity 
(191,192) and have been shown to play a role in protective immunity against influenza A 
virus infections in humans (193). 
Naïve CD8+ T-cells are activated following recognition of viral epitopes associated with 
class I MHC molecules on APCs in the draining lymph nodes, and subsequently 
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differentiate into CTLs. The CTLs then migrate to the infection site and once recognised, 
eliminate the cells infected with the influenza virus infected cells (194). Influenza specific 
CTLs are directed against epitopes of the conserved internal viral proteins 
(M1, NP, PA, PB2), displaying a high degree of cross-reactivity of various 
subtypes (195,196). A lytic response, mediated by perforin and granzyme, as a result of 
T-cell receptor activation by specific class I MHC-epitope complex causes apoptosis of the 
infected cell (197,198). Following infection, a collection of antigen-specific central 
memory and effector CD8+ T-cells are created and form a basis for the more rapid recall 
responses upon secondary infection (199-201).  
 
1.12 Tuberculosis, HIV and Influenza 
1.12.1 Tuberculosis Epidemiology 
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a major global health 
problem (202), resulting in ill-health among millions of people annually and is considered 
parallel to HIV and malaria as the leading cause of public health issues (203). An estimated 
9.6 million new TB cases were reported in 2014 with a reported 1.5 million deaths 
attributed to TB, of which 400 000 were among HIV-infected people (202). 
In most developed countries there has been a considerable decline in the incidence of TB 
and its mortality over the last century. This decrease was aided by public health measures 
such as the eradication of tuberculous cattle and mass radiography screening. After 1950, 
the decline in mortality from TB was quickened by the introduction of anti-TB drugs (204). 
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The reduction in the incidence of the disease in developed countries led to changes in the 
ages of the affected patients. In the past TB infection was commonly a disease of the 
young; however, it soon became largely limited to the elderly in these countries (205). The 
situation remains different in low-middle income countries, where TB remains one of the 
most important infectious diseases. Furthermore, the considerable gains that had slowly 
been achieved were reversed because of the emergence of the HIV/AIDS epidemic and 
other factors (206). Recently there has been a resurgence of TB, even in groups where 
HIV/AIDS has yet to make a major impact, possibly due to new levels of urban deprivation 
and the influx of immigrants and refugees from countries with a high incidence of the 
disease (207). In the United Kingdom (UK), for example, immigrants from the Indian 
subcontinent have rates of TB 25-fold higher than the Caucasian population (208). The 
decline in the incidence of TB in the UK slowed towards 1987 and has subsequently 
reversed. The situation is similar in many other developed countries (209).  
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Figure 1.3: The replication cycle of influenza A virus and the adaptive immune response. 
The influenza HA protein mediates the attachment of the virus to the host cell receptors 
(A). Antibodies are generated against the NA protein and in so doing limit the release of the 
virus from the hosts infected cells (B). Antibodies that are generated against the external 
domain of the M2 protein interfere with the virus assembly (C). CD8+ T-cell responses to 
conserved influenza virus components enhance clearance of virally infected cells (D). 
Image from (73).  
 
It is estimated that about one-third of the world’s population (approximately 2 billion 
people) has latent TB, while the prevalence of active disease is approximately 20 million 
worldwide (210). Despite the prevalence of TB, the human response to infection is good. In 
the absence of immunosuppressive disorders such as HIV infection, only 10% of those 
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infected develop clinically evident disease (211). The basis of these patients’ susceptibility 
is not well understood but tobacco smoking is a predisposing cause (212) and genetic 
factors appear to be involved (213). 
 
1.12.2 Tuberculosis Pathogenesis 
Tuberculosis is spread by airborne droplets (1 – 5 µm in diameter) that contain the 
bacterium M. tuberculosis. Due to their small size, aerosol droplets are able to remain 
airborne for minutes and even hours following release by coughing, sneezing or talking 
from individuals with pulmonary or laryngeal TB (Figure 1.4) (214-216). Once the droplets 
are inhaled they can reach the alveoli where they are engulfed by alveolar macrophages. It 
is at this juncture where the fate of the infection is decided (217). In healthy individuals, the 
immune system is capable of successfully controlling infection; however individuals with 
immunocompromised conditions often progress to primary TB infection (218,219). 
Mycobacterium tuberculosis has the ability to inhibit phagosome–lysosome fusion, 
permitting the bacteria to survive within the host’s phagocytes (220,221). Its cell wall is 
enriched with uncommon lipids and glycolipids, creating a hydrophobic layer that functions 
as a shield during antibiotic treatment (222).  
Early host immune defence involves both alveolar type II pneumocytes and airway 
epithelial cells and the cytokines they produce (223-225). An influx of activated T-cells and 
macrophages together with the phagocytised droplets form a structure known as the 
granuloma: the microenvironment that prevents the spread of M. tuberculosis (226). The 
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granuloma causes destruction of the macrophage and thereby leading to necrosis at the site 
of attachment in the alveoli (218). Infected dendritic cells migrating to local lymph nodes 
activate adaptive immune responses in order to halt the bacterium’s growth, as well as 
initiating its entry into the latent phase (227). 
Neutrophils are subsequently attracted to these infection sites by the dying infected 
macrophages, where they exert their killing effect by nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase-dependent mechanisms (228). If these neutrophils fail to clear 
the infection, macrophages internalise the TB and process TB-antigens for T-cells, natural 
killer T-cells and natural killer (NK) cells activation. Dendritic cells are then attracted to 
activated CD4+ and CD8+ T-cells in lymph nodes (229). Activated CD4+ T-cells are the 
most abundant cell type recruited, forming organised aggregates surrounding the granuloma 
(230). Eventually, CD8+ T-cells are recruited and arranged in the periphery of the 
granuloma while B-lymphocytes occur mostly in the central portion of lymphoid 
aggregates. The outer margin of the granuloma consists of collagen and various other 
extracellular matrix components (231).  
Typically, when granuloma contain infection successfully, they will shrink with 
calcification (232), however, in most cases of TB infection, a stand-off is reached between 
the onset of active disease and the abolition of infection, called latent infection. Such 
latency is volatile and can be stimulated by exogenous infections, such as HIV or by 
internal immune incompetency such as malnutrition (233). If such conditions arise, TB may 
multiply rapidly, resulting in granuloma disintegration, reactivated disease and 
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disseminated propagation of the pathogen (234). Both the adaptive and innate host immune 
responses are stimulated during TB infection. 
Figure 1.4: Infection with TB and the associated host immune responses. Image from (234). 
 
1.13 Immune Responses to Tuberculosis Infection 
1.13.1 Adaptive Immune Responses  
Adaptive immune responses involve both humoral and CMI. In most infected individuals, 
CMI develops 2 – 8 weeks after infection (217). TB antigens are presented by class II MHC 
to CD4+ T-cells, resulting in their activation (235). TB antigens then activate CD8+ T-cells 
through the action of class I MHC exposure through a process known as cross-priming 
(236). Once activation of T-cells has occurred, activated effector T-cells decrease rapidly 
with only a fraction developing into memory T-cells (237), where some memory T-cells 
reside in infection sites as effector memory T-cells or migrate to lymph nodes as central 
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memory T-cells. CD4+ Th1 cells are crucial in fighting intracellular pathogens and secrete 
IFN-γ and tumour necrosis factor-α (TNF-α) to activate innate immune cells, and IL-2 to 
activate T-cells (238-240). Concurrently, Th17 produces IL-17 which stimulates 
recruitment of neutrophils and IFN-γ producing CD4+ T-cells, which, in turn, synergise the 
function of Th1 (238). Contrary to the protective immune functions of Th1 and Th17, Th2 
cells activate the secretion of IL-4, IL-5 and IL-10. These ILs have a negative effect by 
inhibiting Th1 responses (241). The class I MHC-restricted CD8+ T-cells also play an 
important role in TB infection control. Activation of CD8+ T-cells eliminates TB directly 
by releasing granulysin or indirectly by lysing macrophages (242). Two distinct pathways 
of cytolysis are granule exocytosis, coordinated by perforin and granzyme A or B, and the 
programmed cell death through Fas aggregation on target cells attracted by FasL (243). 
 
1.13.2 Innate Immune Responses  
At the site of entry, TB is controlled by macrophages and neutrophils, which form part of 
the innate immune response. These macrophages recognise TB by phagocytic receptors 
(244). Phagocytosis of TB by macrophages exposes the pathogen to a harsh acidic and 
superoxidic intracellular environment containing oxygen and nitrogen species (222). 
Tuberculosis is highly evolved and has devised strategies for resisting digestion. It 
counteracts the killing of macrophages by firstly arresting phagosomes at an early stage in 
order to avoid fusion with lysosome (245). Secondly, TB catalaseperoxidase protein and 
alkyl hydroperoxide reductase protein protects it from toxic superoxides (246). Thirdly, 
virulent TB bypasses apoptosis resulting in necrosis and on-going infection of new 
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macrophages (247). Lastly, TB manipulates cytokine profiles of host defence mechanisms 
in order to avoid elimination (248). Dendritic cells recognise TB glycolipids through 
pattern recognition receptors (such as toll-like receptors) and C-type lectin receptors (249). 
Following activation, dendritic cells present the “processed” pathogen components to prime 
naïve T-cells in draining lymph nodes, thereby bridging the innate and adaptive immune 
responses. Neutrophils also play a protective role in innate responses through specific 
production of INF-γ (244,250).  
 
1.14 Impact of HIV Infection on Tuberculosis 
A compromised immune system is associated with an increased risk of TB disease. In 
populations that are affected by TB, HIV infection generally exists. This coexistence is 
influenced by socioeconomic and environmental factors which have the ability to affect TB 
exposure, risk of infection, the progression of disease, potentially exacerbating the problem 
(251). Qualitative and quantitative impairments of CMI responses represent the key 
pathogenic factors responsible for the increased risk of disease (252). HIV infection 
induces progressive CD4+ T-cell depletion and is therefore associated with increased risk 
of TB (253). The risk of TB infection is enhanced in HIV-infected individuals throughout 
the course of HIV infection, even in the early stages of HIV infection when CD4+ T-cell 
counts are moderately high (254,255). Even with the introduction of ART, which assists in 
restoring CD4+ T-cell counts in HIV-infected individuals, does not completely reverse the 
effect of HIV on the risk of TB (256). Co-infection of HIV/TB has been shown to increase 
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the risk of new additional opportunistic infections and mortality compared to HIV-infected 
individuals without TB when CD4+ T-cell counts are the same (257-259).  
It has been proposed that the primary cause for increased TB susceptibility in HIV-infected 
individuals is attributed to immunological disruptions of the TB granuloma (260,261), 
which comprise of an array of organised immunological cells that form in response to 
M. tuberculosis infection (232). The relationship between the granuloma and the bacteria 
however is complicated. Granulomas can prevent dissemination and kill the bacteria, but 
can also allow persistence of TB, even be permissive to its growth (262,263). Several 
studies have indicated that HIV may disrupt this balance by causing granuloma 
disorganisation, killing resident CD4+ T-cells and deregulating normal T-cells and 
macrophage function, which leads to increase in susceptibility to both active and 
disseminated TB disease (260,261,264-268). The mechanism whereby HIV infection 
promotes TB is probably related to the pattern of cytokines produced by T-lymphocyte 
subsets. Th1 lymphocytes produce INF-γ and are central to anti-mycobacterial immune 
defence. However, when peripheral blood lymphocytes from HIV-infected patients with TB 
are exposed to mycobacterium in vitro they produce less INF-γ than lymphocytes from 
HIV-uninfected patients with TB, suggesting that a reduced Th1 response contributes to 
HIV-infected patients’ susceptibility to TB (269). HIV also affects other immune mediating 
cells, including macrophages, and influences cytokine production, which usually prevents 
contracting initial or latent TB infection (270-272). Chemokines induced by TB infection of 
phagocytic cells may also play a role in recruiting target cells susceptible to HIV to the site 
of HIV replication, increasing HIV viral replication at TB infection sites (273).  
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Not surprisingly in view of the interrelationship of HIV and the mycobacterium, the TB 
associated with HIV infection is particularly aggressive, being characterised by widespread 
dissemination throughout the body and a poor host response (274). 
 
1.15 Tuberculosis in South Africa 
South Africa has one of the highest rates of TB (834 per 100 000 population), which is 
driven by the high prevalence of HIV (202). The prevalence of HIV in South Africa, 
although stable over the past few years, is estimated at 12% in the general population and 
24% in women of reproductive age. Based on the annual risk of infection with TB in South 
Africa being approximately 3% – 4%, about three quarters of the adult population would be 
infected by TB by 18 years of age. The risk of progressing to active TB is greatest within 
the first year of being infected by TB, and especially high in children under two years of 
life (43%) compared to a 10% life-time risk in otherwise healthy TB-infected adults (275). 
However, the risk of TB infection progressing to TB disease is heightened in 
immunocompromised adults, including an annual risk of 10% in HIV-infected adults not on 
ART (276). Case fatality ratios of 15% – 35% have been reported in HIV/TB co-infected 
individuals who had not started ART during TB treatment (277).  
Furthermore, TB may occur in the relatively early stages of HIV-infection compared to 
many other opportunistic infections. Although improved access and management of 
HIV-infected individuals with ART has resulted in decline in the burden of TB, these 
individuals remain at a 20-fold greater risk of developing TB compared to the general 
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healthy population (278). Pre-2012, the South African ART treatment guidelines 
recommended initiation of ART for TB-HIV co-infected individuals if they had WHO stage 
4 disease or if they met specific CD4+ T-cell count criteria: <200 cells/mm3 in the 2004 
guidelines, and <350 cells/mm3 in the 2010 guidelines (279,280). In 2012, the South 
African ART program adopted the WHO recommendation that all TB patients begin 
ART (281).  
 
1.16 Tuberculosis-Influenza Co-Infection  
There is currently a paucity of data reporting on the effectiveness of influenza vaccination 
in persons infected with TB (282), with conflicting study-findings involving TB and 
influenza co-infection. An interaction between influenza A and pulmonary TB has been 
suggested with underlying TB considered the identifiable risk factors for severe influenza 
infection (283,284). This is attributed to immunosuppression by TB as well as the 
significant percentages of patients treated for TB that present sequela of the disease, which 
may predispose them to life-threatening influenza A infections (285). In contrast, in a more 
recent study conducted in Thailand, researchers were unable to identify an increased risk of 
severe outcomes or mortality in patients co-infected with TB and seasonal influenza 
compared to those singly infected with TB or influenza (286). This study, however, 
included a small group of co-infected participants and patients with a more chronic 
presentation were not enrolled.  
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De Paus et al. investigated the potential relationship between influenza infection and the 
role it plays in developing active TB, either directly after exposure to TB or through 
reactivation of latent TB infection (287). They observed no correlation between TB cases 
and the sero-prevalence of antibodies against influenza viruses. They did find that antibody 
titers against circulating A/H3N2 influenza virus were slightly enhanced in TB patients 
compared to controls, and highest in cases of advanced TB, suggesting that TB patients 
were recently infected with influenza, before clinical manifestation of the TB. Overall they 
concluded that influenza virus infection is not a major determinant for developing clinically 
relevant TB (287).  
During pandemics, individuals most at risk of influenza infection are HIV-infected, 
TB-infected, and those with chronic hepatitis B or C (24). Increased mortality from TB has 
been observed during influenza pandemics (288,289). In a recent research article, the 
relationship between TB and influenza deaths during the A/H1N1 pandemic of 1918 – 19 
was reported (290). The data showed an association between TB and influenza mortality 
(p=0.09), where none was observed in TB-uninfected controls.  
A study by Redford et al. explored the role of type I interferon signalling pathway on 
mycobacterial growth in TB-influenza co-infected mice. The authors showed that influenza 
A virus infection of mice prior to TB infection significantly impaired long-term 
mycobacterial control in the lungs, leading to a decrease in host survival. In addition, 
co-infection of mice with TB and influenza A virus enhanced mycobacterial growth in the 
lungs through a type I IFN signalling dependent pathway (291). The potential mechanisms 
underlying the detrimental effect of type I IFN during TB infection could include the 
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down-regulation of the IFN-γ receptors (292), important because macrophage activation by 
IFN-γ is essential for eliminating intracellular bacterial infections (291). Another study in 
mice aimed at determining the impact of pulmonary delivery of a recombinant influenza A 
virus on the induction of TB-specific CD4+ and CD8+ T-cell responses and the resultant 
protection against TB infection, found that the induction of pulmonary TB epitope-specific 
CD4+, but not CD8+ T-cells, are essential for protection against acute TB infection in the 
lung (293).  
To date there are limited studies on the role of HIV/TB co-infection in relation to the risk of 
severe influenza infection and vaccine immune responses. Immune responses induced by 
influenza vaccination are generally lower in HIV-infected adults. A meta-analysis 
published in 2006 yielded a pooled relative risk reduction of 66% (95% CI: 36 – 82) for 
influenza vaccine against influenza illness in HIV-infected adults (294). The meta-analysis, 
which involved the only four published studies, concluded that substantial methodological 
shortcomings in the studies provided only limited evidence supporting the efficacy of TIV 
in HIV-infected adults. One study conducted in South Africa looked at the efficacy of IIV3 
in HIV-infected individuals (137). The authors showed an efficacy of IIV3 against 
confirmed influenza illness was 75% (95% CI: 9.2 – 95.6) and a risk difference of 0.2 per 
100 person-weeks in IIV3 recipients. Among the IIV3-recipients, sero-conversion rates for 
A/H1N1, A/H3N2 and B/Victoria were 52.6%, 60.8% and 53.6%, respectively (137). These 
findings were in agreement with the meta-analysis on IIV3 in HIV-infected individuals 
(138).  
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In South Africa, 10% of cases that died during the 2009 A/H1N1 pandemic were 
co-infected with TB (295). In a study that modelled the excess influenza-associated 
mortality to monthly TB and non-TB respiratory deaths, using laboratory-confirmed 
influenza as a covariate, it was found that TB deaths increase each influenza season 
(winter) (84). The mean annual influenza-associated TB mortality rate was 164 per 100 000 
for HIV-infected and 5 per 100 000 for HIV-uninfected individuals, regardless of age. 
Among adults less than 65 years, influenza-associated TB mortality risk was increased 
compared to influenza-associated non-TB respiratory deaths in HIV-infected (relative risk 
[RR]: 5.2 95% CI: 4.6 – 5.9) and HIV-uninfected (RR: 61.0 95% CI: 41.4 – 91.0) 
individuals. Observations included an increased risk of influenza-associated mortality in 
persons with TB compared to non-TB respiratory deaths (84). An additional paper by the 
same group found that in patients hospitalised with confirmed pulmonary TB and having 
symptoms ≥7 days in South Africa, TB-influenza co-infection was associated with 
increased risk of death (RR: 6.1 95% CI: 1.60 – 23.4) compared to TB only, suggesting that 
influenza infection contributes to the mortality rate among patients with TB, particularly 
among patients with longer duration of symptoms (282).  
 
1.17 ELISPOT for Quantifying Cellular Immunity 
The enzyme-linked immunospot (ELISPOT) assay is one of the most common methods for 
measuring antigen-specific T-cells responses. It is a highly quantitative method, with high 
sensitivity to identify a single cell secreting a particular cytokine, can measure a broad 
range of responses, as well as assessing critical cellular immune-related activities (INF-γ 
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secretion and granzyme B release). The ELISPOT assay was first described in 1983 by 
Czerkinsky et al. (296) and differs from older techniques by excluding the need for red 
blood cells and instead, replacing them with a solid plastic surface on which antigens can 
bind. This method has subsequently been accepted as one of the most validated assays for 
human clinical trials (297,298). The spatial separation of antigen-specific cells and the use 
of a visible spot to enumerate the cells allowed for improved quantitation of secreting cells 
(299). Other advantages include a platform that can accommodate multiple cell types 
(T- and B-cells) and secretions (cytokines and granzyme B), can be standardised across 
numerous laboratories, as well as having a lower limit of detection than flow-based 
immunoassays.  
The method involves the isolation of peripheral blood mononuclear cells (PBMC) and the 
addition of a set number of cells to a capture antibody-coated plate, such as anti-INF-γ. 
Cells are then stimulated with a pre-determined concentration of specific antigens which 
causes antigen-specific T-cells to secrete cytokines that are then captured by the antibody 
coating the plate. Following an incubation period (approximately 16 – 24 hours, depending 
on the stimulation), the cells are removed by sequential washing and the remaining bound 
cytokine are then detected using a reagent conjugated to an enzyme label (alkaline 
phosphatase). This enzyme reagent catalysis the colormetric spot formation when in the 
presence of a chromogenic substrate (5-bromo-4-chloro-3’-indolyphosphate p-toluidine 
salt). Enumeration of the number of antigen-specific cells through calculation of the 
number of spot forming units (SFU) allows for quantitative analysis by use of a plate reader 
(196,299).  
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There is currently no general consensus as to the nature and threshold of a significant T-cell 
response needed for immune protection against influenza; however the arbitrary threshold 
of a 2-fold increase in IFN-γ secreting cells is commonly used to compare T-cell responses. 
A study by Forrest et al. using a protection curve detected that the majority of infants and 
young children with ≥100 SFU/106 PBMC were protected against clinical influenza illness 
and thereby possibly establishing a target level of CMI for future influenza vaccine 
development (123). Although the ELSPOT assay has many advantages, limitations are 
evident: phenotyping cells secreting cytokines are difficult to perform in parallel; the 
amount of secreted cytokine per cell cannot be quantified and; the assay has a potential to 
become expensive (299).  
To date numerous studies have been conducted that used the IFN-γ ELISPOT assay to 
determine the immunogenicity of influenza vaccines, with varying results. Most are based 
on CMI responses in healthy adults (179,300-305), while others focused on CMI responses 
in HIV-infected children (306-308), healthy children (123,182), HIV-infected adults 
(309,310) and one study in HIV-infected pregnant women (173). A similar trend was 
observed among the healthy adult participants when comparing pre- to post-vaccination 
IFN-γ SFU against various influenza virus or vaccine strains. Iorio et al. explored the 
cellular immunity induced by the seasonal 2007/2008 influenza vaccine in healthy 
individuals (300). Although the study participant numbers were low, a significant mean 
SFU increase was observed from baseline to post-vaccination for all three vaccine strain, 
with mean fold increases of 3.4 for A/H1N1 (p=0.03), 2.7 for A/H3N2 (p=0.03) and 3.2 for 
B/Yamagata (p=0.03) (300). Similarly, a study by Subbramanian et al. found significant 
 45 
 
increases in pre- to post-vaccination SFU for A/H1N1 present in the 2007/2008 influenza 
vaccine (304). A mean fold increase of 1.6 was observed, with 60% of participants having a 
2-fold increase two weeks post-vaccination (304). Contrary to these findings, two other 
studies investigating the CMI responses to IIV3 among healthy individuals found no 
significant increase in SFU from pre- to post-vaccination (301,305). Notably when the 
authors stratified the participants’ responses based on baseline SFUs they were able to 
show that low-baseline responses significantly correlated to higher post-vaccination 
responses against A/H1N1 and A/H3N2 (r2=0.4, p<0.005 and r2=0.2, p=0.005, 
respectively) (305).  
Two separate studies by Weinberg et al. evaluated the role of CMI responses to IIV3 
vaccine (307) and monovalent pandemic influenza vaccine (308) in HIV-infected children 
and youth, respectively. Both studies confirmed that administration of influenza vaccines to 
HIV-infected children and youth was associated with a temporary decrease in Th1 CMI as 
measured by IFN-γ ELISPOT 28 days post-vaccination. Although not statistically 
significant, Forrest et al. noted an upward trend in median IFN-γ ELISPOT SFUs from 
pre- to 13 days post-IIV3 in healthy young children in response to stimulation with 
A/H1N1, A/H3N2 and B/Yamagata strains (123).  
Agrati et al. explored pandemic vaccination efficiency in boosting vaccine-specific T-cell 
CMI in HIV-infected individuals by comparing T-cell responses pre- and post-vaccination 
by IFN-γ ELISPOT assay. In this study a response was considered when a 2-fold increase 
in IFN-γ producing T-cells from baseline to post-vaccination was achieved (309). 
According to this threshold, a response for A/H1N1 was observed in 68.4% of 
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HIV-infected participants (309). The authors speculate that the reason why their data do not 
strongly match those of previous studies (311,312), might be due to high baseline responses 
to virus antigens, perhaps attributable to previous exposure with seasonal influenza virus.  
Finally, a prospective, open label study conducted in Denver, Colorado from 2005 to 2009, 
evaluated the immunogenicity of IIV3 vaccination in 20 HIV-infected pregnant women 
(173). An increase in IFN-γ secreting T-cells post-vaccination was observed, however the 
investigators were unable to demonstrate significant increases in CMI post-vaccination 
which was speculated to be due to the general immunosuppression associated with 
pregnancy.  
 
1.18 Study Rationale 
A main objective of this project was to measure CMI responses to IIV3 vaccination in 
population groups who are at high-risk of influenza morbidity, and to compare those 
responses to that of the more general population. Additionally, the use of ELISPOT and 
HAI assays performed in this study will provide novel information on the influenza-specific 
CMI and HAI responses in TB infected and HIV/TB co-infected individuals in the era of 
highly active antiretroviral therapy (HAART).  
This thesis is divided into two different sections. In the first part of the thesis, we report on 
the cell-mediated immune responses to trivalent inactivated influenza vaccine in 
HIV-infected pregnant, HIV-infected non-pregnant, HIV-uninfected pregnant and 
HIV-uninfected non-pregnant women. In the second part, we report on cell-mediated and 
humoral immune responses to the trivalent inactivated influenza vaccine among HIV/TB 
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co-infected, HIV-infected TB-uninfected, HIV-uninfected TB-infected and HIV-uninfected 
TB-uninfected adults. By assessing blood samples taken prior to and one month post 
influenza vaccination, we were able to compare and evaluate the effect of influenza 
vaccination among high-risk individuals in a South African setting. 
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2.0 Methods 
2.1 Study Objectives 
The objectives of this thesis were to measure and compare cell-mediated immune (CMI) 
responses to a single-dose of trivalent inactivated influenza vaccine (IIV3) in: 
1. HIV-infected pregnant (HIV+Preg) and non-pregnant women (HIV+NP);  
2. HIV-uninfected pregnant (HIV-Preg) and non-pregnant women (HIV-NP);  
3. HIV-infected (HIV+), TB-uninfected and HIV-uninfected (HIV-) TB-uninfected 
adults.  
As well as to measure and compare humoral immune responses to single-dose of IIV3 in: 
1. HIV-infected adults with TB (HIV+TB+) and HIV-infected adults without 
TB (HIV+TB-); 
2. HIV-uninfected adults with TB (HIV-TB+) and HIV-uninfected adults without 
TB (HIV-TB-).  
 
2.2 Ethical Consideration 
This project consists of four different studies that were individually submitted and approved 
by the Human Research Ethics Committee (HREC) on Human Subjects at the University of 
the Witwatersrand. The studies were also registered in ClinicalTrials.gov. For all studies 
signed informed consent for collection of blood and clinical and demographic information 
was obtained from the study participants. The studies are: 1) “Immunogenicity and safety 
of different dosing schedules of trivalent influenza vaccine in HIV-infected pregnant 
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women: a randomised controlled trial” HREC number 111114 and ClinicalTrials.gov 
NCT01527825 (HIV+Preg women); 2) “Immunogenicity and safety of trivalent influenza 
vaccine in non-pregnant HIV- infected women: An open label trial” HREC number 130101 
and ClinicalTrials.gov NCT01812980 (HIV+NP women); 3) “Immunogenicity and safety 
of trivalent influenza vaccine in pregnant and non-pregnant HIV- uninfected women: An 
open label trial” HREC 121109 and ClinicalTrials.gov NCT01816464 (HIV-Preg and 
HIV-NP women); 4) “Effect of HIV and/or active tuberculosis on the humoral and cell 
mediated immune responses to unadjuvanted trivalent sub-unit influenza vaccine in adults” 
HREC number 130102 and ClinicalTrials.gov NCT018111823.  
 
2.3 Study Population 
These studies were undertaken in Soweto, Johannesburg, South Africa, an urban 
low-income community of 1.4 million Black-African inhabitants of a diversity of ethnic 
backgrounds, including Zulu, Xhosa and Sotho heritage. The majority of households have 
access to running water; however, at least 25% live in informal settlements and use fossil 
fuels for heating and cooking. The community is greatly affected by HIV infection, with 
<5 year old mortality rate of 39 per 1 000 live births in 2014 (313).  
There are 23 primary health care (PHC) clinics in the Soweto region and during the period 
the studies described in this thesis took place there was a single public hospital (Chris 
Hani-Baragwanath Academic Hospital (CHBAH)) which was the sole referral hospital for 
all PHC clinics. Prior to delivery, approximately 99% of pregnant women attend one of 
 50 
 
PHC antenatal clinics or have antenatal care at CHBAH. Each year, approximately 29 000 
births occur in the community, including 23 000 at CHBAH. 
All HIV testing was undertaken by trained counsellors with pre- and post-test counselling 
provided as part of standard of care. The prevalence of HIV infection in women attending 
antenatal clinics in Soweto has stabilised at 30% since 2005, and the vertical transmission 
of HIV have declined from 5.9% in 2008 to 1.5% in 2012 due to more effective 
mother-to-child preventive antiretroviral treatment regimens strategies (314). Mothers and 
children infected with HIV were provided with free highly active anti-retroviral treatment 
(HAART) through established HIV clinics in accordance with national guidelines for 
treatment. In addition to HAART where indicated, pregnant HIV-infected women were 
provided with zidovudine (300 mg) from 14 weeks of gestational age and a single dose of 
nevirapine (200 mg), three-hourly zidovudine (300 mg) during labour and single dose 
(500 mg) Truvada post-partum and newborns were provided with nevirapine within 72 hour 
of birth and one week of zidovudine. Ninety-five percent of mothers agreed to HIV testing 
during pregnancy. Evaluation of CD4+ T-lymphocyte cell (T-cell) count was undertaken on 
all individuals diagnosed as being HIV sero-positive.  
In addition to free access to antiretroviral treatment for all HIV-infected individuals (based 
on national treatment guidelines of 2013); all HIV-infected individuals also had access to 
cotrimoxazole prophylaxis. Criteria for initiating cotrimoxazole prophylaxis in 
HIV-infected individuals included a CD4+ T-cell count <200 cells/µL.  
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2.4 Selection and Enrolment of Participants 
For the purpose of this thesis the different trials were divided into two main groups: i) 
Maternal influenza (MatFlu) studies, which included HIV-infected pregnant women (study 
1A), HIV-infected non-pregnant women (study 1B) and HIV-uninfected pregnant and 
non-pregnant women (study 1C); ii) HIV/TB influenza study (study 2) that included 
4 arms, HIV-infected with TB (HIV+TB+), HIV-infected without TB (HIV+TB-), 
HIV-uninfected with TB (HIV-TB+) and HIV-uninfected without TB(HIV-TB-). 
Study 1A, HIV-infected pregnant (HIV+Preg) women were enrolled at Lillian Ngoyi, 
Mofolo, Diepkloof, Michael Maponya and Chiawelo clinics in Soweto, which offered 
antenatal services to HIV-infected women. 
Study 1B, HIV-infected non-pregnant (HIV+NP) women were identified from screening 
logs and databases within our research unit (Respiratory and Meningeal Pathogens 
Research Unit (RMPRU) located at CHBAH). This included adult female past-participants 
and mothers of infant participants on other non-influenza clinical trials conducted by 
RMPRU in the past 2 years. Confirmation of HIV status was obtained at least 12 weeks 
prior to enrolment. 
Study 1C, HIV-uninfected pregnant (HIV-Preg) and non-pregnant (HIV-NP) women were 
enrolled at CHBAH or one of the community antenatal clinics in Soweto. Enrolment into 
the study occurred following screening of mothers for HIV, which was undertaken as part 
of a routine, well-functioning existing prevention of mother-to-child transmission 
(PMTCT) program.  
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Study 2, IIV3_HIV_TB: Study participants aged 18 to 55 years were identified at HIV and 
TB clinics at CHBAH and the adjacent Lilian-Ngoyi Clinic. Individuals with HIV infection 
received routine HIV-related treatment at the clinic in accordance with the South African 
national treatment guidelines. 
 
2.5 Inclusion and Exclusion Criteria 
2.5.1 Study 1 (MatFlu) 
Inclusion criteria: All women 
(i) Women age ≥18 to <39 years of age.  
(ii) Able to understand and comply with planned study procedures. 
(iii) Provide written informed consent prior to initiation of study.  
Exclusion criteria: All women 
(i) Receipt of IIV3, other than through the study, during the current and previous two 
influenza seasons, documented by medical history or record.  
(ii) Receipt of any live licensed vaccine ≤28 days or any other vaccine (except for 
tetanus toxoid vaccine) ≤14 days prior to study-vaccine.  
(iii) Receipt of a non-licensed agent (vaccine, drug, biologic, device, blood product, or 
medication) ≤28 days prior to vaccination in this study, unless study approval is 
obtained. 
(iv) Any significant (in the opinion of the site investigator) acute illness and/or oral 
temperature ≥ 38C ≤24 hours prior to study entry.  
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(v) Use of anti-cancer systemic chemotherapy or radiation therapy ≤48 weeks of study 
enrolment, or had immunosuppression as a result of an underlying illness or 
treatment. 
(vi) Long term use of glucocorticoids, including oral or parenteral prednisone 
≥20 mg/day or equivalent for more than 2 consecutive weeks (or 2 weeks total) 
≤12 weeks of study entry, or high-dose inhaled steroids (>800 mcg/day of 
beclomethasone dipropionate or equivalent) ≤12 weeks before study entry (nasal 
and topical steroids are allowed). 
(vii) Receipt of immunoglobulin or other blood products (with exception of Rho D 
immune globulin) ≤12 weeks prior to enrolment in this study or was scheduled to 
receive immunoglobulin or other blood products. 
(viii) Receipt of IL2, IFN, GM-CSF or other immune mediators ≤12 weeks before 
enrolment. 
(ix) Uncontrolled major psychiatric disorder. 
(x) History of a severe adverse reaction to previous IIV3.  
(xi) Any condition that would, in the opinion of the site investigator, place the subject at 
an unacceptable risk of injury or render the subject unable to meet the requirements 
of the protocol. 
In addition to the above criteria: 
Inclusion criteria for study 1A include: 
(i) Gestational age ≥12 weeks to <36 weeks documented by the approximate date of 
the last menstrual period and corroborated by physical/ sonargraphic exam. 
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(ii) Documented to be HIV-infected on two assays prior to study-enrolment. 
Exclusion criteria for study 1A include: 
(i) Features of WHO clinical category 3 or 4 of AIDS at the time of enrolment. 
(ii) Receipt of corticosteroids for preterm labour ≤14 days before study entry. 
(iii) Pregnancy complications (during the current pregnancy) such as pre-term labour, 
hypertension (blood pressure (BP) >140/90 in the presence of proteinuria or 
BP >150/100, with or without proteinuria or where on antihypertensive medication) 
and pre-eclampsia.  
Inclusion criteria for study 1B include: 
(i) Documented to be HIV-infected on one assay used in the PMTCT/other program 
undertaken within 12 weeks of study enrolment.  
(ii) Not pregnant at time of enrolment (confirmed by urine testing). If pregnant in past 
year, participant had to be at least 6 months post-delivery at time of enrolment.  
Inclusion criteria for study 1C include: 
(i) Documented to be HIV-uninfected on one assay used in the PMTCT/other program.  
(ii) Gestational age ≥20 weeks to <36 weeks documented by the approximate date of 
the last menstrual period and corroborated by physical exam and sonar report if 
available (pregnant women only). 
Exclusion criteria for study 1C include (pregnant women only): 
(i) Receipt of corticosteroids for preterm labour ≤14 days before study entry. 
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(ii) Pregnancy complications (during the current pregnancy) such as pre-term labour, 
hypertension (BP >140/90 in the presence of proteinuria or BP >150/100, with or 
without proteinuria or where on antihypertensive medication) or pre-eclampsia.  
 
2.5.2 Study 2 (IIV3_HIV_TB) 
Inclusion criteria: 
(i) CD4+ T-cell count of >100/µL within the previous 3 months (applicable to 
HIV-infected participants) prior to enrolment.  
(ii) Ability to attend the clinic for immunogenicity and illness visits. 
(iii) Having a microbiologic confirmed diagnosis of tuberculosis (TB) (defined as the 
presence of acid-fast-bacilli (AFB) on a sputum smear or other specimen and/or a 
positive culture for M. tuberculosis) within the previous 120 days (applicable to 
TB-infected participants) prior to enrolment.  
(iv) Aged 18 to 55 years. 
Exclusion criteria:  
(i) Any contraindication to influenza vaccine. 
(ii) Any contraindication to intramuscular injections. 
(iii) Any existing grade 3 or grade 4 laboratory or clinical toxicity as per DAIDS 
toxicity tables. 
(iv) Systemic steroid treatment for >21 days within the past 30 days prior to 
enrolment.  
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(v) Pregnancy at time of enrolment (confirmed by urine testing on all women of 
childbearing age). 
 
2.6 Participant Enrolment 
Study 1A, HIV+Preg: Women evaluated in this group were enrolled into a randomised 
controlled trial that evaluated the immunogenicity and safety of different dosing schedules 
of trivalent influenza vaccine in HIV-infected pregnant women. For this thesis only women 
who received a single-dose IIV3 (15 µg HA/strain) were evaluated. A total of 200 women 
between 12 and 36 weeks gestational age were enrolled prior to the onset of the anticipated 
influenza season in 2013 and received a single-dose IIV3 (figure 2.1A). Blood samples 
(20 – 26 ml) were collected from each participant pre-vaccination (baseline) and 28 – 35 
days post-vaccination (post-IIV3).  
Study 1B, HIV+NP: A prospective, open labelled trial evaluating the immunogenicity of a 
single-dose IIV3 (15 µg HA/strain) in HIV+NP women. A total of 100 HIV+Preg women 
were vaccinated prior to the onset of the anticipated influenza season in 2013 (figure 2.1B). 
Blood samples (20 – 26 ml) were collected from each participant pre-vaccination (baseline) 
and 28 – 35 days post-vaccination (post-IIV3).  
Study 1C, HIV-Preg/NP: A prospective, open labelled trial evaluating the immunogenicity 
of a single-dose IIV3 (15 µg HA/strain) in HIV-Preg and HIV-NP women. A total of 
75 HIV-Preg and 75 HIV-NP women were vaccinated with IIV3 post-influenza season in 
2013 (figure 2.2). Blood samples (20 – 26 ml) were collected from each participant 
pre-vaccination (baseline) and 28 – 35 days post-vaccination (post-IIV3).  
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Figure 2.1: Participant enrolment design for MatFlu study 1A and 1B. HIV-infected women 
were enrolled for the maternal influenza study assessing immunogenicity of IIV3 in 200 
HIV-infected pregnant (HIV+Preg) (A) and 100 HIV-infected non-pregnant (HIV+NP) (B) 
women. PBMC were isolated at baseline and at post-IIV3.  
 
 
 
Figure 2.2: Participant enrolment design for MatFlu study 1C. 75 HIV-uninfected pregnant 
(HIV-Preg) (A) and 75 HIV-uninfected non-pregnant (HIV-NP) (B) women were enrolled 
for the maternal influenza study assessing immunogenicity of IIV3. PBMC were isolated at 
baseline and post-IIV3. 
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Study 2, IIV3_HIV_TB: A prospective, open labelled four arm trial evaluating the 
immunogenicity of a single-dose IIV3 (15 µg HA/strain) in: 80 HIV+TB+; 80 HIV+TB-; 
80 HIV-TB-; and 61 HIV-TB+ individuals, enrolled between March and September 2014 
(figure 2.3). Blood samples (20 – 26 ml) were collected from each participant 
pre-vaccination (baseline) and 28 – 35 days post-vaccination (post-IIV3).  
 
Figure 2.3: Participant enrolment design for IIV3_HIV_TB study. Participants PBMC and 
plasma were isolated at baseline and post-IIV3 in order to assess the immunogenicity of 
IIV3.  
 
2.7 Study Vaccines 
The IIV3 formulation recommended by World Health Organisation (WHO) for use in the 
Southern Hemisphere in 2013 was used in Study 1 (MatFlu) and its composition 
was: A/California/7/2009 NYMC X-179A (A/California/7/2009 [H1N1]pdm09-like); 
A/Victoria/361/2011 IVR-165 (A/Victoria/361/2011 [H3N2]–like); and 
B/Hubei-Wujiagang/158/2009 NYMC BX-39 (B/Wisconsin/1/2010-like, Yamagata 
lineage) (15 µg of each strain specific HA per 0.5 mL dose).  
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The IIV3 formulation recommended by WHO for use in the Southern Hemisphere in 2014 
was used in Study 2 (IIV3_HIV_TB) and the composition was: A/California/7/2009 
NYMC X-179A (A/California/7/2009 [H1N1]pdm09 - like); A/Texas/50/2012 NYMC 
X-223A (A/Texas/50/2012 [H3N2] – like); B/Massachusetts/2/2012 NYMC BX-51B 
(B/Massachusetts/2/2012-like, Yamagata lineage) (15 µg of each strain specific HA per 
0.5 mL dose). Vaccination was administered aseptically by a study-doctor or study-nurse in 
the deltoid muscle. 
 
2.8 Antigens and Viruses 
The viruses for the interferon gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) 
assays and antigens for the hemagglutination inhibition (HAI) assays were obtained from 
the National Institute for Communicable Diseases (NICD), South Africa and the Centre of 
Disease Control and Prevention (CDC), USA, respectively, and were stored in appropriate 
environments as described by the manufacturer. 
Viruses used for the ELISPOT assay were attenuated influenza viruses corresponding to the 
vaccine strains for 2013: A/California/7/2009 NYMC X-179A (A/California/7/2009 
[H1N1]pdm09-like); A/Victoria/361/2011 IVR-165 (A/Victoria/361/2011 [H3N2]–like); 
and B/Hubei-Wujiagang/158/2009 NYMC BX-39 (B/Wisconsin/1/2010-like) 
and for 2014: A/California/7/2009 NYMC X-179A (A/California/7/2009 
[H1N1]pdm09 -like); A/Texas/50/2012 NYMC X-223A (A/Texas/50/2012 [H3N2] – like); 
B/Massachusetts/2/2012 NYMC BX-51B (B/Massachusetts/2/2012-like). For simplicity, 
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the following abbreviations are used throughout this thesis for both 2013 and 2014 strains: 
A/H1N1, A/H3N2 and B/Yamagata.  
Original HA titers for vaccine strains A/H1N1, A/H3N2 and B/Yamagata were 1:64, 
1:2048 and 1:64 for the 2013 IIV3 and 1:64, 1:32 and 1:128 for the 2014 IIV3, 
respectively.  
 
2.9 Optimisation of ELISPOT Experimental Conditions 
To ensure that results obtained from the study were comparable with other published 
ELISPOT studies, a number of quality control measures were assessed. Several 
experiments were undertaken prior to study sample analyses to establish validity of the 
ELISPOT experiments as described below (315).  
 
2.9.1 Optimisation of Virus Concentration for IFN-γ ELISPOT Assay 
In order to optimise the viruses concentration for valid ELISPOT assay quantification, each 
of the strains for both 2013 and 2014 vaccines were diluted 1:2, 1:4, 1:8, 1:16, 1:32, 1:64 
and 1:128 in ELISPOT assay media (EAM) and tested against PBMC known to respond 
well to the influenza vaccine strains in both years. The results are shown in figure 2.4A and 
2.4B. In this optimisation experiment, it was necessary to choose dilutions that would yield 
both easily distinguishable spot forming units (SFU). Based on these criteria, the following 
dilutions were chosen for optimal enumeration: for strains present in the 2013 vaccine 1:16, 
1:32 and 1:32 and for the 2014 vaccine strains 1:16, 1:8 and 1:16 for A/H1N1, A/H3N2 and 
B/Yamagata, respectively.  
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Figure 2.4: Effect of varying the virus concentrations on ELISPOT assay response for 
strains present in the 2013 (A) and 2014 (B) Southern Hemisphere IIV3. PBMC known to 
elicit responses to the three strains (2013: -▲-A/H1N1, -▲-A/H3N2 and -▲- B/Yamagata; 
2014: -■- A/H1N1, -■- A/H3N2 and -■- B/Yamagata) was used to determine the optimum 
antigen concentration. Antigens were diluted in EAM and assayed in duplicate, and 
normalised by subtracting background (-▲-) SFU. Results expressed as SFU/106 PBMC. 
Error bars indicate standard deviation from the mean.  
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2.9.2 Optimisation of Cell Concentration for IFN-γ ELISPOT Assay 
In previous studies cell concentrations or absolute number of cells per well used in 
ELISPOT assays vary depending on the antigens and cell populations tested, but are 
generally between 2 x 105 – 5 x 105 cells/well. Critical features to have in consideration 
when determining the amount of cells to use include: having sufficient cells to detect a 
response, not having excess cells (which may result in non-specificity) and cell viability 
and the number of cells available for the assay. For this project cell availability was a 
concern and it was necessary to determine the optimal concentration of cells per well to 
accommodate this threshold. According to the manufacturer’s (BD® Biosciences) 
recommendations, a cell concentration of 5 x 103 – 10 x 106 cells per well was suggested, 
due to this wide range, optimisation was essential for clear, accurate quantification. 
Agrati et al. optimised their ELISPOT cell concentrations at 3 x 105 cells/well (309), and 
using this as a reference point we used dilutions ranging from 1 x 105 – 6 x 105 cells/well, 
with the already established antigen concentrations stated earlier. This was further 
supported by Hobeika et al. and Britten et al. who stated that cell numbers of 
1 x 105 - 4 x 105 cells/well yielded the highest ratio of spots to cells number (316,317). 
Isolation of PBMC from two participants known to respond well to the influenza virus 
stains were frozen (as described below) and stored until required for cell concentration 
optimisation determination. It was clear from figure 2.5A and 2.5B that responses were 
detected at all concentrations for both participants PBMC. Overall responses were lower 
when 1 x 105 cells/well was used, raising concern regarding sensitivity. However, 
sensitivity was greater at higher cell concentrations with a clear plateau effect noticeable at 
4 x 105 cells/well, with the acceptable specificity concentration chosen at 3 x 105 cells/well. 
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Additionally, using this concentration ensured that there were sufficient cells from all 
participants to perform the ELISPOT assay in duplicates.  
 
Figure 2.5: Effect of varying cell concentrations on ELISPOT assay responses for 
participant 1 (A) and participant 2 (B). Each participant cells were exposed to the three 
strains present in the 2013 Southern Hemisphere IIV3 at antigen dilutions of 1:16, 1:32 and 
1:32 for A/H1N1, A/H3N2 and B/Yamagata, respectively. Antigens and varying cell 
concentrations were diluted in EAM and assayed in duplicate, and normalised by 
subtracting background SFU. Results expressed as SFU/106 PBMC. Error bars indicate 
standard deviation from the mean. 
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2.10 Peripheral Blood Mononuclear Cells and Plasma Isolation 
Blood samples from participants were centrifuged at 400 g for 10 minutes within 
4 - 6 hours of collection. In a laminar flow hood plasma was removed from the top layer 
using a sterile pipette. Plasma was aliquoted into cryopreservation tubes and stored 
at -80°C. The remaining blood cells were then diluted with PBS (1:1) and resuspended 
thoroughly in 50 mL conical polypropylene (Falcon, BD™ Biosciences) tubes. In separate 
50 mL conical polypropylene tubes containing 15 mL of Ficoll-Hypaque (Sigma) 30 mL of 
diluted blood was overlayed; tubes were then centrifuged at 900 g for 15 minutes without 
centrifuge brakes to preserve the different layers formed. The PBMC were then removed 
from the overlay and transferred to new sterile conical polypropylene tubes. Peripheral 
blood mononuclear cells were washed twice with PBS and centrifuged at 400 g for 
10 minutes with centrifuge brakes. The supernatant was aspirated and the pellet diluted into 
1 mL of PBS, 10 µL of the suspension were transferred to a U-bottom plate well and mixed 
with 10 µL of 0.4% w/v Trypan Blue. The PBMC-Trypan Blue suspension (10 µL) was 
transferred to a Counting Slide (Bio-Rad) and viability and cell concentration determined 
using a TC20™ Automated Cell Counter (Bio-Rad). Once the cells were counted, the 
polypropylene tubes were filled with PBS and centrifuged. The final pellet was 
resuspended in Freezing Media (10% DMSO, HI-FBS) at a concentration of 
1 x 106 cells/mL and aliquoted in 1 mL aliquots in cryovials, that were subsequently placed 
in a Mr Frosty Control Freeze container (Nalgene) for overnight slow freezing at -70°C 
before being transferred to liquid nitrogen.  
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2.11 Thawing of Peripheral Blood Mononuclear Cells 
Prior to thawing, Thawing Media (TM) was warmed to 37°C and 1 mL was added to 15 
mL sterile polypropylene (Falcon, BD™ Biosciences) tubes. One 15 mL sterile centrifuge 
tube was required for each PBMC cryovial. Each 15 mL tube was labelled accordingly. The 
PBMC cryovials were removed from the liquid nitrogen (4 vials at a time) and placed in a 
37°C water bath for approximately 1 – 3 minutes, or until a small amount of ice remained. 
Once thawed the vials were briefly submerged in 70% alcohol to sterilise the exterior 
surface before opening. The cells were then transferred drop-wise to the 15 mL tube 
containing pre-warmed TM. After 1 minute, 500 µL of pre-warmed TM were added 
drop-wise to the PBMC. After waiting 1 minute, another 1 mL of TM was added to the 
PBMC. After 1 minute an additional 1 mL of TM was added to the cell suspension 
(repeated three times). The initial process was completed by filling the 15 mL tube with 
TM to a total of 10 ml. The cell suspension was then mixed by gently inverting the tubes 
and subsequently centrifuged at 400 g for 10 minutes. The supernatant was removed and 
the pellet resuspended in 10 mL TM and centrifuged at 400 g for 10 minutes. The 
supernatant was once again removed and the pellet resuspended in 10 mL of TM and 
thoroughly mixed. Ten microliters of the suspension were transferred to a U-bottom plate 
well and mixed with 10 µL of 0.4% w/v Trypan Blue. The PBMC-Trypan Blue suspension 
(10 µL) was transferred to a Counting Slide and viability and cell concentration determined 
using the TC20™ Automated Cell Counter. The cells were then centrifuged at 400 g for 
10 minutes, supernatant removed, and diluted into TM to a final concentration of 
1 x 106 cells/mL for overnight resting in a 37°C, 5% CO2 humidified incubator.  
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2.12 IFN-γ ELISPOT Assay 
The IFN-γ ELISPOT assay was performed according to the manufacturer’s instruction 
(BD™ Biosciences). Each test and control wells were performed in duplicate and both 
visits (baseline and post-IIV3) from the same participant were performed on the same plate 
on the same day to minimise variability.  
Day one consisted of pre-treatment of ELSPOT plates and involved coating the wells 
overnight at 4°C with 100 µL diluted (1:200, final concentration of 5 µg/ml) Capture 
Antibody (Purified NA/LE Anti-human IFN-γ) in PBS.  
On day two the plates were washed once with 100 µL EAM, and subsequently “blocked” 
with 200 µL EAM for 2 hours at room temperature (RT). All media were brought to RT 
while positive control, negative control and viruses were prepared during this 2 hour 
waiting step as follows:  
The positive control used in this assay was reconstituted phytohemagglutinin (PHA-M, 
lyophilised, Sigma-Aldrich) in deionised water (dH2O) to a final concentration of 5 µg/ml, 
EAM was used to detect spontaneous cytokine production (background, negative control) 
and viruses were diluted in EAM according to their optimum concentration as determined 
earlier.  
The PBMC that were incubated overnight were centrifuged at 400 g for 10 minutes and the 
pellet was diluted into 1 mL of EAM in preparation for cell count and viability testing as 
done earlier. The PBMC were centrifuged at 400 g for 10 minutes and diluted in EAM to a 
final working concentration of 3 x 105 PBMC/well.  
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The “Blocking” solution was discarded and 50 µL of positive control (PHA-M), negative 
control (EAM) and diluted viruses (A/H1N1, A/H3N2 and B/Yamagata) were added to 
their respective wells (Figure 2.6). Participant PBMC suspensions were added (50 µL/well) 
at a concentration of 3 x 105 cells/well to a final volume of 100 µL/well. Special care was 
taken at all steps not to accidently damage the membrane at the bottom of the well. Prior to 
incubation the lid was replaced to avoid any potential evaporation, and the ELISPOT plate 
(including the lid) placed bottom side down onto a piece of aluminium foil approximately 
10 x 15 cm in size. This was tucked around the base of the plate and remained in-situ until 
after removal of the chromogen solution. The purpose of using aluminium foil was to 
reduce the possibility of “edge-effect”, whereby the external wells of the 96-well plate 
produce unreliable results (318). The ELISPOT plate was placed in a 37°C, 5% CO2 
humidified incubator overnight (20 – 24 hours). Care was taken to ensure that the plates 
were not disturbed while incubating overnight in order to avoid “smudging”, which may 
occur when agitating IFN-γ-producing cells.  
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Figure 2.6: Representative ELISPOT assay plate layout used for all assays performed. 
Duplicates were performed for all participants, with PBMC from baseline and post-IIV3 
assayed on the same plate to avoid potential variability. A total of four participants were 
assayed in one plate, each with a positive control (PHA-M), negative control (EAM) and 
test wells containing A/H1N1, A/H3N2 and B/Yamagata, respectively.  
 
On day three the cell suspensions were discarded and plates washed (5 times) by manually 
filling each well with 200 µL PBS for 1 minute per wash. After each washing step, the 
plates were inverted and blotted against clean paper towels. During the final wash the 
Detection Antibody (Biotinylated anti-human IFN-γ) was diluted (1:250, final 
concentration 2 µg/ml) in Dilution Buffer (1 x PBS, 10% HI-FBS) according to the 
manufacturer’s instructions. One hundred microliters of the Detection Antibody were added 
to each well and incubated at RT for 2 hours. The Detection Antibody solution was then 
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discarded and the wells washed (3 times) with PBS. Again, during the final washing step 
the Enzyme Conjugate (Streptavidin-HRP) was prepared according to the manufacturer’s 
instruction by diluting (1:100) in Dilution Buffer and 100 µL were added to each well and 
incubated at RT for 1 hour. The Enzyme Conjugate was discarded and the plate wells 
washed (6 times) as previously described. The Final Substrate Solution (a stabilised 
chromogen mixture of 3-amino-9-ethylcarbazole [AEC] and 2.2% N,N-dimethylformamide 
[DMF], prepared according to the manufacturer’s instructions) was added to each well (100 
µL). Spot formation was monitored for a maximum of 5 minutes before discarding the 
Final Substrate Solution and the reaction stopped by rinsing the plate wells with dH20. The 
aluminium foil and flexible plastic casing were removed, the bottom of the plate wiped 
thoroughly with clean paper towels and the plate was left to air-dry completely at RT for at 
least 2 hours. The plates were then ready for spot enumeration.  
 
2.13 Reading of ELISPOT Plates 
Plates were sent in batches of 50 to Cellular Technology Ltd. (CTL-Europe GmbH, Bonn, 
Germany) for scanning and images were available for digital download and analysed using 
ImmunoSpot® Professional Software (version 5.3.21). Specific parameters for optimal spot 
counting analyses were as follows: Normalise Counts of Mask: Off; Sensitivity: 180; 
Minimum Spot Size: 0.0020 mm2; Maximum Spot Size: 0.1032 mm2; Spot Separation: 3.0; 
Diffuseness: Normal; Background Balance: On (80); Edge Compensation Level: 1.0. 
Uniform settings were used for all experiments to enable comparisons. Each well was 
manually reviewed using the software’s built-in quality control functions to exclude the 
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possibility of aberrant counting. Absolute numbers of spots were counted and the results 
exported to Excel (Microsoft) for further analysis. Results were reported as geometric mean 
(GM) SFU/106 PBMC and only experiments that fulfilled the following criteria at both 
baseline and post-IIV3 were included in the final analysis:  
i) test wells (prior to subtraction of background SFUs) had to exhibit SFUs ≥2 
times the background; 
ii) test wells had to have ≥10 SFU/106 PBMC following subtraction of background 
SFUs and 
iii) in the background wells SFUs needed to be <50 SFU/106 PBMC. 
Furthermore a significant response to vaccination was defined as ≥2-fold increase in 
SFUs from baseline to post-IIV3. 
 
2.14 Hemagglutination Inhibition Assay 
The following steps were undertaken sequentially for each assay day: 
Receptor destroying enzyme treatment and inactivation 
Plasma collected from participants were thawed at RT and diluted (1:4) with receptor 
destroying enzyme (RDE) and incubated at 37°C overnight. The RDE was then inactivated 
by incubating the samples at 56°C for 30 minutes. 
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Turkey red blood cell standardisation 
Standardisation of turkey red blood cells (TRBC) was performed during the 30 minute wait 
for the inactivation incubation of the plasma-RDE mix. In a biosafety hood, 5 mL of TRBC 
were added to a 15 mL conical polypropylene (Falcon, BD™ Biosciences) tube and filled 
with sterile PBS to a final volume of 15 ml. The mixture was inverted, centrifuged at 
2 200 rpm for 10 minutes and the supernatant was discarded. The TRBC at the bottom of 
the tube were washed three times by adding PBS, centrifuging and aspirating the 
supernatant, finally 25 µL of washed TRBC were added to 300 µL of sterile saline solution. 
The plasma-RDE mix following inactivation was added to the 325 µL of this 0.5% TRBC, 
mixed thoroughly and then incubated at 4°C for 1 hour in order to remove non-specific 
agglutinins. The mixture was inverted every 15 minutes during this 1 hour incubation. The 
mixture was then centrifuged at 900 g for 5 minutes and the supernatant removed and 
aliquoted into 96-well U bottom plates (2 wells per plasma sample).  
Detection of non-specific agglutinins 
In a separate 96-well V-bottom plate (figure 2.7), 25 µL PBS were added to wells 
B through H for every plasma specimen tested, with an additional column for the cell 
control (A12). Treated plasma (50 µL) was added to each well in row A (1 – 11), while 
50 µL PBS was added to well A12 as the TRBC control. Serial dilutions of plasma were 
prepared by transferring and mixing 25 µL from row A through H, discarding the 
remaining 25 µL after well H, each well then received 25 µL PBS and the contents mixed 
gently by agitating the plate. Packed TRBC (50 µL) was diluted in 10 mL PBS for a 0.5% 
TRBC suspension. Fifty microliters of this suspension was added to every well, mixed, and 
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incubated for 30 minutes at RT. Successful results were indicated by the presence of a 
“halo” of TRBCs in each well.  
 
Figure 2.7: Plate layout for detection of non-specific agglutination. See text for details. 
 
Haemagglutinin titration of antigens 
Antigens that corresponded with the strains present in the 2014 Southern Hemisphere IIV3 
were received from the CDC, USA. The antigens were diluted 1:10 in PBS. In a 96-well 
V-bottom plate (figure 2.8), 50 µL PBS was added to each well, excluding row 1. Titration 
was performed in duplicates for each strain. Diluted antigen (100 µL) was added to row 
1 and serially diluted by transferring 50 µL from well to well, making sure to mix the 
antigens before each dilution series. After row 10 the remaining 50 µL were discarded. To 
each well, 50µL 0.5% TRBC was added and gently mixed by agitating the plate and finally 
the plate was left to incubate for 30 minutes at RT. The highest dilution of antigens that 
causes complete agglutination was regarded as the titration endpoint. This endpoint dilution 
was divided by 8, and the stock antigen diluted to this value (e.g. if the highest dilution was 
320, then 320/8=40, hence the stock antigen was diluted 1:40). 
1 2 3 4 5 6 7 8 9 10 11 12
A RBC 
CTL
B
C
D
E
F
G
H
50l Serum
25l PBS
Plas a
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Figure 2.8: Plate layout for haemagglutinin titration of antigens. See text for details.  
 
Back titration 
In a new 96-well V-bottom plate, 50 µL PBS was added to wells 2 – 12 for each column 
used in triplicate. Then, 100 µL of the standardised antigen was added to wells 1 for each 
lettered column. A serial dilution was performed by transferring 50 µL of standardised 
antigen from wells 1 through to wells 10. Wells 11 and 12 were used as controls. Fifty 
microliters of 0.5% TRBC was added to each well and mixed by gently agitating the plate, 
and incubated for 30 minutes at RT. Results were considered positive if the back titration 
agreed with the original titration. 
 
 
H G F E D C B A Dilution 
of Ag
1 10
2 20
3 40
4 80
5 160
6 320
O 7 640
O 8 1280
O 9 2560
O 10 5120
O 11 RBC
O 12 RBC
50l PBS
100l Ag
HA titer is 
320
320/8=40
Dilute 
stock Ag 
1:40
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HAI Assay 
25 µL PBS was added to wells B through H of each numbered column in a new 96-well 
V-bottom plate (figure 2.9). Plasma samples (50 µL) were added to the appropriate wells in 
each row A. The control in well A12 received 50 µL PBS. Serial dilutions were made by 
transferring 25 µL from wells in row A to successive well and mixed thoroughly after each 
dilution step. The remaining 25 µL was discarded after row H. Standardised antigen was 
added (25 µL) to each well, except the control well in column 12. The contents were mixed 
by gently agitating the plate, and incubated for 15 minutes at RT. Following incubation, 
50 µL of 0.5% TRBC were added to each well, mixed by agitating the plate and incubated 
for 30 minutes at RT. The results were recorded where the HAI titer was the last dilution of 
plasma that completely inhibited hemagglutination (as shown by a “halo” of TRBC). For 
plasma that displayed no “halos”, a result of <1:10 was recorded, whereas complete 
agglutination of all dilutions, a recorded result of ≥1:1280 is given.  
 
Figure 2.9: Plate layout for HAI assay. See text for details.  
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A O O 10
B O O 20
C O O 40
D O O 80
E O 160
F O 320
G O 640
H O 1280
RBC no Ag25 µl Ag with 1 – 10 sera and 11 control
HA titer =8025l PBS
50l Serum
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2.15 Statistical Analysis 
To compare demographic data between study groups (HIV+Preg vs. HIV+NP; HIV-Preg 
vs. HIV-NP; HIV+TB+ vs. HIV+TB-; and HIV-TB+ vs. HIV-TB- participants) the 
unpaired Student’s t-test was used. Chi-square or Fisher’s exact test was used to compare 
categorical data. Only participants that adhered to the inclusion criteria were analysed. 
Demographic data was described using means, medians, interquartile ranges and standard 
deviations, where applicable. Where applicable, p-values were adjusted using logistic and 
linear regression analyses for significant differences in baseline characteristics among study 
groups and are stated only if a change in significance resulted.  
All data obtained from the HAI and ELISPOT assays were logarithmic converted to 
approach a normal distribution, and presented as geometric means with 95% confidence 
interval (CI). When comparing baseline to post-IIV3, a paired Students t-test was used for 
analysis within the same groups. When comparing across groups in terms of baseline and 
post-IIV3, the unpaired Student’s t-test was used. Where relevant, the Chi-square or 
Fisher’s exact test was used to compare categorical data reported as percentages.  
For ELISPOT assay data, a fold increase index was used after stratification by low-baseline 
and high-baseline responses where SFU/106 PBMC from post-IIV3 was divided by the 
baseline SFU/106 PBMC and analysed using the non-parametric Mann-Whitney test.  
Haemagglutinin inhibition antibody titers ≥1:40 were considered evidence of immunity 
(sero-protection). Participants with a ≥4-fold increase from baseline to post-IIV3 and with 
post-IIV3 titers ≥1:40 were considered as sero-converters. For each virus strain, the 
 76 
 
proportion of participants in each group with HAI antibody titers ≥1:40 were compared 
between baseline and post-IIV3 using the Chi-square or Fisher’s exact test where 
applicable. HAI titers <1:10 were considered undetectable and were assigned a value of 
1:5.  
Differences were considered significant when the p-value was less than 0.05. All statistical 
analysis was performed using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA) 
and STATA 13 (Stata Corp., College Station, TX).  
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3.0 Cell-Mediated Immune Responses to Trivalent Inactivated Influenza Vaccine 
in HIV-Infected Pregnant and Non-Pregnant Women 
3.1 Results 
3.1.1 Baseline Characteristics 
In 2013 we enrolled 200 pregnant (HIV+Preg) and 100 non-pregnant (HIV+NP) women 
infected with HIV; all participants received one single dose (15 g per antigen) of trivalent 
inactivated influenza vaccine (IIV3). Enrolment of the pregnant cohort started 11 February 
and was concluded 5 June and non-pregnant women were enrolled from 2 May to 4 June. 
At enrolment the pregnant women were slightly younger (mean age 29.4 years [standard 
deviation (SD): 5.2]) than non-pregnant women (mean age 31.3 years [SD: 4.7], p=0.003), 
and a higher percentage of HIV+Preg women were receiving antiretroviral therapy (ART) 
compared to HIV+NP women (98.0% vs. 59.0%, p<0.001).  Overall the median 
CD4+ T-cell count was 428 cells/mm3 and the median HIV viral load was 5780 copies/ml 
and this was similar between the two cohorts. At enrolment the mean gestational age 
among HIV+Preg women was 23.5 weeks (Table 3.1). The mean time between the two 
study visits was 29.4 days. All 200 of the HIV+Preg women and all 100 of the HIV+NP 
women completed the study.  
A comparison of baseline characteristics between HIV-infected pregnant and non-pregnant 
women who qualified for enzyme-linked immunospot (ELISPOT) analysis is available in 
Table 3.2 (see section 3.1.2). Ninety HIV+Preg and 71 HIV+NP women qualified for 
ELISPOT analysis (Table 3.5). As in the overall cohort HIV+Preg women were slightly 
younger than HIV+NP women (31.5 years [SD: 4.7] vs. 29.2 [SD: 5.0], p=0.003) and 
higher percentages of HIV+Preg women compared to HIV+NP women were on ART and 
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had CD4+ T-cell counts greater than 350 cells/mm3. The mean time between visits was 
29.2 days (SD: 4.3). 
Table 3.3 and Table 3.4 show the comparison for baseline demographic characteristics 
between women who qualified for ELISPOT analysis and those that did not in the 
HIV+Preg and HIV+NP cohorts, respectively. No significant differences in baseline 
characteristics were recorded, except for CD4+ T-cell count among HIV+Preg women, 
where those analysed by ELISPOT assay had a higher median count compared to women 
not analysed (470 cells/mm3 vs. 361 cell/mm3, p=0.007).  
Table 3.1: Baseline characteristics of the HIV-infected pregnant and non-pregnant women enrolled into 
the study in 2013  
Overall HIV+Preg HIV+NP P value 
Total no. women 300 200 100 - 
Mean days between visits 29.4 ± 5.1 29.0 ± 4.4 30.0 ± 6.2 0.11 
Ethnicity (%)     
Black 300 (100) 200 (100) 100 (100)  
Mean age - years 30.0 ± 5.1 29.4 ± 5.2 31.3 ± 4.7 0.003 
Median BMI 
(IQR) 
29.4 
(25.1 – 34.0) 
29.2 
(25.1 – 33.7) 
29.5 
(25.1 – 34.6) 0.77 
Mean gestational age - weeks - 23.5 ± 5.5 - - 
No. Primigravid (%) - 31 (15.5) - - 
Median gravidity 
(IQR) - 
2.0 
(2.0 – 3.0) - - 
Median parity 
(IQR) - 
1.0 
(1.0 – 2.0) - - 
No. on ART (%) 255 (85.0) 196 (98.0) 59 (59.0) <0.001 
Median CD4+ T-cell count cells/mm3 
(IQR) 
428 
(281 – 602) 
403 
(265 – 578) 
488 
(344 – 636) 0.13 
No. CD4+ T-cell>350 cell/mm3 (%) 155 (51.7) 115 (57.5) 40 (40.0) 0.05 
Median HIV viral load copies/ml 
(IQR) 
5780  
(504 – 36398) 
6030 
(652 – 35614) 
381 
(94 – 40298) 0.48 
No. HIV viral load<40 copies/ml 27 (9.0) 21 (10.5) 6 (6.0) 0.28 
Plus-minus values are means ± standard deviation 
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
ART, antiretroviral therapy 
HIV, human immunodeficiency virus 
No., number of 
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Table 3.2: Baseline characteristics of the HIV-infected pregnant and non-pregnant women analysed by 
ELISPOT assay 
Overall HIV+Preg HIV+NP P value 
Total no. women 157 90 71 - 
Mean days between visits 29.2 ± 4.3 28.9 ± 3.3 29.6 ± 5.3 0.33 
Ethnicity (%)     
Black 161 (100) 90 (100) 71 (100) 1.0 
Mean age - years 30.2 ± 5.0 29.2 ± 5.0 31.5 ± 4.7 0.003 
Median BMI 
(IQR) 
29.7 
(25.7 – 33.9) 
29.6 
(25.3 – 33.0) 
30.0 
(26.0 – 34.1) 0.31 
Mean gestational age - weeks - 23.8 ± 5.5 - - 
No. Primigravid (%) - 16 (17.8) - - 
Median gravidity 
(IQR) - 
2.0 
(2.0 – 3.0) - - 
Median parity 
(IQR) - 
1.0 
(1.0 – 2.0) - - 
No. on ART (%) 132 (82.0) 89 (98.9) 43 (60.1) <0.001 
Median CD4+ T-cell count cells/mm3 
(IQR) 
478 
(312 – 683) 
470 
(293 – 688) 
501 
(357 – 690) 0.56 
No. CD4+ T-cell>350 cell/mm3 (%) 100 (62.2) 58 (64.4) 29 (40.8) 0.004 
Median HIV viral load copies/ml 
(IQR) 
9205 
(485 – 39339) 
9475 
(830 – 35864) 
343 
(78 – 49241) 0.48 
No. HIV viral load<40 copies/ml 13 (8.3) 7 (7.8) 6 (8.5) 1.00 
Plus-minus values are means ± standard deviation.  
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
ART, antiretroviral therapy 
HIV, human immunodeficiency virus 
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Table 3.3: Baseline characteristics of the HIV-infected pregnant analysed and not analysed  
Overall Analysed NA P value 
Total no. women 200 90 110 - 
Mean days between visits 29.0 ± 4.4 28.9 ± 3.3 29.1 ± 5.2 0.80 
Ethnicity (%)     
Black 200 (100) 90 (100) 110 (100) 1.0 
Mean age - years 29.4 ± 5.2 29.2 ± 5.0 29.6 ± 5.4 0.54 
Median BMI 
(IQR) 
29.2 
(25.1 – 33.7) 
29.6 
(25.3 – 33.0) 
28.8 
(25.1 – 34.0) 0.84 
Mean gestational age - weeks 23.5 ± 5.5 23.8 ± 5.5 23.4 ± 5.5 0.62 
No. Primigravid (%) 31 (15.5) 16 (17.8) 15 (13.6) 0.44 
Median gravidity 
(IQR) 
2.0 
(2.0 – 3.0) 
2.0 
(2.0 – 3.0) 
2.0 
(2.0 – 3.0) 0.63 
Median parity 
(IQR) 
1.0 
(1.0 – 2.0) 
1.0 
(1.0 – 2.0) 
1.0 
(1.0 – 2.0) 0.28 
No. on ART (%) 196 (98.0) 89 (98.9) 107 (97.3) 0.63 
Median CD4+ T-cell count cells/mm3 
(IQR) 
403 
(265 – 578) 
470 
(293 – 688) 
361 
(241 – 536) 0.007 
No. CD4+ T-cell>350 cell/mm3 (%) 115 (57.5) 58 (64.4) 57 (51.8) 0.12 
Median HIV viral load copies/ml 
(IQR) 
6030 
(652 – 35614) 
9475 
(830 – 35864) 
5088 
(595 – 35708) 0.52 
No. HIV viral load<40 copies/ml 21 (10.5) 7 (7.8) 14 (12.3) 0.35 
Plus-minus values are means ± standard deviation.  
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
ART, antiretroviral therapy 
HIV, human immunodeficiency virus 
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Table 3.4: Baseline characteristics of the HIV-infected non-pregnant analysed vs. not analysed  
Overall Analysed NA P value 
Total no. women 100 71 29 - 
Mean days between visits 30.0 ± 6.2 29.6 ± 5.3 31.1 ± 8.0 0.28 
Ethnicity (%)     
Black 100 (100) 71 (100) 29 (100) 1.00 
Mean age - years 31.3 ± 4.7 31.5 ± 4.7 30.6 ± 4.6 0.40 
Median BMI 
(IQR) 
29.5 
(25.1 – 34.6) 
30.0 
(26.0 – 34.1) 
27.4 
(22.2 – 34.9) 0.11 
No. on ART (%) 59 (59.0) 43 (60.1) 16 (55.2) 0.13 
Median CD4+ T-cell count cells/mm3 
(IQR) 
478 
(329 – 618) 
501 
(357 – 690) 
404 
(296 – 608) 0.24 
No. CD4+ T-cell>350 cell/mm3 (%) 59 (59.0) 29 (40.8) 17 (58.6) 1.00 
Median HIV viral load copies/ml 
(IQR) 
381 
(94 – 40298) 
343 
(78 – 49241) 
506 
(168 – 13650) 0.37 
No. HIV viral load<40 copies/ml 6 (6) 6 (8.5) 0 (0) - 
Plus-minus values are means ± standard deviation.  
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
ART, antiretroviral therapy 
HIV, human immunodeficiency virus 
 
 
3.1.2 Participants Selection 
Participants with HIV-infection enrolled in the MatFlu study in 2013 (HIV+Preg, N=200; 
HIV+NP, N=100) were immunised with a single dose of IIV3 to determine cell-mediated 
immune (CMI) responses one month post-vaccination (post-IIV3), assessed by detecting 
interferon-gamma (IFN-γ) production using ELISPOT assay. Blood was collected on the 
day of vaccination, just prior to IIV3 administration (baseline) and one month post-IIV3. 
For participants to qualify for EISPOT analyses they needed to have peripheral blood 
mononuclear cells (PBMC) viability ≥75% and have sufficient number of cells to perform 
duplicate assays (319) at both baseline and post-vaccination visits. Table 3.5 shows the 
total numbers of participants in each study cohort that qualified for IFN-γ ELISPOT 
assessment based on these criteria. Within these subpopulations, only experiments that 
fulfilled the following criteria at both baseline and post-IIV3 were included in the final 
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analysis: i) test wells, prior to subtraction of background spot forming units (SFU) had to 
exhibit SFU ≥2 times the background, ii) test wells had to have ≥10 SFU/106 PBMC 
following subtraction of background SFU and iii) in the background wells SFU needed to 
be <50 SFU/106 PBMC. Furthermore a significant response to vaccination was defined as 
≥2-fold increase in SFU from baseline to post-IIV3.  
Table 3.5: Number of participants eligible for IFN-γ ELISPOT analysis 
No. participants (%); [95% CI] 
Study Group 
Study 
Population 
Viability  
≥75%‡ A/H1N1§ A/H3N2 § B/Yamagata§ 
HIV+Preg 200 90 (45.0);  [38.0 – 52.2] 
55 (61.1); 
[50.3 – 71.2] 
50 (55.6); 
[44.7 – 66.0] 
44 (48.9); 
[38.2 – 59.7] 
HIV+NP 100 71 (71.0);  [61.1 – 79.6] 
46 (64.8); 
[52.5 – 75.8] 
25 (35.2); 
[24.2 – 47.5] 
23 (32.4); 
[21.8 – 44.5] 
‡ Participants with ≥75% viable live-cells prior to ELISPOT assay 
§ Participants displaying test wells SFU ≥2 times background SFU, ≥10 SFU/106 PBMC after background subtraction, and background 
wells with <50 SFU/106 PBMC per vaccine strain 
 
 
3.1.3 Cell-Mediated Immune Responses  
Baseline 
Of the 200 HIV+Preg and the 100 HIV+NP women enrolled, 90 (45.0%) and 71 (71.1%), 
respectively, had cell viability ≥75% at both study visits and qualified for the analyses of 
CMI responses to IIV3 as measured by IFN-γ ELISPOT assay (Table 3.5). At baseline, 
geometric mean (GM) SFU/106 PBMC were higher in HIV+Preg compared to HIV+NP 
women for A/H3N2 (56.7 [95% confidence interval (CI): 41.7 – 77.2] vs. 32.3 [95% CI: 
22.7 – 45.7], p=0.03) and a similar trend was observed for the other two vaccine strains 
(Figure 3.1A and Table 3.6). We further performed age and ART adjusted analysis for each 
vaccine strain and similar results to the non-adjusted analysis were obtained (for A/H1N1 
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adjusted: p=0.61 and B/Yamagata adjusted: p=0.25 while the adjusted p-value for A/H3N2 
remained significant p=0.003). 
 
Figure 3.1: Cell-mediated immune responses to the different influenza vaccine strains in 
HIV-infected pregnant (HIV+Preg) and HIV-infected non-pregnant (HIV+NP) women at 
baseline (A) and post-vaccination (B). The number of A/H1N1, A/H3N2, and B/Yamagata 
specific IFN-γ producing peripheral blood mononuclear cells was evaluated at baseline and 
post-vaccination by ELISPOT assay. Statistical analysis was performed using unpaired 
t-test. *p=0.03. 
 
Post-vaccination 
An increase in GM SFU/106 PBMC from baseline to post-IIV3 was observed in both study 
groups for all three vaccine strains. In HIV+Preg women the increase was, however, 
statistically significant only for A/H1N1 (52.0 [95% CI: 39.6 – 68.2] at baseline vs. 68.5 
[95% CI: 51.5 – 91.0] at post-IIV3, p=0.03) and in HIV+NP women for A/H1N1 (44.6 
[95% CI: 33.3 – 59.8] at baseline vs. 66.4 [95% CI: 49.7 – 88.6] at post-IIV3, p=0.005) and 
B/Yamagata (30.9 [95% CI: 21.5 – 44.4] at baseline vs. 49.8 [95% CI: 33.7 – 73.5] at 
post-IIV3, p=0.02) (Figure 3.2, Table 3.6).  
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Post-IIV3 both HIV+Preg and HIV+NP women achieved similar GM SFU/106 PBMC for 
the three vaccine strains in both unadjusted and adjusted analyses (Figure 3.1B, Table 3.6). 
Similarly, HIV+Preg compared to HIV+NP women had similar GM fold-increases from 
baseline to post-IIV3 all for strains (Table 3.6). Cell-mediated immune responses to IIV3, 
as defined by ≥2-fold increase in GM SFU/106 PBMC from baseline to post-IIV3, were 
achieved by 27.3%, 22.0%, and 25.0% of HIV+Preg women for A/H3N2, A/H1N1 and 
B/Yamagata, respectively; the corresponding proportions of HIV+NP women were 34.8%, 
32.0% and 34.8%, respectively (Table 3.6). The difference in the percentage of women who 
had a ≥2-fold increase in GM SFU/106 PBMC between the study groups was not 
significant. Among HIV+NP women, significantly higher GM SFU/106 PBMC were 
achieved among those on ART compared to those not on ART at post-vaccination for 
A/H1N1 only (83.8 [95% CI: 57.8 – 121.6] vs. 46.1 [295 – 72.3], p = 0.03).   
 
 
Figure 3.2: Cell-mediated immune responses to the different influenza vaccine strains at 
baseline and post-IIV3 in HIV-infected pregnant (HIV+Preg) (A) and HIV-infected 
non-pregnant (HIV+NP) (B) women measured by IFN-γ ELISPOT assay. Statistical 
analysis was performed using paired t-test. *p<0.05; **p=0.005.  
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Table 3.6: Cell-mediated immune responses to inactivated influenza vaccine in HIV-infected women  
Measure A/H1N1 A/H3N2 B/Yamagata 
 HIV+Preg HIV+NP P Value§ HIV+Preg HIV+NP P Value§ HIV+Preg HIV+NP P Value§ 
No. participants 55 46  50 25  44 23  
GM SFU/106 PBMC  
[95% CI] 
 Baseline 52.0 
[39.6 – 68.2] 
44.6 
[33.3 – 59.8] 
0.45/ 
0.61 
56.7  
[41.7 – 77.2] 
32.3  
[22.7 – 45.7] 
0.03/ 
0.003 
40.5  
[29.1 – 56.3] 
30.9  
[21.5 – 44.4] 
0.30/ 
0.25 
 Post-IIV3 68.5  
[51.5 – 91.0] 
66.4  
[49.7 – 88.6] 
0.88/ 
0.55 
69.0  
[50.7 – 93.9] 
47.2  
[30.7 – 72.4] 
0.15/ 
0.24 
43.6  
[31.9 – 59.5] 
49.8  
[33.7 – 73.5] 
0.60/ 
0.81 
 P value‡ 0.03 0.005  0.15 0.12  0.64 0.02  
GM factor increase    
[95% CI] 
1.3  
[1.0 – 1.7] 
1.5  
[1.1 – 2.0] 
0.52 1.2 
[0.9 – 1.6] 
1.5 
[0.9 – 2.4] 
0.79 1.1  
[0.8 – 1.5] 
1.6  
[1.1 – 2.4] 
0.16 
No. ≥2 fold increase  
post-IIV3 (%); [95% CI] 
15 (27.3);  
[16.1 – 41.0] 
16 (34.8);  
[21.4 – 50.3] 
0.52/ 
0.05 
11 (22.0);  
[11.5 – 36.0] 
8 (32.0);  
[14.9 – 53.5] 
0.40/ 
0.07 
11 (25.0);  
[13.2 – 40.3] 
8 (34.8);  
[16.4 – 57.3] 
0.58/ 
0.45 
‡, P values comparing baseline vs. post-IIV3 within groups 
§, Unadjusted/adjusted P values comparing HIV+Preg vs. HIV+NP 
§, Adjusted P values for age, number of women on ART and number of women with CD4 T-cell count >350 cells/mm3 
IIV3, trivalent inactivated influenza vaccine 
SFU, spot forming units 
GM, geometric mean with 95% confidence interval 
No., number of 
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3.1.4 Trivalent Inactivated Influenza Vaccine-Specific Cell Mediated Immunity 
According to Baseline Responses  
Similar to studies by Agrati et al. (309), He et al. (320), Co et al. (305) and Subbramanian 
et al. (304), we investigated if CMI responses to IIV3 were associated with baseline 
SFU/106 PBMC. Participants were stratified evenly according to their individual baseline 
SFU/106 PBMC into low-baseline (LB) and high-baseline (HB) responses (304). In 
situations where an uneven number of participants occur, the remainder participant was 
allocated to the high-baseline response group. In the HIV+Preg group for A/H1N1, 
A/H3N2 and B/Yamagata 27, 25 and 22 women were classified as LB and 28, 25 and 22 as 
HB, for each strain respectively. In the HIV+NP group the corresponding numbers were 23, 
12 and 11 for LB and 23, 13 and 12 for HB, respectively.  
Lower baseline GM SFU/106 PBMC were associated with significant increase post-IIV3 
response in HIV+Preg and HIV+NP women for the three vaccine strains (p<0.05 for all 
comparisons, Figure 3.3A and 3.3B). Interestingly, higher baseline GM SFU/106 PBMC 
were associated with non-significant decreased responses post-IIV3 for all three vaccine 
strains in HIV+Preg women (Figure 3.3C and 3.3D).  
Although statistically significant increases from baseline to post-IIV3 were observed in the 
LB sub-groups, LB participants did not reach the levels of GM SFU/106 PBMC observed in 
HB participants post-IIV3 (Table 3.7). 
Receipt of IIV3 resulted in significantly higher GM SFU/106 PBMC fold-increases in the 
LB compared to the HB sub-group in HIV+Preg women for A/H1N1 (LB: 2.0 [95% CI: 1.4 
– 2.8] vs. HB: 0.9 [95% CI: 0.7 – 1.2], p=<0.001), A/H3N2 (LB: 1.7 [95% CI: 1.2 – 2.4] 
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vs. HB: 0.9 [95% CI: 0.6 – 1.3], p=0.009) and B/Yamagata (LB: 1.7 [95% CI: 1.2 – 2.3] vs. 
HB: 0.7 [95% CI: 0.4 – 1.1], p=0.003) (Figure 3.4A). In HIV+NP women GM SFU/106 
PBMC fold-increases were significantly higher in the LB compared to the HB sub-group 
for A/H1N1 (LB: 2.4 [95% CI: 1.7 – 3.4] vs. HB: 0.9 [95% CI: 0.7 – 1.3], p<0.001) and for 
A/H3N2 (LB: 2.4 [95% CI: 1.2 – 4.7] vs. HB: 0.9 [95% CI: 0.5 – 1.9], p=0.02), with a 
similar non-significant trend observed for B/Yamagata (Figure 3.4B). 
 
Figure 3.3: Cell-mediated immune responses post-IIV3 according to the numbers of IFN-γ 
secreting peripheral blood mononuclear cells at baseline. HIV+Preg (A and C) and 
HIV+NP (B and D) women were stratified evenly according to their individual baseline 
responses into low-baseline (LB) response (A and B) and high-baseline (HB) response (C 
and D). Statistical analysis performed using paired t-test. *p<0.05; **p<0.01; ***p<0.001.  
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Table 3.7: Cell-mediated immune responses to inactivated influenza vaccine in HIV-infected women stratified according to low- and high-baseline 
responses  
  A/H1N1 A/H3N2 B/Yamagata Group  N Baseline Post-IIV3 P value§ N Baseline Post-IIV3 P value§ N Baseline Post-IIV3 P value§ 
HIV+Preg 
LB 27 
23.8  
[20.1 – 28.2] 
47.1  
[32.6 – 68.1] <0.001 25 
24.0 
[20.0 – 28.8] 
41.1 
[28.8 – 58.7] 0.003 22 
17.4 
[14.8 – 20.4] 
28.7 
[21.1 – 39.0] 0.007 
HB 28 
110 
[80.6 – 151] 
98.1 
[65.3 – 147] 0.44 25 
134 
[95.9 – 187] 
116 
[74.9 – 178] 0.45 22 
94.4 
[63.7 – 140] 
66.1 
[39.8 – 110] 0.14 
P Value‡   <0.001 0.008   <0.001 <0.001   <0.001 0.006  
HIV+NP 
LB 23 
20.2 
[17.2 – 23.8] 
49.0 
[33.0 – 72.7] <0.001 12 
15.5 
[13.2 – 18.1] 
37.3 
[20.9 – 66.8] 0.01 11 
15.8 
[13.1 – 19.1] 
35.7 
[20.7 – 61.4] 0.02 
HB 23 
98.6 
[72.2 – 135] 
90.0 
[59.6 – 136] 0.58 13 
63.5 
[44.9 – 89.9] 
58.6 
[29.5 – 116] 0.80 12 
57.2 
[37.0 – 88.6] 
67.6 
[38.2 – 120] 0.49 
P Value‡   <0.001 0.03   <0.001 0.29   <0.001 0.09  All values are expressed as geometric mean SFU/ 106 PBMC with 95% confidence interval 
§, P values comparing baseline vs. post-IIV3 within groups 
‡, P values comparing LB vs. HB participants 
LB, low-baseline response  
HB, high-baseline response  
N, number of participants within each group  
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Figure 3.4: Geometric mean SFU/106 PBMC fold-increase from baseline (t0) to post-IIV3 
(t1) for the vaccine strains A/H1N1, A/H3N2 and B/Yamagata stratified by low-baseline 
(LB) and high-baseline (HB) responses in HIV-infected pregnant (HIV+Preg) (A) and 
HIV-infected non-pregnant (HIV+NP) (B) women. Values are presented as a logarithmic 
(log2) scale of fold-increases and vertical bars represent minimum and maximum values. 
Statistical analysis was performed using the Mann-Whitney test. *p=0.02; **p<0.01; 
***p<0.001. 
 
3.2 Discussion 
In this unique study we compared CMI responses to IIV3 using IFN-γ ELISPOT assay in 
HIV-infected pregnant and non-pregnant women in a low-income South African setting. 
While HIV infection immunosuppresses the host, pregnancy adds an extra pressure in the 
immune system that may increase the risk of infections in this already vulnerable 
population. During pregnancy the maternal immune system modulates itself for the 
prevention of foetal rejection, while similarly protecting both mother and foetus from 
various infections (321). The substantial immune alterations that occur during pregnancy 
involve (among other) changes in hormonal levels, leading to a shift from CMI toward 
humoral (antibody) immunity (91). These immune adaptations may contribute to increased 
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risk of complications associated with influenza infection, where CMI would play a critical 
role in viral clearance (92).  
Observational studies have suggested that HIV-infection is associated with varying rates of 
adverse pregnancy outcomes including spontaneous abortions, still-births, perinatal and 
infant mortality and low birth weight (322-324). Due to easily accessible health and 
specialist care in developed countries, HIV is rarely associated with maternal mortality; 
however HIV infection complications are important causes of maternal mortality in 
developing countries (158). Typically around 25% of pregnancy-related deaths in the 
sub-Saharan Africa may be attributed to HIV (162); with reports from Southern Africa 
showing maternal mortality rates 5-fold higher in HIV-infected women compared to 
uninfected women (158). Given the immunosuppressive condition associated with 
HIV-infection (325) combined with immune attenuation during pregnancy (326), 
HIV-infected pregnant women are most likely at an even higher risk of influenza-related 
complications and infection compared to healthy, non-pregnant women.  
In our study HIV-infected pregnant and HIV-infected non-pregnant women had similar 
CMI responses before vaccination for A/H1N1 and B/Yamagata. The GM SFU/106 PBMC 
was however higher for A/H3N2 among pregnant women (p=0.03). Post-IIV3 responses 
were slightly increased over baseline, yet in pregnant women only for A/H1N1 was there a 
significant increase in GM SFU/106 PBMC. These findings are surprising given the 
immunosuppressive condition associated with pregnancy: in a previous study assessing 
CMI responses to a pandemic monovalent A/H1N1 vaccine, Weinberg et al. reported a 
decrease in SFU/106 PBMC following vaccination among HIV-infected pregnant women 
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(327). The study did not include, however, an HIV-infected non-pregnant control group. In 
another study assessing interferon responses to the 2009 pandemic A/H1N1 influenza virus 
strain in HIV-uninfected unvaccinated women, pregnant women had reduced interferon 
producing PBMC compared to non-pregnant women (328). Although vaccination improved 
this response interferon production was still non-significantly reduced in pregnant women 
(328).  
In our study we found that receipt of IIV3 increased the number of IFN-γ producing cells 
after stimulation with A/H1N1 in pregnant women and A/H1N1 and B/Yamagata in 
non-pregnant women. Although current data on CMI responses to influenza vaccination 
among HIV-infected individuals are inconclusive (306,307,329), several studies have 
shown increases among healthy, HIV-uninfected individuals following vaccination 
(123,301,320). Richardson et al., reported non-significant increases in CMI responses to 
pooled influenza vaccine viruses among HIV-infected pregnant women 6 weeks 
post-vaccination using IFN-γ ELISPOT assay (173). A study assessing the cellular immune 
responses to a trivalent MF59-adjuvanted seasonal influenza vaccine in HIV-infected and 
HIV-uninfected adults also reported a non-significant increase one month post-vaccination 
in HIV-infected adults whereas a significant increase was seen for HIV-uninfected 
participants (330). We report an increase in CMI responses among HIV-infected 
non-pregnant women only for A/H1N1 and B/Yamagata post-IIV3. A possible reason for 
the discrepancy in results between our study and those reported by Fabbiani et al. may be 
due to the experimental techniques used: our study looked at IFN-γ secretions by means of 
the ELIPSOT assay, whereas Fabbiani et al. tested an array of individual cytokine 
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production following influenza-specific stimulation by means of a commercially available 
multiplex kit (330). Additionally, the authors demonstrate a significant association between 
lower CD4 T-cell counts and impaired Th1 response, which may be extrapolated to 
pregnancy, where Th1 responses are impaired and Th2 responses are increased in order to 
accommodate a foreign foetus (331).  
In a prospective trivalent virosomal vaccine trial, researchers aimed to assess CMI 
responses to the vaccine using IFN-γ ELISPOT assay in HIV-infected and HIV-uninfected 
individuals (332). The authors showed that HIV-infected individuals with CD4+ T-cell 
counts <350/µl displayed impaired IFN-γ secretions compared to HIV-infected individuals 
with >350/µl one month post-vaccination. Significant increases in response were observed 
in both healthy controls as well as HIV-infected individuals with CD4+ T-cell counts 
>350/µl (but not in those with <350/µl). These results may partly explain those observed in 
our study with regard to the low number of women achieving significant response to 
vaccination. A study from Sweden also found no significant CMI response to influenza 
vaccination in an immunocompromised cohort (333). A total of 18 healthy controls and six 
stem cell transplantation (SCT) patients were immunised with IIV3 and CMI responses 
measured one month post-IIV3 using the IFN-γ ELISPOT assay. As expected, the healthy 
controls elicited significant increases in SFU/106 PBMC post-IIV3 but there was no 
increase in SFU/106 PBMC for SCT patients following receipt of vaccine to any of the 
influenza strains. Interestingly, a previous study assessing humoral immune responses to 
influenza vaccination in SCT patients showed poor antibody responses in those individuals 
with depleted T-cell counts (334), adding further evidence that low CD4+ T-cell counts 
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may play a role in decreased immune responses to influenza vaccination, not only 
cell-mediated but also humoral immunity.  
Agrati et al. performed an analysis on presumably influenza virus-unexposed HIV-infected 
individuals and healthy controls and assessed CMI responses using the IFN-γ ELISPOT 
assay against the A/H1N1 and A/H3N2 virus strains (335). The authors describe a 
significant response to the vaccine strains as >40 SFU/106 PBMC post-vaccination, and 
showed that <37% of HIV-infected individuals achieved this threshold. No significant 
difference between healthy controls and HIV-infected individuals were reported for 
A/H3N2, however a significantly higher proportion of healthy controls (69% vs. 37%, 
p=0.002) achieved this threshold compared to HIV-infected individuals for A/H1N1. 
Furthermore, no significant difference in SFU/106 PBMC were reported among the two 
study groups for A/H3N2, but were significantly higher in healthy controls for A/H1N1 
(p<0.001). Although the participants of the study were not vaccinated, the data suggest that 
HIV-infection has a detrimental effect on CMI responses to the pandemic A/H1N1 virus 
compared to a healthy population. The author’s also assessed humoral immune responses 
using HAI assay against the same vaccine strains and, in line with previous observations 
(300,309,336,337), reported no significant correlation between CMI and humoral responses 
(335).  
Contrary to the findings in this study where we report lower IFN-γ production in 
non-pregnant women compared to pregnant women, a recent evaluation of PBMC from 
pregnant and non-pregnant women, stimulated ex vivo with A/H1N1 and A/H3N2 virus, 
showed that pregnant women had lower IFN-γ production (measured by intracellular 
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cytokine staining) compared to the non-pregnant counterparts (339). A possible explanation 
for this difference may be due to different viruses, different study years as well as using a 
different assay for analyses. Interestingly, following influenza infection both NK and 
T-cells from pregnant women significantly increased. However vaccination did not 
significantly affect NK or T-cell cytokine and chemokine responses in pregnant and 
non-pregnant women (339).  
Another study compared the induction of cytokines by ELISA, cytometric bead array, and 
mRNA levels between pregnant and non-pregnant women following stimulation of PBMC 
with A/H1N1 (328). The production of IFN-γ was significantly reduced in unvaccinated 
pregnant women compared to non-pregnant women, suggesting that pregnancy inhibits 
IFN-γ induction. Following vaccination however, pregnant women displayed normalised 
IFN-γ production as compared to their non-pregnant counterpart. These observations may 
add strength to our current findings, where vaccinating HIV-infected pregnant women 
showed increased CMI responses to all three vaccine strains.  
It has been previously suggested that, when using ELISPOT assay results as a potential 
correlate of protection, fold-changes between baseline and post-vaccination would be more 
informative than to use specific ELISPOT values (196). Here we report similar 
fold-increases among HIV+Preg and HIV+NP women for all three vaccine strains, ranging 
from 1.1 – 1.3 and 1.5 – 1.6, respectively. The proportion of participants yielding a 
significant response to vaccination, defined by ≥2-fold increase in GM SFU/106 PBMC 
over baseline, was achieved by <27% and <35% of HIV+Preg and HIV+NP women, 
respectively, for all three vaccine strains. It should be noted that the 2-fold increase in 
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IFN-γ secreting cells used to compare CMI responses is an arbitrary threshold as no general 
consensus currently exists as to the nature and threshold of a significant CMI responses 
needed for immune protection (304).  
Lastly, we explored the relationship between individual baseline GM SFU/106 PBMC and 
the response to vaccination (304,305,309,340). We discovered that pre-existing CMI to the 
vaccine strains significantly affected vaccine responses. Participants were evenly stratified 
(where possible) into LB and HB responses (304). Significant increases at post-IIV3 to all 
three vaccine strains were observed in both HIV+Preg and HIV+NP LB women (p<0.05 for 
all comparisons). Additionally, significantly greater fold-increases were achieved by LB 
women compared to HB women from baseline to post-IIV3 for at least two of the three 
vaccine strains.  
Although significant increases were seen in LB, but not HB women post-IIV3, LB women 
were unable to achieve the levels of responses observed in HB participants for all three 
strains. As expected, HB women had significantly higher GM SFU/106 PBMC compared to 
LB women at baseline for all three vaccine strains (p<0.001). Among the HIV+Preg 
women, post-IIV3 responses were also significantly higher in HB women compared to LB 
women for all three vaccine strains (p=0.008). A similar trend was observed for HIV+NP 
women, where HB women achieved significantly higher post-IIV3 responses to A/H1N1 
(p=0.03) and non-significantly higher responses to A/H3N2 and B/Yamagata than did LB 
women. He et al. conducted a study involving healthy children and adults and their cellular 
immune responses to either IIV3 or live attenuated influenza vaccine (LAIV) vaccination 
(340). The authors also stratified the participants into low and high baseline responses and 
 96 
 
reported findings similar to those achieved in this study: a lower baseline response was 
directly and significantly related to immune responses post-vaccination (340). Since most 
adults have previous exposure to influenza infection or vaccination (320) they therefore 
have a certain amount of influenza-specific memory T-cells which could explain why those 
with higher baseline values did not significantly increase post-IIV3 and why those with 
lower baseline values displayed significant increases. Other potential reasons for the results 
seen in this study are brought to light in a study by Agrati et al. (309). The authors, who 
also stratified their HIV-infected participants according to low and high baseline responses 
found a significant increase in CMI responses following receipt of vaccine in the low 
baseline sub-group. Their explanation for this phenomenon included 
hyperstimulation-induced T-cell anargy, expansion/deletion of T-cell clones, and 
trafficking to mucosal surfaces (309). Previous observations have shown that stimulation of 
pre-activated T-cells with high doses of antigen can induce T-cell anargy or perhaps 
activation-induced cell death (336,341). Additionally, it has been shown that repeated 
exposure to the same influenza strain leads to limited boosting of CMI responses (342), 
which correlates well with the results we obtained in the HB group of this study.  
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4.0 Cell-Mediated Immune Responses to Trivalent Inactivated Influenza Vaccine 
in HIV-Uninfected Pregnant and Non-Pregnant Women   
4.1 Results 
4.1.1 Baseline Characteristics 
In 2013 we enrolled 75 pregnant (HIV-Preg) and 75 non-pregnant (HIV-NP) women not 
infected with HIV; all participants received one single dose (15 g per antigen) of trivalent 
inactivated influenza vaccine (IIV3). Enrolment of both the pregnant and non-pregnant 
cohorts started 16 September and was concluded 7 October. At enrolment HIV-Preg 
women (mean age 26.4 years [standard deviation (SD): 4.9]) were slightly older than 
HIV-NP women (mean age 24.0 years [SD: 5.0], p=0.05) and the median body mass index 
(BMI) was 29.9 and 27.8 (p=0.17) among HIV-Preg and HIV-NP women, respectively. 
The mean days between baseline and post-IIV3 visits were 28.6 days overall and this was 
similar among HIV-Preg and HIV-NP women. The mean gestational age at enrolment 
among pregnant women was 27.3 weeks (Table 4.1). Of the total 75 HIV-Preg women, five 
did not return for the second visit and did not complete the study, and of the 75 HIV-NP 
women, one did not complete the study.  
The number of participants who qualified for enzyme-linked immunospot (ELISPOT) 
analysis was 63 in the HIV-Preg and 72 in the HIV-NP group (Table 4.5). A comparison of 
baseline characteristics between pregnant and non-pregnant women who qualified for 
ELISPOT analysis is available in Table 4.2 and in Tables 4.3 and 4.4 participants who 
qualified for ELISPOT analysis are compared to participants that did not qualify. No 
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significant differences in baseline characteristics were reported in either of the analyses, 
and only in the non-pregnant group the 3 women who did not qualify for ELISPOT analysis 
had a significant longer time between the two study visits (30.9 mean days [SD: 9.7]) 
compared to the women who qualified (28.4 mean days [SD: 1.3], p=0.035).  
Table 4.1: Baseline characteristics of the HIV-uninfected pregnant and non-pregnant women enrolled 
into the study in 2013 
Overall HIV-Preg HIV-NP P value 
Total no. women 150 75 75  Mean days between visits‡§ 28.6 ± 3.0 28.4 ± 1.7 28.8 ± 3.9 0.45 
Ethnicity (%)     Black 148 (98.7) 74 (98.7) 74 (98.7) - 
Other 2 (1.3) 1 (1.3) 1 (1.3) - 
Mean age - years 25.2 ± 5.1 26.4 ± 4.9 24.0 ± 5.0 0.05 
Median BMI 
(IQR) 
29.0 
(26.0 – 34.2) 
29.9 
(26.7 – 34.6) 
27.8 
(25.0 – 32.8) 0.17 
Mean gestational age - weeks - 27.3 ± 4.1 - - 
No. Primigravid (%) - 20 (26.7) - - 
Median gravidity 
(IQR) - 
2.0 
(1.0 – 3.0) - - 
Median parity 
(IQR) - 
1.0 
(0.0 – 1.0) - - 
Plus-minus values are means ± standard deviation 
‡, based on 70 HIV-Preg, 5 women did not complete visit 2 
§, based on 74 HIV-NP, 1 woman did not complete visit 2 
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
HIV, human immunodeficiency virus 
No., number of 
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Table 4.2: Baseline characteristics of the HIV-uninfected pregnant and non-pregnant women analysed 
by ELISPOT assay 
Overall HIV-Preg HIV-NP P value 
Total no. women 135 63 72 - 
Mean days between visits 28.4 ± 1.6 28.5 ± 1.8 28.4 ± 1.3 0.78 
Ethnicity (%)     
Black 133 (98.5) 62 (98.4) 71 (98.6) 1.0 
Other 2 (1.5) 1 (1.6) 1 (1.4) 1.0 
Mean age - years 25.1 ± 5.3 26.1 ± 5.0 24.3 ± 5.4 0.05 
Median BMI 
(IQR) 
28.9 
(26.0 – 33.2) 
29.6  
(23.1 – 28.5) 
27.4  
(24.9 – 32.4) 0.13 
Mean gestational age - weeks  27.5 ± 4.3 - - 
No. Primigravid (%) - 16 (25.4) - - 
Median gravidity 
(IQR) - 
2.0  
(1.0 – 3.0) - - 
Median parity 
(IQR) - 
1.0 
(0.0 – 1.0) - - 
Plus-minus values are means ± standard deviation 
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
HIV, human immunodeficiency virus 
No., number of 
 
Table 4.3: Baseline characteristics of the HIV-uninfected pregnant analysed vs. not analysed  
Overall Analysed Not Analysed P value 
Total no. women 75 63 12 - 
Mean days between visits 28.4 ± 1.7 28.5 ± 1.8 28.1 ± 0.3 0.49 
Ethnicity (%)     
Black 74 (98.7) 62 (98.4) 12 (100) 1.0 
Other 1 (1.3) 1 (1.6) 0   
Mean age - years 26.4 ± 4.9 26.1 ± 5.0 28.1 ± 4.6 0.14 
Median BMI 
(IQR) 
29.9 
(26.7 – 34.6) 
29.6  
(23.1 – 28.5) 
31.7 
(26.9 – 37.5) 0.52 
Mean gestational age - weeks 27.3 ± 4.1 27.5 ± 4.3 27.2 ± 3.8 0.80 
No. Primigravid (%) 20 (26.7) 16 (25.4) 5 (41.7) 0.30 
Median gravidity 
(IQR) 
2.0 
(1.0 – 3.0) 
2.0  
(1.0 – 3.0) 
2.0  
(1.0 – 3.0) 0.95 
Median parity 
(IQR) 
1.0 
(0.0 – 1.0) 
1.0 
(0.0 – 1.0) 
0.5 
(0.0 – 2.0) 0.90 
Plus-minus values are means ± standard deviation 
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
HIV, human immunodeficiency virus 
No., number of 
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Table 4.4: Baseline characteristics of the HIV-uninfected non-pregnant analysed vs. not analysed 
Overall Analysed Not Analysed P value 
Total no. women 75 72 3  
Mean days between visits 28.8 ± 3.9 28.4 ± 1.3 30.9 ± 9.7 0.035 
Ethnicity (%)     
Black 74 (98.7) 71 (98.6) 3 (100) 1.0 
Other 1 (1.3) 1 (1.4) 0 1.0 
Mean age - years 24.0 ± 5.0 24.3 ± 5.4 22.7 ± 2.9 0.33 
Median BMI 
(IQR) 
27.8 
(25.0 – 32.8) 
27.4  
(24.9 – 32.4) 
27.4 
(24.9 – 32.4) 0.49 
Plus-minus values are means ± standard deviation 
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
HIV, human immunodeficiency virus 
No., number of 
 
4.1.2 Participants Selection 
Participants without HIV-infection enrolled in the MatFlu study in 2013 (HIV-Preg, N=75; 
and HIV-NP, N=75) were immunised with a single dose of IIV3 to determine cell-mediated 
immune (CMI) responses one month post-vaccination (post-IIV3), assessed by detecting 
interferon-gamma (IFN-γ) production using enzyme linked immunospot (ELISPOT) assay. 
Collection of blood was conducted pre-vaccination (baseline) and at one month post-IIV3. 
For participants to qualify for EISPOT analyses they needed to have peripheral blood 
mononuclear cell (PBMC) viability ≥75% and have sufficient number of cells to perform 
duplicate assays (319) at both baseline and post-IIV3 visits. Table 4.5 shows the total 
numbers of participants in each study group that qualified for IFN-γ ELISPOT assessment 
for both study visits based on these criteria. Within these subpopulations, only experiments 
that fulfilled the following criteria at both baseline and post-IIV3 were included in the final 
analysis: i) test wells, prior to subtraction of background spot forming units (SFU) had to 
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exhibit SFU ≥2 times the background, ii) test wells had to have ≥10 SFU/106 PBMC 
following subtraction of background SFU and iii) in the background wells SFU needed to 
be <50 SFU/106 PBMC. Furthermore a significant response to vaccination was defined as 
≥2-fold increase in SFU from baseline to post-IIV3.  
Table 4.5: Number of participants eligible for IFN-γ ELISPOT analysis 
No. participants (%); [95% CI] 
Study 
Group 
Study 
Population 
Viability  
≥75%‡ A/H1N1§ A/H3N2 § B/Yamagata§ 
HIV-Preg 75 63 (84.0); [73.3 – 91.5] 
43 (68.3); 
[55.3 – 79.4] 
37 (58.7); 
[45.6 – 71.0] 
25 (39.7); 
[27.6 – 52.8] 
HIV-NP 75 72 (96.0);  [88.8 – 99.2] 
60 (83.3); 
[72.7 – 91.1] 
52 (72.2); 
[60.4 – 82.1] 
50 (69.4); 
[57.5 – 79.8] 
‡ Participants with ≥75% viable live-cells prior to ELISPOT assay 
§ Participants displaying test wells SFU ≥2 times background SFU, ≥10 SFUs/106 PBMC after background subtraction, and background 
wells with <50 SFU/106 PBMC per vaccine strain 
 
 
4.1.3 Cell-Mediated Immune Responses 
Baseline 
Of the 75 HIV-Preg and the 75 HIV-NP women enrolled, 63 (84.0%) and 72 (96.0%, 
p=0.030), respectively, had cell viability ≥75% at both study visits and qualified for the 
analyses of CMI responses to IIV3 as measured by IFN-γ ELISPOT assay (Table 4.5). At 
baseline, HIV-NP women showed significantly higher geometric mean (GM) SFU/106 
PBMC compared to HIV-Preg women for A/H1N1 (85.1 [95% confidence interval (CI): 
65.0 – 111] vs. 44.8 [95% CI: 34.1 – 59.0], p=0.002) and A/H3N2 (61.2 [95% CI: 47.3 – 
79.1] vs. 32.9 [95% CI: 24.4 – 44.3], p=0.002), and a similar trend was observed for 
B/Yamagata (Table 4.6 and Figure 4.1A).  
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Figure 4.1: Cell-mediated immune responses to the different influenza vaccine strains in 
HIV-uninfected pregnant (HIV-Preg) and HIV-uninfected non-pregnant (HIV-NP) women 
at baseline (A) and post-vaccination (B). The number of A/H1N1, A/H3N2, and 
B/Yamagata specific IFN-γ producing peripheral blood mononuclear cells was evaluated at 
baseline and post-vaccination by ELISPOT assay. Statistical analysis was performed using 
unpaired t-test. *p=0.03; **p <0.01; ***p<0.001. 
 
Post-vaccination 
Receipt of IIV3 resulted, in general, in a very weak increase in CMI responses from 
baseline to post-IIV3 in both study groups. For HIV-Preg women there was, however, a 
slight non-significant decrease in GM SFU/106 PBMC from baseline to post-IIV3 for 
A/H1N1 (Table 4.6 and Figure 4.2). Post-IIV3 GM SFU/106 PBMC were significantly 
higher in HIV-NP compared to HIV-Preg women for A/H1N1 (90.3 [95% CI: 66.9 – 122] 
vs. 41.6 [95% CI: 32.9 – 52.5], p<0.001), A/H3N2 (69.8 [95% CI: 51.7 – 94.2] vs. 35.6 
[95% CI: 27.9 – 45.3], p=0.001) and B/Yamagata: (55.4 [95% CI: 40.4 – 76.0] vs. 32.6 
[95% CI 24.4 – 43.4], p=0.03) (Table 4.6 and Figure 4.1B). Similar GM fold-increases 
from baseline to post-IIV3 were observed in both study groups (Table 4.6).  
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Following administration of IIV3, 18.6%, 27.0% and 20.0% of HIV-Preg and 38.3%, 
26.9% and 42.0% of HIV-NP women achieved a ≥2-fold increase from baseline for 
A/H1N1, A/H3N2 and B/Yamagata, respectively, and this was significantly higher in 
HIV-NP compared to HIV-Preg women for A/H1N1 (p=0.03) (Table 4.6).  
 
4.1.4 Trivalent Inactivated Influenza Vaccine-Specific Cell Mediated Immunity 
According To Baseline Responses  
Using the same criteria described previously for HIV-infected women (see: 3.1.4 IIV3-
specific CMI according to baseline responses in HIV-infected women), we investigated if 
CMI responses to IIV3 were associated with baseline SFU/106 PBMC. Participants were 
again stratified evenly (where possible) according to their individual baseline SFU/106 
PBMC into low-baseline (LB) and high-baseline (HB) responses (304). For A/H1N1, 
A/H3N2 and B/Yamagata: 21, 18 and 12 were classified as LB and 22, 19 and 13 as HB in 
the HIV-Preg group, while 30, 26 and 25 were classified as LB and 30, 26 and 25 as HB in 
the HIV-NP group, respectively. 
In both study groups, lower baseline CMI responses were associated with significant 
increases post-IIV3 for A/H1N1, A/H3N2 and B/Yamagata (p<0.05 for all comparisons, 
Figure 4.3A and Figure 4.3B, Table 4.7). Similar to what was observed in HIV-infected 
women, higher baseline GM SFU/106 PBMC was associated with significant decreases in 
CMI responses post-IIV3 for all three IIV3 vaccine strains in HIV-Preg (p<0.05 for all 
comparisons) and for A/H1N1 in HIV-NP women (197 [95% CI: 157 – 247] at baseline vs. 
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91.8 [95% CI: 58.1 – 145] at post-IIV3, p=0.006), with non-significant decreases observed 
for A/H3N2 and B/Yamagata in HIV-NP women (Figure 4.3C and Figure 4.3D, Table 4.7). 
 
Figure 4.2: Cell-mediated immune responses to the different influenza vaccine strains at 
baseline and post-IIV3 in HIV-uninfected pregnant (HIV-Preg) (A) and HIV-uninfected 
non-pregnant (HIV-NP) (B) women measured by IFN-γ ELISPOT assay. Statistical 
analysis was performed using paired t-test. 
 
As expected baseline GM SFU/106 PBMC were significantly higher in the HB compared to 
LB group for all three IIV3 vaccine strains in both HIV-Preg and HIV-NP women (p<0.001 
for all comparisons), and higher GM SFU/106 PBMC were observed in HB compared to 
LB for both groups at post-IIV3 for all three strains, but none reached statistical 
significance (Table 4.7). 
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Table 4.6: Cell-mediated immune responses to inactivated influenza vaccine in HIV-uninfected women 
Measure A/H1N1 A/H3N2 B/Yamagata 
 HIV-Preg HIV-NP P Value§ HIV-Preg HIV-NP P Value§ HIV-Preg HIV-NP P Value§ 
No. participants 43 60  37 52  25 50  
GM SFU/106 PBMC  
[95% CI] 
 
 
 Baseline 44.8  
[34.1 – 59.0] 
85.1  
[65.0 – 111] 
0.002 32.9  
[24.4 – 44.3] 
61.2  
[47.3 – 79.1] 
0.002 30.6  
[21.6 – 43.6] 
42.6  
[32.2 – 56.4] 
0.16 
 Post-IIV3 41.6  
[32.9 – 52.5] 
90.3  
[66.9 – 122] 
<0.001 35.6  
[27.9 – 45.3] 
69.8  
[51.7 – 94.2] 
0.001 32.6  
[24.4 – 43.4] 
55.4  
[40.4 – 76.0] 
0.032 
 P value‡ 0.57 0.77  0.64 0.50  0.71 0.13  
GM factor increase 
[95% CI] 
0.9  
[0.7 – 1.2] 
1.1  
[0.7 – 1.6] 
0.38 1.1  
[0.8 – 1.5] 
1.1  
[0.8 – 1.7] 
0.92 1.1  
[0.8 – 1.5] 
1.3  
[0.9 – 1.8] 
0.15 
No. ≥2 fold increase      
post-IIV3 (%); [95% CI] 
8 (18.6);  
[8.4 – 33.4] 
23 (38.3);  
[26.1 – 51.8] 
0.031 10 (27.0);  
[13.8 – 44.1] 
14 (26.9);  
[15.6 – 41.0] 
1.00 5 (20.0);  
[6.8 – 40.7] 
21 (42.0);  
[28.2 – 56.8] 
0.07 
‡, P values comparing baseline vs. post-IIV3 within groups 
§, P values comparing HIV-Preg vs. HIV-NP 
IIV3, trivalent inactivated influenza vaccine 
SFU, spot forming units 
GM, geometric mean with 95% confidence interval 
No., number of 
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Following administration of IIV3, significantly higher GM SFU/106 PBMC fold-increases 
in LB compared to HB were observed in HIV-Preg for A/H1N1 (LB: 1.6 [95% CI: 1.2 – 
2.1] vs. HB: 0.6 [95% CI: 0.4 – 0.8], p<0.001), A/H3N2 (LB: 2.0 [95% CI: 1.4 – 2.9] vs. 
HB: 0.6 [95% CI: 0.4 – 0.9], p<0.001) and B/Yamagata (LB: 1.8 [95% CI: 1.2 – 2.7] vs. 
HB: 0.6 [95% CI: 0.4 – 0.9], p<0.001) (Figure 4.4A). Similarly in HIV-NP women LB 
participants had significantly higher GM SFU/106 PBMC fold-increases compared to HB 
participants for A/H1N1 (LB: 2.4 [95% CI: 1.5 – 3.8] vs. HB: 0.5 [95% CI: 0.3 – 0.8], 
p<0.001), A/H3N2 (LB: 2.1 [95% CI: 1.2 – 3.5] vs. HB: 0.6 [95% CI: 0.4 – 0.9], p=0.003) 
and B/Yamagata (LB: 2.2 [95% CI: 1.6 – 3.0] vs. HB: 0.8 [95% CI: 0.5 – 1.4], p=0.007) 
(Figure 4.4B). 
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Figure 4.3: Cell-mediated immune responses post-IIV3 according to the numbers of IFN-γ 
secreting peripheral blood mononuclear cells at baseline. HIV-Preg (A and C) and HIV-NP 
(B and D) were stratified evenly according to their individual baseline responses into low-
baseline (LB) response (A and B) and high-baseline (HB) response (C and D). Statistical 
analysis performed using paired t-test. *p<0.05; **p<0.005; ***p<0.001. 
 108 
 
Table 4.7: Cell-mediated immune responses to inactivated influenza vaccine in HIV-uninfected women stratified according to low- and high-baseline 
responses 
  A/H1N1 A/H3N2 B/Yamagata 
Group  N Baseline Post-IIV3 P value§ N Baseline Post-IIV3 P value§ N Baseline Post-IIV3 P value§ 
HIV-Preg 
LB 21 21.1 [18.3 – 24.3] 
34.2 
[25.6 – 45.6] 0.001 18 
15.0 
[12.8 – 17.7] 
29.8 
[22.6 – 39.4] 0.002 12 
14.9 
[12.9 – 17.2] 
27.4 
[17.5 – 42.9] 0.007 
HB 22 92.0 [69.7 – 121] 
50.2 
[34.7 – 72.6] 0.001 19 
69.0 
[53.2 – 89.5] 
42.0 
[28.2 – 62.7] 0.021 13 
59.5 
[40.3 – 87.8] 
38.1 
[25.2 – 57.7] 0.024 
P Value‡   <0.001 0.10   <0.001 0.15   <0.001 0.25  
HIV-NP 
LB 30 36.8 [29.1 – 46.6] 
88.8 
[58.5 – 135] <0.001 26 
31.3 
[26.0 – 37.6] 
64.5 
[41.7 – 99.8] 0.010 25 
19.8 
[16.7 – 23.5] 
42.6 
[29.5 – 61.4] <0.001 
HB 30 197 [157 – 247] 
91.8 
[58.1 – 145] 0.006 26 
120 
[87.8 – 164] 
75.5 
[48.7 – 117] 0.06 25 
91.6 
[66.9 – 126] 
72.1 
[42.9 – 121] 0.39 
P Value‡   <0.001 0.91   <0.001 0.60   <0.001 0.09  
All values expressed as geometric mean SFU/ 106 PBMC with 95% confidence interval 
§, P values comparing baseline vs. post-IIV3 within groups 
‡, P values comparing LB vs. HB participants 
LB, low-baseline response  
HB, high-baseline response  
N, number of participants within each group  
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Figure 4.4: Geometric mean SFU/106 PBMC fold-increase from baseline (t0) to post-IIV3 
(t1) for the vaccine strains A/H1N1, A/H3N2 and B/Yamagata stratified by low-baseline 
(LB) and high-baseline (HB) responses in HIV-uninfected pregnant (HIV-Preg) (A) and 
HIV-uninfected non-pregnant (HIV-NP) (B) women. Values are presented as a logarithmic 
(log2) scale of fold-increases and vertical bars represent minimum and maximum values. 
Statistical analysis was performed using the Mann-Whitney test. **p<0.01; ***p<0.001. 
 
4.2 Discussion 
In this chapter we compared the CMI responses to IIV3 in pregnant and non-pregnant 
women without HIV-infection in a low-income African setting. Pregnant women are at 
high risk for complications due to influenza virus infection (343), attributed to 
physiological and immunological changes that occur during pregnancy (170). With the 
progression of pregnancy, hormonal levels change and there is a shift from CMI toward 
humoral immunity (344). Given the attenuation of CMI during pregnancy the majority of 
the studies evaluating immune responses to influenza vaccination have been focused on 
antibody production (345-347); with only a few immunogenicity studies assessing CMI 
responses and reporting variable results (173,300,328,333,348).  
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Currently the inactivated influenza vaccine is recommended for pregnant women (349), 
which has shown to elicit poor CMI responses compared to the live attenuated influenza 
vaccine (LAIV) in children (182). In healthy adults however, Subbramanian et al., reported 
that inactivated influenza vaccine (IIV) elicited good CMI responses post-vaccination, 
albeit to a lesser degree than LAIV (304). Additionally, the authors reported that IIV 
elicited significant hemagglutination inhibition (HAI) geometric mean titers (GMT) 
increases measured post-vaccination, whereas LAIV did not, concluding that antibody and 
CMI responses are likely independent parameters in the host immune responses against 
influenza (304). In this study we aimed to measure cell-mediated immune (CMI) responses 
to the 2013 Southern Hemisphere IIV3 at baseline and one month following vaccination by 
means of the IFN-γ ELISPOT assay in HIV-Preg women and compare these responses with 
HIV-NP women. We found that IIV3 elicited variable CMI responses in HIV-Preg and 
HIV-NP women to the three influenza vaccine strains accordingly to their pre-vaccination 
responses. 
Pregnant women had significantly lower CMI responses to A/H1N1 and A/H3N2 at 
baseline and to A/H1N1, A/H3N2 and B/Yamagata post-IIV3 compared to HIV-NP 
women. These observations are consistent with a report by Vanders et al., who explored 
IFN-γ secretion from PBMC isolated from unvaccinated pregnant and non-pregnant women 
when stimulated with the A/H1N1 influenza virus. In that study the analysis was done 
using flow cytometry and the authors reported a decreased response to A/H1N1 in pregnant 
compared to non-pregnant women (p<0.04) (348). Similarly, Forbes et al. reported 
significantly less IFN-γ secretion from PBMC isolated from unvaccinated pregnant women 
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compared to unvaccinated non-pregnant women following stimulation with A/H1N1 
influenza virus (p<0.01). This impaired response was, however, improved in pregnant 
women by influenza vaccination, yet still showed a reduced IFN-γ response compared to 
non-pregnant vaccinated women (328). Although these studies support our findings, it is 
important to note that in our study both study groups were enrolled and vaccinated 
following the influenza season (September – October) and therefore may have been 
exposed to the circulating influenza strains before vaccination. This pre-exposure to 
influenza strains explanation was also suggested in the study by Nayak et al., whose 
participants were enrolled prior to the onset of influenza season and reported a significant 
CMI response to the monovalent A/H1N1 vaccine (p=0.002) (350). This, together with the 
pregnancy-associated attenuation of CMI and general immunosuppression associated with 
pregnancy (344), might explain the disproportionately higher responses in HIV-NP, but 
poor responses by HIV-Preg women at both baseline and post-IIV3.  
Fold-increases in CMI responses from baseline to post-IIV3 were similar for all three 
strains in both study groups. While less than 28% of HIV-Preg women achieved ≥2-fold 
increase over baseline for at least one strain, 38% and 42% of HIV-NP women achieved a 
≥2-fold increase for A/H1N1 and B/Yamagata, respectively. Nevertheless, it should be 
emphasized that the 2-fold increase in IFN-γ secreting cells used to compare CMI 
responses is an arbitrary threshold as no general consensus currently exists as to the nature 
and threshold of a significant CMI responses needed for immune protection (304). Studies 
by Iorio et al. and Avetisyan et al. have shown that 59% and 72%, respectively, of the 
healthy participants in their studies achieved a ≥2-fold increase in CMI responses post-IIV3 
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(300,333). A possible reason for the lower proportion of HIV-NP women achieving a 
≥2-fold increase in our study may be, as mentioned, the time of enrolment post-influenza 
season, which would have exposed participants to circulating influenza virus strains and as 
a result, IFN-γ responses was already maximal (328). The proportions we observe in 
HIV-Preg women can possibly be attributed to the same reason and to the shift from CMI 
to humoral immunity during pregnancy. 
Although HIV-NP women had slightly improved responses to all three strains compared to 
HIV-Preg women, they were also unable to reach significant increases post-IIV3. These 
findings correlate with the results from Richardson et al., who explored IFN-γ secreting 
PBMC from HIV-uninfected pregnant women following administration of IIV3 and 
reported no significantly increased response 6 weeks post-vaccination (173). Co et al. also 
reported an overall moderate non-significant increase in the number of IFN-γ producing 
cells post-IIV3 for both A/H1N1 and A/H3N2 strains in healthy adults (305). Importantly, 
although HIV-Preg participants’ CMI responses to IIV3 were poor compared to HIV-NP 
women, and that no significant increase occurred from baseline to post-IIV3, this does not 
necessarily equate to a lack of protection. Numerous studies on the immunogenicity of the 
influenza vaccine have been conducted measuring humoral responses and have shown 
significant protection following receipt of vaccine (100,103,104,347,351,352) 
Finally, we explored the possible relationship between baseline GM SFU/106 PBMC and 
post-IIV3 responses. Although both groups had no significant increases in CMI responses 
following vaccination, subsets of participants demonstrated distinct responses. We found 
that pre-existing CMI to the vaccine strains affected the ability of vaccination to induce 
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significant increases post-IIV3. When participants were stratified into LB and HB 
responses (304), both HIV-Preg and HIV-NP LB women achieved significant increases 
post-IIV3 (p<0.05 for all comparisons), as well as displaying significantly greater 
fold-increases compared to HB women from baseline to post-IIV3 for all three vaccine 
strains. Previous studies involving influenza vaccination in healthy adults and children have 
found similar results (304,305,309,320). Agrati et al. stratified participants into low 
responders (<60 SFU/106 PBMC) and high responders (>60 SFU/106 PBMC) based on 
individual baseline CMI responses. By using an “Efficacy Index” (SFU at baseline/SFU at 
post-IIV3), the authors found a non-significant association between lower baseline and 
higher post-vaccination responses in health care workers (309). Another example of this 
association was reported by He et al., where, after receipt of the LAIV, 58% of adult 
participants had significantly increased CMI responses, whereas 42% had decreased CMI 
responses. Participants in the first group had significantly lower baseline responses 
compared to the second group (p<0.05), strengthening the possibility that a lower baseline 
CMI response is associated with a higher post-vaccination CMI response (320). A potential 
explanation for this trend reported in our study and others might be that in individuals with 
low baseline-high post-vaccination responses, IFN-γ producing T-cells may be responding 
to the HA and the NA proteins contained in the inactivated vaccine (305). The reason 
behind this possible explanation comes from studies reporting having found a considerable 
amount of nucleoprotein and M1 protein in inactivated influenza vaccines, which may be 
additional targets for CD8+ T-cell responses (302,353,354). Additionally, the reason for 
low responses post-vaccination in individuals with high baseline responses may be due to 
the presence of CD8+ and CD4+ influenza specific T-cells, which may rapidly eliminate 
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antigen presenting cells containing vaccine antigens, thereby limiting subsequent activation 
of T-cells upon re-exposure (305). Other mechanisms have been suggested, including 
hyper-stimulation-induced T-cell anargy, expansion/deletion of T-cell clones and 
trafficking to mucosal surfaces (309).  
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5.0 Humoral and Cell Mediated Immune Responses to Trivalent Inactivated 
Influenza Vaccine in HIV/TB Infected Individuals 
5.1 Results 
5.1.1 Baseline Characteristics  
At enrolment HIV/TB-uninfected (HIV-TB-) study participants were younger (25.6 years 
standard deviation [SD]: 6.6) than the other participants and had higher median baseline 
body-mass index (BMI) compared to HIV-uninfected/TB-infected (HIV-TB+) and 
HIV/TB-co-infected (HIV+TB+), but lower than the HIV-infected/TB-uninfected 
(HIV+TB-) participants. Among the HIV-infected participants those infected with TB 
(HIV+TB+) were younger, had a lower BMI, lower CD4+ T-cell count and a lower 
percentage were on antiretroviral therapy compared to HIV+TB- (Table 5.1).  
The baseline characteristics of the participants that underwent hemagglutination inhibition 
(HAI) assays are shown in Table 5.2. Only participants who had pair blood samples 
pre-vaccination and at one month post-vaccination available for HAI assay were included 
in the analysis. At enrolment HIV-TB- participant were younger (26.3 years [SD: 6.8]) than 
HIV+TB+ and HIV-TB+ participants and had greater median BMI compared to 
HIV-TB+ participants. Among the HIV-infected participants, those infected with TB were 
significantly younger (37.0 [SD: 8.5]), had a greater BMI and higher median CD4+ T-cell 
count than those without TB-infection (Table 5.2).  
Baseline characteristics of the TB-uninfected participants who fulfilled the criteria to be 
included in the cell-mediated immune (CMI) response experiments are shown in Table 5.3. 
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HIV-infected participants (HIV+TB-) were significantly older (41.2 [SD: 7.7] vs. 26.1 [SD: 
7.0], p<0.001) than HIV-infected (HIV+TB-) participants. 
5.1.2 Participants Selection 
All the participants enrolled in the IIV3_HIV_TB study in 2014, including 80 HIV+TB+, 
80 HIV+TB-, 61 HIV-TB+ and 80 HIV-TB- adults, were immunised with a single dose 
(15 g per antigen) of trivalent inactivated influenza vaccine (IIV3) to determine humoral 
and CMI responses one month post vaccination (post-IIV3). Humoral responses were 
assessed by HAI assay in all study groups, and CMI responses were measured by detecting 
interferon-gamma (IFN-γ) production using enzyme-linked immunospot (ELISPOT) assay 
in the HIV+TB- and HIV-TB- participants. Collection of blood was conducted on the day 
of vaccination, just prior to IIV3 administration (baseline) and at one month post-IIV3. For 
participants to qualify for EISPOT analyses they needed to have peripheral blood 
mononuclear cell (PBMC) viability ≥75% and have sufficient number of cells to perform 
duplicate assays (319) at both baseline and post-vaccination visits. In table 5.4 the total 
numbers of participants in each study group that qualified for IFN-γ ELISPOT assessment 
for both study visits based on these criteria are shown. Within this subpopulation, only 
experiments that fulfilled the following criteria per vaccine strain at both baseline and post-
IIV3 visits were included in the final analysis: i) test wells, prior to subtraction of 
background spot forming units (SFU) had to exhibit SFU ≥2 times the background, ii) test 
wells had to have ≥10 SFU/106 PBMC following subtraction of background SFU and iii) in 
the background wells SFU needed to be <50 SFU/106 PBMC. Furthermore a significant 
response to vaccination was defined as ≥2-fold increase in SFU from baseline to post-IIV3. 
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Table 5.1: Baseline characteristics of HIV/TB study participants in 2014 
Overall HIV+TB+ HIV+TB- P value HIV-TB+ HIV-TB- P value 
Total no. participants 301 80 80 - 61 80 - 
Mean days between visits¶ 30.2 ± 4.8 28.8 ± 1.8 31.2 ± 6.1 0.002 29.8 ± 4.8 30.9 ± 5.0 0.21 
Ethnicity (%)         Black 299 (99.3) 80 (100) 80 (100) 1.00 60 (98.4) 79 (98.8) 1.00 
 Other 2 (0.7) 0 (0) 0 (0)  1 (0.6) 1 (0.2)  Mean age - years 34.0 ± 9.9 36.8 ± 8.4 40.8 ± 7.4 0.001 32.1 ± 10 25.6 ± 6.6 <0.001 
Median BMI  
(IQR)‡ 
23.5 
(21.0 – 27.2) 
22.9 
(20.8 – 26.2) 
24.9 
(22.3 – 31.1) 0.002 
21.2 
(19.5 – 24.7) 
23.9 
(21.5 – 30.3) 0.003 
Median CD4+ T-cell  
Count cells/mm3(IQR)§ 
- 250 (158 – 404) 
513 
(341 – 659) <0.001 - - - 
No. on ART (%) - 36 (45.0) 64 (80.0) <0.001 - - - 
No. on TB treatment (%) - 70 (87.5) - - 58 (95.1) - - 
Plus minus values are means ± standard deviation 
¶, 5 HIV-TB-, 1 HIV+TB-, 6 HIV-TB+ and 5 HIV+TB+ participants did not complete visit 2 
‡, 3 HIV+TB+ participants did not have BMI data 
§, 1 HIV+TB- participant did not have CD4+ data 
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
HIV, human immunodeficiency virus 
TB, tuberculosis 
ART, antiretroviral therapy compared 
No., number of 
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Table 5.2: Baseline characteristics of HIV/TB study participants in 2014 analysed by HAI 
Overall HIV+TB+ HIV+TB- P value HIV-TB+ HIV-TB- P value 
Total no. participants 263 74 71 - 51 67 - 
Mean days between visits¶ 29.3 ± 2.2 28.8 ± 1.9 30.0 ± 2.4 <0.001 28.7 ± 1.7 29.5 ± 2.3 0.037 
Ethnicity (%)         Black 261 (99.2) 74 (100) 71 (100) 1.00 50 (98.0) 66 (98.5) 1.00 
 Other 2 (0.8) 0 0 - 1 (2.0) 1 (1.5) 1.00 
Mean age - years 34.2 ± 9.9 37.0 ± 8.5 40.7 ± 7.5 0.006 31.8 ± 10.3 26.3 ± 6.8 <0.001 
Median BMI  
(IQR)‡ 
23.6 
(21.1 – 27.7) 
23.1 
(20.8 – 26.2)‡ 
24.9 
(22.4 – 31.2) 0.001 
21.5 
(19.5 – 24.6) 
24.0 
(21.8 – 30.6) <0.001 
Median CD4+ T-cell  
Count cells/mm3(IQR)§ 
- 262 (158 – 408) 
510 
(331 – 655)§ <0.001 - - - 
No. on ART (%) - 32 (43.3) 56 (78.9) <0.001 - - - 
No. on TB treatment (%) - 73 (98.6) - - 50 (98.0) - - 
Plus minus values are means ± standard deviation 
‡, 1 participants did not have BMI data 
§, 1 participant did not have CD4+ data 
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
HIV, human immunodeficiency virus 
TB, tuberculosis 
ART, antiretroviral therapy compared 
No., number of 
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Table 5.3: Baseline characteristics of study participants enrolled in CMI sub-study 
Overall HIV+TB- HIV-TB- P value 
Total no. participants 116 56 60 - 
Mean days between visits 30.9 ± 4.8 30.9 ± 5.5 30.9 ± 4.2 0.98 
Ethnicity (%)     
Black 115 (99.1) 56 (100) 59 (98.3) 1.00 
Other 1 (0.9) 0 (0) 1 (1.6) - 
Mean age - years 33.4 ± 11.0 41.2 ± 7.7 26.1 ± 7.0 <0.001 
Median BMI 
(IQR) 
24.0 
(21.5 – 30.7) 
23.8 
(21.6 – 30.3) 
24.3 
(21.5 – 31.0) 0.95 
Median (IQR) CD4+ 
T-cell count cells/mm3 - 
516 
(372 – 656) - - 
No. on ART (%) - 46 (82.1) - - 
Plus-minus values are means ± standard deviation 
IIV3, trivalent inactivated influenza vaccine 
BMI, body mass index (weight in kilograms divided by the square of height in meters) 
IQR, interquartile range 
HIV, human immunodeficiency virus 
TB, tuberculosis 
ART, antiretroviral therapy compared 
No., number of 
 
 
Table 5.4: Number of participants eligible for IFN-γ ELISPOT analysis 
No. participants (%); [95% CI] 
Study 
Group 
Study 
Population 
Viability  
≥75%‡ A/H1N1§ A/H3N2 § B/Yamagata§ 
HIV+TB- 80 56 (70.0); [58.7 – 79.7] 
35 (43.8); 
[32.7 – 55.3] 
33 (41.3); 
[30.4 – 52.8] 
33 (41.3); 
[30.4 – 52.8] 
HIV-TB- 80 60 (75.0); [64.1 – 84.0] 
29 (36.3); 
[25.8 – 478.8] 
17 (21.3); 
[12.9 – 31.8] 
27 (33.8); 
[23.6 – 45.2] 
‡ Participants with ≥75% viable live-cells prior to ELISPOT assay 
§ Participants displaying test wells SFU ≥2 times background SFU, ≥10 SFU/106 PBMC after background subtraction, and 
background wells with <50 SFU/106 PBMC per vaccine strain 
 
 
5.1.3 Humoral Immune Responses to Trivalent Inactivated Influenza Vaccine in 
HIV/TB Co-Infected and HIV-Infected TB-Uninfected Participants 
Baseline 
Humoral responses to IIV3 were assessed in 74 HIV+TB+ and 71 HIV+TB- participants 
using HAI assay. Baseline geometric mean titers (GMT) were similar among HIV+TB+ 
and HIV+TB- participants for A/H1N1 and A/H3N2, while HIV+TB+ participants had 
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significantly higher baseline GMT compared to HIV+TB- for B/Yamagata (18.6 
[95% CI: 16.1 – 21.6] vs. 14.2 [95% CI: 12.7 – 16.0], p=0.008) (Table 5.5). At baseline the 
percentage of participants with sero-protective titers (≥1:40) ranged from 8.5% to 27.0% in 
the HIV+TB- group and from 16.2% to 27.0% in the HIV+TB+ group. This percentage was 
similar in the HIV+TB+ and HIV+TB- group for A/H1N1 (16.2% vs. 21.1%) and A/H3N2 
(27.0% vs. 19.7%), but significantly higher in HIV+TB+ participants for B/Yamagata 
(27.0% vs. 8.5%, p=0.005, Table 5.5). Following multi-variant adjusted analysis for the 
baseline characteristics (age, BMI, CD4+ T-cell counts and number of participants on 
ART), we found no change in significance for any of the vaccine strains.  
Post-vaccination 
Post-IIV3 significant increases in GMTs from baseline were noted in both study groups for 
all strains (p<0.01 for all comparisons, Table 5.5). HIV+TB+ and HIV+TB- participants 
achieved similar GMTs post-IIV3 for A/H1N1 and A/H3N2; for B/Yamagata higher titers 
were achieved in HIV+TB+ compared to HIV+TB- participants (29.8 [95% CI: 25.0 - 35.5] 
vs. 19.8 [95% CI: 16.3 – 23.9], p<0.001). The geometric mean fold-increase ranged from 
1.2 for B/Yamagata to 4.5 for A/H1N1 and was similar between study groups except for 
A/H3N2 with HIV+TB+ participants having a lower fold-increase compared to HIV+TB- 
(2.7 vs. 4.4, p=0.008); however, after adjustment for baseline characteristics (age, BMI, 
CD4+ T-cell counts and number of participants on ART) the association was no longer 
significant (adjusted p-value=0.26).  
A significant increase in the proportion of participants with sero-protective titers from 
baseline to post-IIV3 was observed in both study groups (p<0.005 for all comparisons), 
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with less than 79% of participants achieving sero-protective titers for at least one strain. A 
higher percentage of HIV+TB+ participants compared to HIV+TB- had sero-protective 
titers for B/Yamagata (55.4% vs. 28.2%, p=0.001) and a trend in the opposite direction was 
detected for A/H3N2 (59.5% vs. 78.9%, respectively, p=0.05); following adjustment for 
baseline characteristics (age, BMI, CD4+ T-cell counts and number of participants on 
ART), the percentage of HIV+TB- participants that had sero-protective titers 
post-vaccination became significantly higher compared to HIV+TB+ participants for 
A/H3N2 (adjusted p-value=0.012).  
Sero-conversion rates to at least one strain were observed in less than 62% of the 
participants. No significant differences in the proportion of HIV+TB+ and HIV+TB- 
participants that sero-converted was detected for A/H1N1 (60.8% vs. 62.0%) and 
B/Yamagata (13.5% vs. 18.3%), whereas for A/H3N2, a significantly higher proportion of 
HIV+TB- participants sero-converted post-IIV3 compared to HIV+TB+ participants 
(35.1% vs. 54.9%, p=0.020); this significant association could no longer be detected 
following adjustment for baseline characteristics (age, BMI, CD4+ T-cell counts and 
number of participants on ART) (adjusted p-value=0.07).  
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Table 5.5: Humoral immune responses to inactivated influenza vaccine in HIV-infected participants 
Measure A/H1N1 A/H3N2 B/Yamagata 
 HIV+TB+ HIV+TB- P Value§ HIV+TB+ HIV+TB- P Value§ HIV+TB+ HIV+TB- P Value§ 
No. participants 74 71  74 71  74 71  
HAI GMT  
[95% CI] 
         
 Baseline 14.5  
[12.3 – 17.2] 
16.9 
[13.9 – 20.6] 
0.28/ 
0.31 
20.5  
[16.1 – 26.2] 
17.6 
[14.6 – 21.2] 
0.77/ 
0.99 
18.6  
[16.1 – 21.6] 
14.2 
[12.7 – 16.0] 
0.008/ 
0.019 
 Post-IIV3 64.6  
[46.1 – 90.5] 
75.4 
[55.4 – 103] 
0.44/ 
0.59 
55.8  
[39.7 – 78.4] 
78.1 
[57.5 – 106] 
0.14/ 
0.12 
29.8  
[25.0 – 35.5] 
19.8 
[16.3 – 23.9] 
<0.001/ 
0.009 
 P value‡ <0.001 <0.001  <0.001 <0.001  <0.001 0.007  
Factor increase in 
GMT [95% CI] 
4.5  
[3.3 – 6.1] 
4.5 
[3.42 – 5.82] 
0.70 2.7  
[2.1 – 3.5] 
4.4 
[3.2 – 6.1] 
0.008 
 
1.6  
[1.4 – 1.8] 
1.4 
[1.2 – 1.7] 
0.79 
HAI titre ≥1:40 –No. 
(%); [95% CI] 
         
 Baseline 12 (16.2); 
[8.7 – 26.6] 
15 (21.1); 
[12.3 – 32.4] 
0.52/ 
0.40 
20 (27.0); 
[17.4 – 38.6] 
14 (19.7); 
[11.2 – 30.9] 
0.33/ 
0.86 
20 (27.0); 
[17.4 – 38.6] 
6 (8.5); 
[3.2 – 17.5] 
0.005/ 
0.014 
 Post-IIV3 51 (68.9); 
[57.1 – 79.2] 
52 (73.2); 
[61.4 – 83.1] 
0.59/ 
0.97 
44 (59.5); 
[47.4 – 70.7] 
56 (78.9); 
[67.6 – 87.7] 
0.05/ 
0.012 
41 (55.4); 
[43.4 – 67.0] 
20 (28.2); 
[18.1 – 40.1] 
0.001/ 
0.004 
 P value‡ <0.001 <0.001  <0.001 <0.001  <0.001 0.004  
No. SC post-IIV3 
(%); [95% CI] 
45 (60.8); 
[48.8 – 72.0] 
44 (62.0); 
[49.7 – 73.2] 
1.00/ 
0.60 
26 (35.1); 
[24.4 – 47.1] 
39 (54.9); 
[42.7 – 66.8] 
0.020/ 
0.07 
10 (13.5); 
[6.7 – 23.5] 
13 (18.3); 
[10.1 – 29.3] 
0.50/ 
0.49 
‡, P values comparing baseline vs. post-IIV3 within groups 
§, Unadjusted/adjusted P values comparing HIV+TB+ vs. HIV+TB- 
§, Adjusted P values for age, BMI, median CD4+ T-cell count and number of adults on ART 
IIV3, trivalent inactivated influenza vaccine 
HAI, hemagglutination inhibition 
GMT, geometric mean titer with 95% confidence interval 
No., number of 
SC, sero-converted 
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5.1.4 Humoral Immune Responses to Trivalent Inactivated Influenza Vaccine in 
HIV-Uninfected TB-Infected and HIV-Uninfected TB-Uninfected Participants 
Baseline 
Analysis of humoral immune responses by HAI assay to IIV3 was conducted in 51 HIV-
TB+ and 67 HIV-TB- participants. Baseline GMT were significantly higher in HIV-TB+ 
compared to HIV-TB- participants for B/Yamagata (21.1 [95% CI: 17.9 – 24.7] vs. 13.0 
[95% CI: 11.7 – 14.5], p<0.001), and similar for the other two strains. Similarly a higher 
percentage of HIV-TB+ compared to HIV-TB- participants had sero-protective titers for 
B/Yamagata (7.5% vs. 25.5%, p=0.009) while no differences were detected for A/H1N1 
(35.3% vs. 43.3%, p=0.45) and A/H3N2 (39.2% vs. 37.3%, p=0.85) (Table 5.6). 
Post-vaccination 
Both HIV-TB+ and HIV-TB- participants achieved significant increases in GMTs 
post-IIV3 for all three vaccine strains (p<0.001 for all comparisons, Table 5.6). Receipt of 
IIV3 resulted in significantly higher GMT in HIV-TB+ compared to HIV-TB- for A/H1N1 
(233 [95% CI: 158 – 343] vs. 166 [95% CI: 128 – 216], p=0.02) and B/Yamagata (80.4 
[95% CI: 60.8 – 106] vs. 33.6 [95% CI: 28.2 – 40.2], p<0.001). Similar GMT were 
achieved among HIV-TB+ and HIV-TB- participants for A/H3N2 (Table 5.6). The 
geometric mean fold-increase post-IIV3 was significantly greater in HIV-TB+ compared to 
HIV-TB- participants for A/H1N1 (9.6 vs. 5.2, p=0.02) and B/Yamagata (3.8 vs. 2.6, 
p=0.04), yet similar for A/H3N2 (6.6 vs. 6.6, p=0.83). Once adjusted for baseline 
characteristics (age and BMI) however, the difference between HIV-TB+ and HIV-TB- 
participants for A/H1N1 was no longer significant (adjusted p-value=0.43).  
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IIV3 vaccination resulted in >90% of HIV-TB+ and HIV-TB- achieving sero-protective 
titers for A/H1N1 and A/H3N2. This was less pronounced for B/Yamagata, where a 
significantly higher proportion of HIV-TB+ participants reached sero-protective titers than 
HIV-TB- participants (84.3% vs. 59.7%, p=0.004) (Table 5.6), but this was non-significant 
after adjustment for baseline characteristics (age, BMI, CD4+ T-cell counts and number of 
participants on ART) (adjusted p-value=0.09).  
Sero-conversion rates ranged from 42% for B/Yamagata to 80% for A/H1N1 and were 
similar among HIV-TB+ and HIV-TB- participants for A/H3N2 (68.6% vs. 73.1%, p=0.68) 
and B/Yamagata (58.8% vs. 41.8%, p=0.09) (Table 5.6). For A/H1N1 a higher percentage 
of HIV-TB+ participants compared to HIV-TB- participants seroconverted (80.4% vs. 
58.2%, p=0.016), however this was non-significant after adjustment for baseline 
characteristics (age and BMI) (adjusted p-value=0.06).  
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Table 5.6: Humoral immune responses to inactivated influenza vaccine in HIV-uninfected participants 
Measure A/H1N1 A/H3N2 B/Yamagata 
 HIV-TB+ HIV-TB- P Value§ HIV-TB+ HIV-TB- P Value§ HIV-TB+ HIV-TB- P Value§ 
No. participants 51 67  51 67  51 67  
HAI GMT  
[95% CI] 
         
 Baseline 24.3 
[18.4 – 32.2] 
31.7 
[24.0 – 41.9] 
0.20/ 
0.96 
31.7 
[22.6 – 44.4] 
27.8 
[21.9 – 35.2] 
0.80/ 
0.43 
21.1 
[17.9 – 24.7] 
13.0 
[11.7 – 14.5] 
<0.001/ 
<0.001 
 Post-IIV3 233 
[158 – 343] 
166 
[128 – 216] 
0.021/ 
0.038 
209 
[146 – 299] 
183 
[144 – 233] 
0.26/ 
0.46 
80.4 
[60.8 – 106] 
33.6 
[28.2 – 40.2] 
<0.001/ 
<0.001 
 P value‡ <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  
Factor increase in 
GMT [95% CI] 
9.6 
[6.6 – 13.9] 
5.2 
[3.7 – 7.3] 
0.021 6.6 
[4.5 – 9.7] 
6.6 
[4.8 – 9.2] 
0.83 3.8 
[2.8 – 5.1] 
2.6 
[2.1 – 3.2] 
0.04 
HAI titre ≥1:40 –
No. (%); [95% CI] 
         
 Baseline 18 (35.3); 
[22.4 – 49.9] 
29 (43.3); 
[31.2 – 56.0] 
0.45/ 
0.72 
20 (39.2); 
[25.8 – 53.9] 
25 (37.3); 
[25.8 – 50.0] 
0.85/ 
0.84 
13 (25.5); 
[14.3 – 39.6] 
5 (7.5); 
[2.5 – 16.6] 
0.009/ 
0.09 
 Post-IIV3 46 (90.2); 
[78.6 – 96.7] 
62 (92.5); 
[83.4 – 97.5] 
0.74/ 
0.24 
46 (90.2); 
[78.6 – 96.7] 
65 (97.0); 
[89.6 – 99.6] 
0.24/ 
0.71 
43 (84.3); 
[71.4 – 93.0] 
40 (59.7); 
[47.0 – 71.5] 
0.004/ 
<0.001 
 P value‡ <0.001 <0.001  <0.001 <0.001  <0.001 <0.001  
No. SC post-IIV3 
(%); [95% CI] 
41 (80.4); 
[66.9 – 90.2] 
39 (58.2); 
[45.5 – 70.2] 
0.016/ 
0.06 
35 (68.6); 
[54.1 – 80.9] 
49 (73.1); 
[60.9 – 83.2] 
0.68/ 
0.94 
30 (58.8); 
[44.2 – 72.4] 
28 (41.8); 
[29.8 – 54.5] 
0.09/ 
0.05 
‡, P values comparing baseline vs. post-IIV3 within groups 
§, Unadjusted/adjusted P values comparing HIV-TB+ vs. HIV-TB+ 
§, Adjusted P values for age and BMI 
IIV3, trivalent inactivated influenza vaccine 
HAI, hemagglutination inhibition 
GMT, geometric mean titer with 95% confidence interval 
No., number of 
SC, sero-converted 
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5.1.5 Cell-Mediated Immune Responses to Trivalent Inactivated Influenza Vaccine 
in HIV-Infected TB-Uninfected and HIV-Uninfected TB-Uninfected 
Participants 
Baseline 
Cell-mediated immune responses were assessed in 56 HIV+TB- and 60 HIV-TB- 
participants at baseline and one month post-IIV3, as measured by IFN-γ ELISPOT assay. 
At baseline GM SFU/106 PBMC were significantly higher in HIV+TB- compared to HIV-
TB- participants for A/H1N1 (205 [95% CI 145 – 290] vs. 97.5 [95% CI 72.0 – 132], 
p=0.002) and B/Yamagata (166 [95% CI 120 – 228] vs. 89.6 [95% CI 64.3 – 125], 
p=0.009), while a similar trend, yet non-significant was observed for A/H3N2 (Figure 
5.1A, Table 5.7).  
 
Figure 5.1: Cell-mediated immune responses to the different influenza vaccine strains in 
HIV-infected TB-uninfected (HIV+TB-) and HIV-uninfected TB-uninfected (HIV-TB-) 
participants at baseline (A) and post-IIV3 (B). The number of A/H1N1, A/H3N2, and 
B/Yamagata specific IFN-γ producing peripheral blood mononuclear cells was evaluated at 
baseline and post-vaccination by ELISPOT assay. Statistical analysis was performed using 
unpaired t-test. **p<0.01; ***p<0.001. 
 
 127 
 
Post-vaccination 
Post-IIV3 HIV+TB- participants had a minimal non-significant increase in GM SFU/106 
PBMC for A/H3N2 and B/Yamagata and no change was observed for A/H1N1; whereas 
HIV-TB- participants had a significant decrease in GM SFU/106 PBMC for A/H3N2 from 
baseline to post-IIV3 (68.6 [95% CI: 50.9 – 92.6] at baseline vs. 32.3 [95% CI: 21.1 – 49.4] 
at post-IIV3, p<0.001) and no change for A/H1N1 and B/Yamagata (Figure 5.2, Table 5.7). 
Post-IIV3 GM SFU/106 PBMC were significantly higher in HIV+TB- compared to 
HIV-TB- participants for A/H1N1 (214 [95% CI: 151 – 303] vs. 99.6 [95% CI: 73.3 – 135], 
p=0.002), A/H3N2 (140 [95% CI: 98.0 – 200] vs. 32.3 [95% CI: 21.1 – 49.4], p<0.001) and 
B/Yamagata (212 [95% CI:144 – 313] vs. 81.5 [95% CI: 61.0 – 109], p<0.001) (Figure 
5.1B, Table 5.7). From baseline to post-IIV3 HIV+TB- compared to HIV-TB- participants 
had similar GM fold-changes for A/H1N1, but higher GM fold-changes were observed for 
A/H3N2 (1.4 [95% CI: 1.0 – 1.9] vs. 0.5 [95% CI: 0.3 – 0.7], p<0.001) and B/Yamagata 
(1.3 [95% CI: 0.9 – 1.8] vs. 0.9 [95% CI: 0.6 – 1.3], p=0.05) (Table 5.7). 
The proportion of participants achieving ≥2 fold increase from baseline to post-IIV3 was 
similar between HIV+TB- and HIV-TB- for A/H1N1 (14.3% vs. 17.2%, p=1.00) and 
B/Yamagata (27.3% vs. 14.8%, p=0.35) but significantly greater in HIV+TB- participants 
for A/H3N2 (42.4% vs. 5.9%, p=0.009). Comparisons of immune responses between the 
two groups did not change following adjustment for age at both baseline and 
post-vaccination.  
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Figure 5.2: Cell-mediated immune responses to the different influenza vaccine strains at 
baseline and post-IIV3 in HIV-infected TB-uninfected (HIV+TB-) (A) and HIV-uninfected 
TB-uninfected (HIV-TB-) (B) participants measured by IFN-γ ELISPOT assay. Statistical 
analysis was performed using paired t-test. ***p<0.001. 
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Table 5.7: Cell-mediated immune responses to inactivated influenza vaccine in HIV-infected TB-uninfected and HIV-uninfected TB-uninfected 
participants  
Measure A/H1N1 A/H3N2 B/Yamagata 
 HIV+TB- HIV-TB- P Value§ HIV+TB- HIV-TB- P Value§ HIV+TB- HIV-TB- P Value§ 
No. of participants 35 29  33 17  33 27  
GM SFU/106 PBMC  
[95% CI] 
         
 Baseline 205 
[145 – 290] 
97.5 
[72.0 – 132] 
0.002 104 
[71.4 – 151] 
68.6 
[50.9 – 92.6] 
0.14 166 
[120 – 228] 
89.6 
[64.3 – 125] 
0.009 
 Post-IIV3 214 
[151 – 303] 
99.6 
[73.3 – 135] 
0.002 140 
[98.0 – 200] 
32.3 
[21.1 – 49.4] 
<0.001 212 
[144 – 313] 
81.5 
[61.0 – 109] 
<0.001 
 P value‡ 0.79 0.91  0.07 <0.001  0.14 0.62  
GM factor increase  
[95% CI] 
1.0 
[0.8 – 1.4] 
1.0 
[0.7 – 1.5] 
0.55 1.4 
[1.0 – 1.9] 
0.5 
[0.3 – 0.7] 
<0.001 1.3 
[0.9 – 1.8] 
0.9 
[0.6 – 1.3] 
0.05 
No. ≥2 fold increase post-
IIV3 (%); [95% CI] 
5 (14.3); 
[4.8 – 30.3] 
5 (17.2); 
[5.8 – 35.8] 
1.00 14 (42.4); 
[25.5 – 60.8] 
1 (5.9); 
[1.5 – 28.7] 
0.009 9 (27.3); 
[13.3 – 45.5] 
4 (14.8); 
[4.2 – 33.7] 
0.35 
‡, P values comparing baseline vs. post-IIV3 within groups 
§, P values comparing HIV+TB- vs. HIV-TB- participants 
IIV3, trivalent inactivated influenza vaccine 
SFU, spot forming units 
GM, geometric mean with 95% confidence interval 
No., number of 
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5.2  Discussion 
In this study we report on the immunogenicity of the trivalent inactivated influenza vaccine 
(IIV3) by assessing both humoral and cell-mediated immune (CMI) responses in TB/HIV 
infected adults, prior to immunization and one month post-vaccination. We compare the 
humoral immune responses to IIV3 among: (1) HIV/TB co-infected (HIV+TB+) and 
HIV-infected TB-uninfected (HIV+TB-) adults and; (2) HIV-uninfected TB-infected 
(HIV-TB+) and HIV-uninfected TB-uninfected (HIV-TB-) adults, as well as to compare 
the CMI responses to IIV3 among HIV+TB- and HIV-TB- adults. Humoral immune 
responses were measured and compared using the hemagglutinin inhibition assay (HAI) 
and CMI responses were measured and compared by enzyme-linked immunospot assay 
(ELISPOT) at both pre-vaccination and one month post-vaccination. 
The immunogenicity of IIV3, measured by either HAI or ELISPOT in healthy adults and 
children has been documented (123,307). There is, however, little information about the 
immunogenicity of this vaccine in high-risk groups (such as infants, pregnant women, 
HIV-infected and HIV/TB co-infected adults).  
Tuberculosis (TB) is a major global issue resulting in adverse health among millions of 
individuals and ranks parallel to HIV and malaria as a leading cause of public ill-health 
(203), with an estimated 9.6 million new cases reported in 2014 (202). A compromised 
immune system severely increases the risk of TB disease, and in Southern Africa both 
socioeconomic and environmental factors play a role in potentially exacerbating the disease 
progression (251). The risk of TB infection is elevated most notably among patients with 
HIV, even during the first years after viral acquisition when CD4+ T-cell counts are still 
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high (254,255). Even with the introduction of ART in HIV-infected individuals, the risk of 
TB progression is not entirely reversed (256). Co-infection of HIV/TB has been shown to 
increase the risk of new additional opportunistic infections and of death compared to 
HIV-infected individuals without TB when CD4+ T-cell counts are similar (257-259). The 
relationship between HIV/TB co-infection is particularly aggressive, with both diseases 
being characterised by widespread dissemination throughout the human body as well as 
exhibiting poor host immune responses (274).  
South Africa has one of the highest rates of TB, further compounded by co-existing high 
prevalence of HIV (355). The increased risk of HIV-infected individuals developing TB, 
including early in the clinical course of HIV-infection, relates to the gradual impairment of 
multi-faceted arms of their immune systems (356). Foremost among these is the decrease in 
CD4+ T-cells and their impaired function, which contributes to impaired CMI responses 
which occur at a relatively early stage following HIV-infection (357). This gradual decline 
in the host immune system, coupled with other factors may stimulate the reactivation of 
dormant TB in latently infected individuals. In addition, the impaired immune system is 
also less able to cope with any new environmental exposure/infection by TB, resulting in a 
greater likelihood of infection progressing to disease compared to otherwise healthy 
individuals (357). The depletion of CD4+ T-cells and impaired macrophage function in 
HIV-infected individuals contributes to the susceptibility of co-infection with TB (358) and 
influenza (359). Currently there are no data regarding the immunogenicity of IIV in 
HIV/TB co-infected individuals (295,360). 
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In our study we first assessed the humoral immune responses to IIV3 among HIV/TB 
co-infected (HIV+TB+) and HIV-infected adults without TB (HIV+TB-). At baseline, 
HIV+TB+ were significantly younger and had a lower body-mass index (BMI) and median 
CD4+ count compared to the HIV+TB- participants (Table 5.2). Additionally, a lower 
percentage of HIV+TB+ adults were on ART than HIV+TB- adults (43.3% vs. 78.9%, 
p<0.001). Prior to immunisation, geometric mean titers (GMT) were comparable among 
study participants for A/H1N1 and A/H3N2, whereas greater GMT were obtained among 
the HIV+TB+ participants (Table 5.5), even after adjustment for baseline characteristics. 
Among the HIV+TB+ participants, HAI titers ≥1:40 were observed in 16.2%, 27.0% and 
27.0% for A/H1N1, A/H3N2 and B/Yamagata, respectively. The corresponding percentage 
of HIV+TB- adults having HAI titers ≥1:40 were 21.1%, 19.7% and 8.5%, respectively.  
In this study we found that vaccination with IIV3 elicited significant increases in GMT for 
all three vaccine strains in HIV+TB+ and HIV+TB- participants (p<0.01 for all 
comparisons, Table 5.5), with increases from baseline by a factor of 1.6 – 4.5 among 
HIV+TB+ participants and 1.4 – 4.5 for HIV+TB- participants. Although higher GMT were 
achieved in HIV+TB- participants, interestingly no significant differences in GMT 
post-vaccination was observed between the HIV+TB+ and HIV+TB- participants for 
A/H1N1 and A/H3N2. Contrary to what we expected, HIV+TB+ participants achieved 
significantly greater GMT for B/Yamagata compared to HIV+TB- participants (p<0.001), 
even after adjusting for baseline characteristics.  
Based on the current information available on the association between immune responses 
and HIV/TB co-infection, we expected HIV+TB+ adults to have a significantly lower 
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immune response to IIV3 than HIV+TB- participants: TB infection is often associated with 
a collection of cellular activations and irregularities in both cytokine and chemokine 
pathways that are permissive of HIV replication (258,361) and although clinical and 
experimental evidence suggests active TB accelerates HIV disease (362) it has been shown 
that TB treatment in HIV-infected populations remains as effective as that in 
HIV-uninfected populations (363). This may explain the similar immune responses 
observed in the HIV-infected participant groups, where 98.6% of HIV+TB+ adults in this 
study were on TB-treatment (Table 5.2). 
The percentage of participants having sero-protective HAI titers (≥1:40) post-vaccination 
increased significantly for all three strains in both HIV+TB+ and HIV+TB- participant 
groups (p<0.001 for all comparisons), albeit to a lower degree than those observed in 
healthy populations (300). There was no significant difference in the percentage of 
participants having sero-converted for A/H1N1 and B/Yamagata following vaccination 
between the two groups, however for A/H3N2 a significantly greater percentage of 
HIV+TB- participants sero-converted compared to HIV+TB+ participants (54.9% vs. 
35.1%, p=0.020). These observations are consistent with findings from a previous study: 
Crum-Cianflone et al. reported HIV-infected individuals showing significantly reduced 
sero-conversion (54% vs. 75%, p=0.021) and sero-protection (67% vs. 83%, p=0.005) 
compared to HIV-uninfected individuals one month after receiving the monovalent 
pandemic influenza vaccine (364). Bickel et al. however reported a far more successful rate 
among HIV-infected patients where, after one round of vaccination 68% of patients (with 
mean CD4+ counts of 514 cells/mm3) had sero-converted (311). Although the results 
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obtained in our study were unexpected, it is interesting to note that humoral immune 
responses to IIV3 appeared not to be affected by TB-infection among an HIV-infected 
population on TB-treatment (365). Additionally, in a previous study from 2009, researchers 
showed that a single dose of the monovalent A/H1N1 vaccine was immunogenic in both 
healthy and HIV-infected individuals with CD4+ cell counts >200 cells/mm3 (366), which 
may add strength to the findings in this study, given that HIV+TB+ and HIV+TB- 
participants had a median CD4+ count of 262 cells/mm3 and 510 cells/mm3, respectively.  
Next, we assessed humoral immune responses to IIV3 in HIV-uninfected TB-infected 
(HIV-TB+) and HIV-uninfected TB-uninfected (HIV-TB-) adults. At baseline HIV-TB+ 
participants were significantly older and had a significantly lower BMI compared to 
HIV-TB- participants and 98.0% of HIV-TB+ participants were on TB-treatment (Table 
5.2). In this study we found that IIV3 elicited good humoral immune responses in 
HIV-TB+ and HIV-TB- adults. Baseline GMT were similar among the study groups for 
A/H1N1 and A/H3N2, while HIV-TB+ participants had significantly higher GMT for 
B/Yamagata. These findings are slightly higher to those previously described in healthy 
adults (302,367) yet similar to those observed in pregnant women (103). Sero-protective 
GMT at baseline ranged from 25.5% - 39.2% and 7.5% - 43.3% in HIV-TB+ and HIV-TB- 
participants, respectively, with no significant differences between the two groups for 
A/H1N1 and A/H3N2. However, a significantly greater percentage of HIV-TB+ adults had 
sero-protective titers against B/Yamagata.  
One month after vaccination the percentage of participants who had sero-protective titers 
significantly increased, with >90% of HIV-TB+ and HIV-TB- adults demonstrating GMT 
 133 
 
≥1:40 to at least two of the three vaccine strains. Sero-protection against B/Yamagata 
however remained <60% among HIV-TB- adults, while 84.3% of HIV-TB+ participants 
achieved GMT ≥1:40. Sero-conversion rates were similar between the study groups for 
A/H3N2 and B/Yamagata, but a significantly greater percentage of HIV-TB+ adults 
sero-converted to A/H1N1 (80.4% vs. 58.2%, p=0.016), however, after adjusting for 
differences in baseline characteristics (), this difference was no longer significant. These 
findings are in line with results from a study performed in 2009, where HIV-uninfected 
adults achieved a 78.8% sero-conversion rate (366) and from a study performed in 
Indonesia in 2004, where researchers aimed at determining if influenza virus infections 
promote the development of TB disease. The authors reported significantly higher GMT for 
A/H3N2 in TB-infected participants compared to the healthy controls (244 vs. 145, 
p=0.002) and a non-significantly higher GMT to A/H1N1 (72 vs. 51, p=0.33) (287). A 
possible reason for this result may be due to the relationship that exists between the 
influenza virus and the clinical manifestation of TB, but caution that this association may 
be confounded: influenza infection in patients with TB may be more severe or possibly 
longer lasting due to damage caused in the lung by M. tuberculosis, and as a result greater 
quantities of antibodies against influenza are generated (287). Furthermore, it was 
previously shown that prior exposure to influenza A virus in mice, followed by TB 
infection lead to enhanced mycobacterial growth and decreased survival and following 
co-infection, mycobacterial growth was enhanced by a type I interferon signalling pathway 
(291).  
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Post-vaccination GMT were significantly higher among HIV-TB+ adults for A/H1N1 and 
B/Yamagata with increases from baseline by a factor of 3.8 – 9.6 in HIV-TB+ adults and 
2.6 – 6.6 in HIV-TB- adults for all three strains. These observations, although slightly less 
in our study, are consistent with findings from Tiu et al. who showed a 13.7-fold GMT 
increase 4 to 6 weeks post-vaccination among HIV-uninfected participants (366).  
Finally, we assessed and compared CMI responses to IIV3 using IFN-γ ELISPOT assay in 
a sub-set of HIV-TB+ (N=56) and HIV-TB- (N=60) participants. A substantial body of 
work on the immunogenicity to IIV in healthy adults and children (measured mainly by 
HAI assay to assess humoral responses) already exists in the literature (123,304). Advanced 
HIV infection is associated with greater seasonal influenza-related morbidity and mortality 
(113,359,368). Studies assessing seasonal influenza vaccination showed good efficacy both 
in HIV-infected persons (369) as well as in healthy adults (309). HIV-infected individuals 
are characterised by a compromised immune cell function due to the loss of CD4+ helper 
T-cells specifically infected by HIV, which are necessary for the activation of B-cells and 
cytotoxic T-cell immune responses (330), as well as affecting macrophages (260).  
At baseline HIV+TB- adults were significantly older than HIV-TB- adults (41.2 years 
[SD: 7.7] vs. 26.1 years [SD: 7.0], p<0.001) and 82.1% of HIV+TB- adults were on ART 
and had a median CD4+ count of 516 cell/mm3 (Table 5.3). HIV+TB- adults compared to 
HIV-TB- adults prior to vaccination had significantly greater CMI responses to A/H1N1 
and B/Yamagata and post-IIV3 to all three vaccine strains (Table 5.7). This is in contrast 
with previous findings, where generally HIV-infected adults and children exhibit impaired 
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or similar cellular immune responses to influenza vaccination compared to healthy, 
HIV-uninfected populations (306,308,309,310,330,335).  
Approximately one month post-vaccination CMI responses were slightly increased over 
baseline in HIV+TB- adults for all three strains, but none reached statistical significance. 
Among HIV-TB- adults however, decreased CMI responses were observed for A/H3N2 
and B/Yamagata. The fold-increases over baseline were in the range of 1.0 – 1.4 in 
HIV+TB- and 0.9 – 1.0 in HIV-TB- adults for the vaccine stains. A small percentage of 
participants achieved a ≥2-fold increase over baseline for all three vaccine stains, ranging 
from 14% – 42% in HIV+TB- and from 65 – 17% in HIV-TB- adults. Our results 
contradict those previously reported among healthy participants, where Iorio et al. and 
Avetisyan et al. showed 59% and 72%, respectively, of study participants achieving 
≥2-fold increase in SFU post-vaccination (300,333). In another study, Agrati et al. reported 
that 52.2% of health care workers versus 68.4% of HIV-infected patients achieved ≥2-fold 
increase over baseline for A/H1N1 following vaccination (309). It should be noted that a 
≥2-fold increase post-vaccination is an arbitrary threshold indicating a significant response 
to IIV3 (196). 
In a study by Fabbiani et al. (330,370) HIV-infected individuals vaccinated with an 
adjuvanted seasonal influenza vaccine showed sustained humoral responses (measured by 
HAI assays) but cellular responses were impaired (330). Interestingly, humoral immune 
responses to IIV3 among HIV+TB- (Table 5.5) and HIV-TB- (Table 5.6) participants were 
shown to be robust, yet CMI responses reported for this sub-group were attenuated (Table 
5.7). We hypothesise that the results obtained in this study, whereby we show 
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comparatively good responses to IIV3 in HIV-TB+ adults, is probably due to the 
effectiveness of TB treatment, with 98.0% on TB treatment. The findings in this study 
appear to show no correlation between the sero-prevelance of antibodies against the 
influenza vaccine strains and the existence of TB-infection. Although antibodies play a 
critical role in protection against influenza infection, activation of T-cells, particularly the 
CD4+ helper subpopulation is essential for supporting virus-specific effector cell functions 
(371).  
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6.0 Conclusion 
In this study we aimed to determine the cell-mediated immune (CMI) responses to the 
seasonal trivalent inactivated influenza vaccine (IIV3) in high-risk groups.  
There are several important findings generated from our study, as well as results that 
further strengthen observations already reported elsewhere. For simplicity, we divided the 
results chapter of this thesis into three major sections. In the first section we report on the 
comparison of CMI responses to IIV3 between HIV-infected pregnant and non-pregnant 
women. Vaccination improved CMI responses in both groups, however only significantly 
for A/H1N1 in both groups and for B/Yamagata in non-pregnant women. We found no 
significant differences in CMI responses to the influenza strains contained in the 2013 IIV3 
formulation at both baseline and post-vaccination between the study groups; however, 
HIV-infected pregnant women did display slightly higher GM SFU/106 PBMC than 
HIV-infected non-pregnant women at both time points. However, although non-significant, 
non-pregnant women tended to have higher fold-increases and a higher percentage 
achieved ≥2-fold increase from baseline to post-IIV3 compared to pregnant women. Prior 
to initiating this study, we hypothesised that HIV-infected pregnant women would show 
diminished CMI responses to the influenza vaccine strains at both baseline and 
post-vaccination compared to the HIV-infected non-pregnant women. Contrary to this 
predicted outcome, there was no significant difference in CMI responses between the study 
groups for any of the three vaccine strains. This observation may be explained by the higher 
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percentage of HIV-infected pregnant women on ART, as well as a significantly larger 
percentage having CD4+ T-cell counts >350 cell/mm3 at baseline. We speculate that ART 
treatment in >98% of the HIV-infected pregnant women enrolled in this study contributed 
to the improved responses observed, when compared to 60.1% of HIV-infected 
non-pregnant women on ART.  
In the second chapter, we described CMI response in HIV-uninfected pregnant and non-
pregnant women. Since the HIV-infected and HIV-uninfected groups were enrolled over 
different periods we were unable to directly compare the results obtained in both groups. 
Following vaccination we found no significant increases in responses in either 
HIV-uninfected pregnant and non-pregnant women. A potential reason for this observation 
is the time of participant enrolment being post-influenza season. Participants were most 
likely exposed to the circulating strains and might have developed naturally acquired 
cellular immunity. Compared to pregnant women, non-pregnant women did achieve 
significantly higher CMI responses to all three influenza vaccine strains at both baseline 
and post-vaccination. Fold-increases were similar between the two groups and other than 
for A/H1N1, no significant differences in women achieving a ≥2-fold increase were 
observed. The results reported are in line with our expected outcomes, where pregnant 
women would show attenuated CMI responses to vaccination compared to HIV-uninfected 
non-pregnant women. 
We also show in this study that pre-existing cellular immunity to influenza viruses has a 
major influence on responses following vaccination. After stratification we discovered that 
women with low baseline responses had significantly improved responses post-vaccination, 
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suggesting that having little or no pre-existing immunity plays a significant role in the 
responses to vaccination. Whereas, having pre-existing CMI to the vaccine strains 
negatively impacted the responses post-vaccination. Women with higher baseline responses 
to the three vaccine strains were unable to reach significant increases post-vaccination, 
where in fact decreases in responses were observed. A possible explanation for this 
observation may be attributed to the maximal quantity of influenza-specific memory T-cells 
available. A threshold may exist where the amount of T-cells circulating in the body, such 
as in the high-baseline response participants, could potentially explain why high-baseline 
responders were unable to achieve significant increases post-vaccination. A possible 
explanation may be due to the regulatory responses that can potentially induce or limit the 
magnitude of response. More often than not, women with high-baseline responses showed a 
reduced response post-vaccination, which may add further evidence that a potential 
threshold exists in individuals with pre-existing CMI, where a drop off may occur. 
Although women with low-baseline responses achieved significantly increased responses, 
they were unable to reach the levels seen in the high-baseline groups. This may add further 
evidence that a potential threshold exists; we observed significant increases in the 
low-baseline response groups, yet it is unclear how far that increase may reach, unless we 
take into account that the high-baseline groups peaked with regard to their CMI responses 
and resulted in a decrease one month after receiving the influenza vaccine. A potential 
exploratory study could be to analyse CMI responses with shorter time intervals. This could 
shed light on the possibility that cellular immunity is short-lived, which could explain the 
potential threshold. If women in the low-baseline groups significantly increased their CMI 
responses, they may not have yet reached this threshold, which is why we do not observe a 
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decrease in responses as was seen in the high-baseline response groups. The high-baseline 
response groups may have reached this threshold sooner than the low-baseline groups, and 
could explain why the decrease was observed. Furthermore, we observed significantly 
greater fold-increases among the low-baseline groups than the high-baseline groups for all 
vaccine strains, adding evidence that having little or no pre-existing T-cells may positively 
influence the CMI response to vaccination. 
In the third and final section, we assessed humoral and cell mediated immune responses in 
a cohort of adults living with or without HIV and TB infection. Among the HIV-infected 
group, individuals with TB infection had significantly lowered CD4+ T-cell counts and a 
lower percentage were on ART compared to the adults without TB. 98.6% of HIV-infected 
adults with TB adults were on TB treatment. Among the HIV-infected adults humoral 
immune responses were similar between those with and without TB at both baseline and 
post-vaccination except for responses to B/Yamagata, which were higher in individuals 
with TB. Vaccination increased the antibody titers against the vaccine strains in both 
HIV-infected groups, however participants were unable to reach the levels of 
sero-conversion and sero-protection reported in healthy adults. An important finding in this 
study was that TB infection did not negatively impact humoral immune responses to 
influenza. Furthermore, vaccination significantly increased the number of adults achieving 
sero-protection and sero-conversion in both groups.  
Among the HIV-uninfected groups, 98.0% of the participants with TB were on TB 
treatment, this could potentially explain why adults with TB achieved a good humoral 
response post-vaccination. As stated earlier, it appears that TB infection, if treated, does not 
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negatively impact the immune responses to IIV3. This is evidenced by the fact that our 
results in this group strongly correlate with results obtained in a healthy population. 
Within the sub-group analysed by ELISPOT assay, we found that HIV-infection does not 
appear detrimental to cellular immunity, as compared to healthy, HIV-uninfected adults. 
Adults with HIV-infection showed significantly higher CMI responses at both baseline and 
after immunisation compared to HIV-uninfected adults. Further, no significant increases in 
CMI responses were observed for either group following vaccination and surprisingly 
HIV-uninfected adults without TB were unable to achieve the level of immune responses 
seen in HIV-infected adults.  
As a secondary observation from our study, it is apparent that CMI measurements are 
problematic in high-risk groups. The ELISPOT assay relies heavily on the quality of 
isolated PBMC. We found that HIV infection appeared to negatively affect the quality of 
PBMC. This is clear from the percentages of viable PBMC we were able to use, in order to 
conduct accurate measurements. The lowest percentage of participants with viable PBMC 
(live cell count >70%) were in the HIV-infected groups, with only 45% HIV-infected 
pregnant women’s PBMC reaching this quality where we were able to conduct the 
ELISPOT assay. The highest percentages of usable PBMC were from the HIV-uninfected 
groups, with >84% of the PBMC isolated having reached the quality that allows for 
ELISPOT analysis. Secondly, no consensus currently exists as to the nature and threshold 
of a significant CMI response representative of protection. With such variations in the 
methodology of the ELISPOT assay reported, including different virus and cell 
concentrations used for each assay, as well as different incubation times, it is more prudent 
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to rely on fold-increases as the best strategy for gauging responses, rather than to rely on 
absolute spot forming units. Further studies are needed to standardise the ELISPOT 
method. Furthermore, it would be advantageous to conduct parallel studies using both the 
HAI assay, where a titer ≥1:40 is predictive of an anticipated vaccine efficacy of 50% in 
adults, and ELISPOT assays in order to determine a potential quantitative threshold for 
protection when using the ELISPOT assay.  
In conclusion, the results reported in this thesis clearly suggest that pregnancy may more 
negatively influence cellular immunity than infection with HIV, most notably when 
pregnant women living with HIV are on ART and have a CD4+ T-cell count 
>350 cells/mm3. We also show that pre-existing memory T-cells have a major impact on 
the magnitude of response to vaccination, regardless of time of vaccination. IIV3 was 
relatively immunogenic in HIV-infected adults with and without TB, albeit not the 
magnitude observed in healthy populations. However, in HIV-uninfected adults we showed 
that influenza vaccination was immunogenic in both with and without TB groups. 
Additionally, we show that infection with TB does not appear to affect CMI responses, 
even in the HIV-infected population. However, this observation should not overshadow the 
effect that HIV does have on vaccine response: although TB infection did not appear to 
play as large a role on immune responses as we expected, the results reported for HIV/TB 
co-infected were dramatically lower than those observed in healthy populations. We also 
show that there appears to be no correlation, albeit an indirect observation, between CMI 
and humoral immune responses to IIV3, as evidenced by the ELISPOT assay results 
obtained for the participants without TB and the corresponding humoral immune responses.  
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8.0 Appendices 
8.1 Laboratory Methods 
8.1.1 Instruments 
Automatic Cell Counter (TC20™) and Slides  Bio-rad, SA 
Cell Culture Incubator      SANYO electric Co. Ltd.  
Centrifuge 5810      Eppendorf, Hamburg 
Laminar Flow       Airvolution (PTY) Ltd. 
Waterbath YCW-01 22L     Gemmy Industrial Corp 
Freezer (-150°C)      ThermoScientific, USA 
BD™ ELISPOT Assay Kit      BD™ Biosciences 
BD™ AEC Substrate Solution Kit     BD™ Biosciences 
LuecoSeps™ Centrifuge Tubes     Greiner Bio-One 
Autoclave       Gemmy Industrial Corp 
Liquid Nitrogen Container      Chart Industries Inc. 
8.1.2 Solutions and Reagents 
Ficoll-Hypaque       Sigma-Aldrich  
Dimethyl Sulfoxide (DMSO)     Sigma-Aldrich  
96-well Microtiter Plate      BD™ Biosciences 
96-well U-Bottom Plates      Nunc™ 
96-well V-Bottom Plates      Nunc™ 
Dilute Antibody Solution      BD™ Biosciences 
Biotinylated anti-human IFN-γ     BD™ Biosciences 
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Enzyme Conjugate (Streptavidin-HRP)    BD™ Biosciences  
Substrate Solution       BD Biosciences 
PHA-M at 5 mg/mL       Sigma-Aldrich 
Fetal Bovine Serum (FBS)      Biowest  
RPMI 1640 (w/glutamine)     Gibco®  
Penicillin-Streptomycin (10 000 U/ml)   Gibco® 
HEPES (1 M)        Gibco® 
Turkey red blood cells in Alsever’s solution   CO Serum Company 
Receptor Destroying Enzyme     Denke Seiken Co. Ltd. 
 Physiologic Saline Solution (0.9% NaCl) 
 
Phosphate Buffered Saline (PBS) pH 7.2 (Autoclave Sterilised), 1 litre 
NaCl          8 g 
KCl          0.2 g 
Na2HPO4         1.44 g 
KH2PO4         0.24 g 
dH2O          1 L 
 
Freezing medium (Filter Sterilised), 50 ml 
Heat inactivated (HI) FBS (Biowest)      45 ml 
DMSO (Sigma-Aldrich)       5 ml  
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Thawing Medium (Filter Sterilised), 500 ml 
RPMI 1640 w/glutamine (Gibco®)      450 ml 
HI-FBS (Biowest)        50 ml 
 
ELISPOT Assay Medium (Filter Sterilised), 500 ml 
RPMI 1640 w/glutamine (Gibco®)      440 ml 
HI-FBS (Biowest)        50 ml 
Penicillin-Streptomycin (10 000 U/ml) (Gibco™)    5 ml 
HEPES (1 M) (Gibco™)       5 ml  
 
Dilution Buffer (Filter Sterilised), 1 litre  
PBS          100 ml 
HI-FBS (Biowest)        900 ml  
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